INVESTIGATING NAT PRODUCTS & PHARMACEUTICALS TARGETING INFLAMMATION IN NEURODEGENERATIVE DISEASES

Shelby L. Johnson
University of Rhode Island, shelby_johnson@uri.edu

Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss

Recommended Citation
Johnson, Shelby L., "INVESTIGATING NAT PRODUCTS & PHARMACEUTICALS TARGETING INFLAMMATION IN NEURODEGENERATIVE DISEASES" (2020). Open Access Dissertations. Paper 1132.
https://digitalcommons.uri.edu/oa_diss/1132

This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
INVESTIGATING NAT PRODUCTS & PHARMACEUTICALS
TARGETING INFLAMMATION IN NEURODEGENERATIVE
DISEASES
BY
SHELBY L. JOHNSON

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY
IN
INTERDISCIPLINARY NEUROSCIENCE PROGRAM

UNIVERSITY OF RHODE ISLAND
2020
DOCTOR OF PHILOSOPHY DISSERTATION
OF
SHELBY L. JOHNSON

APPROVED:

Dissertation Committee:
Major Professor       Navindra P. Seeram
Co-Major Professor    Paula Grammas
                       Angela L. Slitt
                       Matthew J. Bertin

Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2020
ABSTRACT

Alzheimer’s and Parkinson’s disease (AD and PD, respectively) are the two most common neurodegenerative diseases. Currently, no interventions have been successful in stopping the progression of these diseases. Here, we utilize two independent strategies: the use of natural products and repurposed pharmaceuticals to target neuroinflammation in models of neurodegeneration.

Natural products have been used for their medicinal properties for centuries in traditional eastern medicine practices. *Mucuna pruriens* (Mucuna) is a well-known natural source of levodopa, typically prescribed in Ayurveda for PD. A novel levodopa reduced seed extract exhibited protective effects against oxidative stress and PD specific toxic agents, both *in vitro* and *in vivo*. Further phytochemical investigation of our extract led to the isolation and identification of seven newly reported compounds. Isolates failed to protect against toxin inducers of PD in cellular models. These data support that our novel levodopa reduced seed extract, but not isolated compounds, protect against toxin-induced models of PD.

The Mediterranean diet, which is primarily composed of polyphenols, has gained considerable interest in the management of age-related diseases. Therefore, common polyphenols classes, isoflavones, and lignans with their gut-derived microbial metabolites were evaluated. Polyphenol microbial metabolites generally showed greater blood-brain barrier permeability and protection against oxidative stress, as compared to their parent compounds. Moreover, polyphenol microbial metabolites may heavily contribute to the beneficial effects of polyphenol enriched diets in disease prevention.

Repurposing pharmaceuticals is an approach that allows for expedited drug discovery to fast track pharmaceuticals to a new targeted patient population. Here, we analyze direct thrombin inhibitor, dabigatran etexilate (Pradaxa®), against
neuroinflammation in AD and PD models. In a *Drosophila melanogaster* transgenic model of PD, dabigatran treatment improved locomotor ability and reduced neuroinflammatory markers in males. Further, in a tau-based animal model of AD short-term treatment with dabigatran modulates expression of proteins related to antioxidants, mitogen-activated protein kinases, tau, thrombin, and oxidative stress. Taken together, these data indicate short-term treatment with a direct thrombin inhibitor modulates protein expression in the brains of aged Tg4510 mice. These findings support our hypothesis that targeting thrombin, a key mediator of neuroinflammation and neurotoxicity may be effective in reducing neuroinflammation in neurodegenerative diseases.

Our results indicate two common drug discovery methods, namely, investigation of natural products and repurposing pharmaceuticals, may provide insights for targeting neuroinflammation in neurodegenerative diseases. Further research should focus on moving these therapeutics through the drug discovery pipeline to the patient population.
ACKNOWLEDGMENTS

I would like to acknowledge my co-major professors, Drs. Navindra Seeram and Paula Grammas. Thank you both for assisting me on this journey and challenging me to be a better scientist. To my committee members, Drs. Matthew Bertin, Angela Slitt and Brietta Oaks, for providing expertise and consistently pushing my research to be better. To my lab mates, your continued guidance, support, and laughter have been instrumental. To my family, thank you for your constant support.
DEDICATION

The following dissertation is dedicated to my family. You are and have always been the inspiration in my doctoral pursuit. Your daily reminder of the very real impact of neurodegenerative diseases motivates me to do better.

“You are braver than you believe, stronger than you seem, and smarter than you think” A.A. Milne
PREFACE

The following dissertation is presented in manuscript format which creates four major chapters. The publication status of each manuscript is as follows:

Chapter 1: Generate and evaluate the bioactivity of Levodopa-reduced *Mucuna pruriens* extract and isolated compounds in cellular models of PD

   Manuscript 1: Levodopa-reduced *Mucuna pruriens* seed extract shows neuroprotective effects against Parkinson’s disease in murine microglia and human neuroblastoma cells, *Caenorhabditis elegans*, and *Drosophila melanogaster*. Published in Nutrients, 2018.
   
   Manuscript 2: Isolation and identification of compounds from *Mucuna pruriens* seeds. Under review at Chemistry of Natural Products, Nov 2019.

Chapter 2: Examine common polyphenols and corresponding gut-derived microbial metabolites for blood brain barrier permeability, reduction of neuroinflammation and protection in cellular and *Drosophila melanogaster* PD models

   Manuscript 3: Polyphenol microbial metabolites exhibit gut and blood-brain barrier permeability and protect microglia against LPS-induced inflammation. Published in Metabolites, 2019.
   
   Manuscript 4: Phytoestrogen, Equol, provides protection against toxin-induced models of Parkinson’s disease. In preparation.

Chapter 3: Explore the protective ability of direct thrombin inhibitor, Dabigatran, against neuroinflammation and motor impairments in *Drosophila melanogaster* models of PD

   Manuscript 5: Direct thrombin inhibitor, Dabigatran, protects against neuroinflammation in LRRK2 transgenic *Drosophila melanogaster* model of Parkinson’s disease. In preparation.
Chapter 4: Investigate Dabigatran etexilate influence on oxidative stress and neuroinflammation in aged, transgenic tau AD mouse model

Manuscript 6: Direct thrombin inhibitor, dabigatran etexilate, reduces oxidative stress \textit{in vivo} in a transgenic mouse model of Alzheimer's disease. In preparation.
TABLE OF CONTENTS

ABSTRACT .................................................................................................................. ii
ACKNOWLEDGMENTS ................................................................................................. iv
DEDICATION ................................................................................................................. v
PREFACE ..................................................................................................................... vi
TABLE OF CONTENTS ................................................................................................. viii
LIST OF TABLES .......................................................................................................... x
LIST OF FIGURES ....................................................................................................... xi
JUSTIFICATION OF RESEARCH ................................................................................... 1

REFERENCES ............................................................................................................. 9

MANUSCRIPT 1 .......................................................................................................... 18
  ABSTRACT .................................................................................................................. 19
  INTRODUCTION ......................................................................................................... 20
  MATERIALS AND METHODS ................................................................................ 22
  RESULTS AND DISCUSSION .................................................................................. 29
  CONCLUSIONS .......................................................................................................... 35
  REFERENCES ............................................................................................................. 44

MANUSCRIPT 2 .......................................................................................................... 50
  ABSTRACT .................................................................................................................. 51
  BODY ............................................................................................................................ 52
  EXPERIMENTAL ........................................................................................................ 54
  ACKNOWLEDGMENTS ............................................................................................. 56
  REFERENCES ............................................................................................................. 60

MANUSCRIPT 3 .......................................................................................................... 61
  ABSTRACT .................................................................................................................. 62
  INTRODUCTION ......................................................................................................... 63
  MATERIALS AND METHODS ................................................................................ 67
  RESULTS ..................................................................................................................... 71
  DISCUSSION .............................................................................................................. 75
  REFERENCES ............................................................................................................. 86

MANUSCRIPT 4 .......................................................................................................... 93
  ABSTRACT .................................................................................................................. 94
  INTRODUCTION ......................................................................................................... 95
  MATERIALS AND METHODS ................................................................................ 97
  RESULTS ..................................................................................................................... 100
  DISCUSSION .............................................................................................................. 102
  ACKNOWLEDGEMENTS ....................................................................................... 104
  REFERENCES ............................................................................................................. 110

MANUSCRIPT 5 .......................................................................................................... 115
  ABSTRACT .................................................................................................................. 116
  INTRODUCTION ......................................................................................................... 117
  MATERIALS AND METHODS ................................................................................ 120
  RESULTS ..................................................................................................................... 123
  DISCUSSION .............................................................................................................. 126
# Table of Contents

| Section                                      | Page |
|----------------------------------------------|------|
| CONCLUSIONS                                 | 129  |
| ACKNOWLEDGEMENTS                             | 130  |
| REFERENCES                                  | 139  |
| MANUSCRIPT 6                                 | 145  |
| ABSTRACT                                    | 146  |
| INTRODUCTION                                 | 148  |
| MATERIALS AND METHODS                        | 151  |
| RESULTS                                      | 155  |
| DISCUSSION                                   | 158  |
| ACKNOWLEDGEMENTS AND CONFLICT OF INTEREST    | 162  |
| REFERENCES                                  | 171  |
| CONCLUDING REMARKS                           | 181  |
LIST OF TABLES

MANUSCRIPT 1:

Table 1. Levodopa (L-dopa) content for each *Mucuna pruriens* seed extracts as determined by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)………………………………………………………37

Table 2. Survival (median and maximum) of *C. elegans* (N2), as compared with 1-methyl-4-phenylpyridinium (MPP+) treatment (750 μM)……………………41

MANUSCRIPT 2:

Table 1. NMR of Isolated compounds were compared to published literature to confirm structure and name of compounds………………………………………………59

MANUSCRIPT 3:

Table 1. In silico SwissADME predictive permeability of parent polyphenols and their microbial metabolites in the gut and blood–brain barrier (BBB)……79

MANUSCRIPT 6:

Table 1. List of proteins and corresponding abbreviations………………………..162
LIST OF FIGURES

MANUSCRIPT 1:

Figure 1. Effects of Mucuna pruriens Seeds Extract (MPE) (12.5, 25, 50 μg/mL) on cellular viability and reactive oxygen species (ROS) levels in BV-2 cells.................................................................38

Figure 2. Effects of MPE (12.5, 25, 50 μg/mL) on production of nitric oxide in BV-2 microglia and resulting influence in non-contact co-culture in SH-SY5Y neuroblastoma.................................................................39

Figure 3. Effects of MPE (12.5, 25, and 50 μg/mL) on cellular viability of SH-SY5Y human neuroblastoma cells against toxic models of Parkinson's disease.................................................................40

Figure 4. Effects of MPE (20 and 40 μg/mL) on lifespan of C. elegans after MPP+ exposure..................................................................................................................42

Figure 5. Effects of MPE on negative geotaxis in Drosophila melanogaster..................................................................................................................43

MANUSCRIPT 2:

Figure 1. Chemical structures of compounds 1-8 from Mucuna pruriens ethyl acetate (MPEA) seeds extract .................................................................57

Figure 2: Evaluation of single isolated compounds in human neuroblastoma (SH-SY5Y).........................................................................................................58
MANUSCRIPT 3:

Figure 1. Overview of the polyphenol isoflavones and lignan parent compounds and their respective polyphenol microbial metabolites produced by gut microflora..........................................................79

Figure 2. Parallel artificial membrane permeability assay (PAMPA) gut passive permeability at three relevant pH levels: 5.0 (A), 6.2 (B), and 7.4 (C)........81

Figure 3. Assessment of blood–brain barrier passive permeability of polyphenols determined by PAMPA.................................................................82

Figure 4. Effects of isoflavones against LPS-induced oxidative stress in BV-2 murine microglia.................................................................83

Figure 5. Effects of lignans in murine microglia cells. .........................84

MANUSCRIPT 4:

Figure 1. Cytotoxicity evaluation of isoflavones at 20 μM after 24h on human neuroblastoma (SHSY5Y).................................................................104

Figure 2. Effects of isoflavone treated, LPS-induced murine microglia cell supernatant on human neuroblastoma cellular viability..............................105

Figure 3. Isoflavones protect against toxic inducers of PD in human neuroblastoma.................................................................106
Figure 4. Effects of Equol (17.5 and 35 μM) on lifespan of C. elegans exposed to MPP+ (750 μM)........................................................................................................107

Figure 5. Effects of Equol on climbing ability of Drosophila melanogaster..................................................................................................................108

Manuscript 5:

Figure 1. Analysis of treatment induced toxicity in wildtype and transgenic Drosophila melanogaster..................................................................................130

Figure 2. Effects of dabigatran on negative geotaxis in Drosophila melanogaster.............................................................................................................131

Figure 3. Evaluation of nitric oxide species production in Drosophila melanogaster head homogenate.............................................................................132

Figure 4. Effects of dabigatran (25 μM) on reactive oxygen species production in wildtype and transgenic Drosophila melanogaster....................................133

Figure 5. Quantification of tyrosine hydroxylase (TH) by western blot in Drosophila melanogaster head homogenates.................................................134

Figure 6. Western blot analysis of inducible nitric oxide synthase (iNOS) in Drosophila melanogaster head homogenate.................................................135
Figure 7. Superoxide dismutase 1 (SOD1) expression in Drosophila melanogaster

Figure 8. Evaluation of NADPH (NOX4) by western blot in Drosophila melanogaster

Manuscript 6:

Figure 1. One week dabigatran treatment reduces expression of coagulation-associated proteins in Tg4510 mouse brain

Figure 2. One week dabigatran treatment reduces expression of oxidative-stress related proteins in Tg4510 mouse brains

Figure 3. One week dabigatran treatment increases expression of antioxidant proteins in Tg4510 mouse brain

Figure 4. Dabigatran treatment does not alter expression of neuroinflammation-associated proteins in Tg4510 mouse brain

Figure 5. Evaluation of total Tau, and phosphorylated protein expression by western blot

Figure 6. Volcano plots comparing LC-MS/MS SWATH data of wild type mice to Tg-Vehicle (A) and Tg-Vehicle to Tg-Dabigatran (B)
Figure 7. LC-MS/MS SWATH data analyzed for coagulation (A), inflammation (B) and tau-pathology related (C)…………………………………………………………169
JUSTIFICATION OF RESEARCH

Neurodegenerative diseases are broadly defined as age-related disorders where cells of the nervous system gradually lose function. The two most common neurodegenerative diseases are Alzheimer’s (AD) and Parkinson’s disease (PD). In 2016, nearly 5.4 million Americans were affected by AD; PD is expected to affect nearly 930,000 individuals by 2020\(^1\). Although these diseases present vastly different symptoms, there are several commonalities. For instance, both diseases are associated with protein aggregations, genetic predispositions, mitochondrial dysfunction and neuroinflammation, all processes which heavily contribute to neuronal death\(^3\).

Alzheimer’s Disease

AD typically affects the elderly population, characterized by episodic memory deficits later progressing to full-blown dementia with language impairment and severe behavioral changes\(^4\). Specific causes of AD are not known; however, lifestyle, genetics, and environment are all identified as risk factors\(^5,6\). Pathologically, AD is identified postmortem by the presence of \(\beta\)-amyloid (A\(\beta\)) plaques and neurofibrillary tangles, comprised of A\(\beta\) fragments and hyperphosphorylated tau, respectively. The AD brain exhibits extensive neuronal death, believed to originate in the hippocampus and move to adjacent brain regions\(^4\). For decades, the amyloid hypothesis has dominated AD research. This hypothesis suggests there is a cascading event that beings with A\(\beta\) accumulation leading to neurofibrillary tangles, which in turn disrupts synaptic and neuronal function\(^7\). Pharmaceutical interventions targeting disease pathogenesis have not been successful in stopping the progression of the disease.

It has become more widely accepted that AD is much more complicated than the original amyloid hypothesis. Research has shifted to explore age-related decline
through the influence of tau, inflammation, gut microbiota and vascular dysfunction in AD pathogenesis\textsuperscript{8–11}. Our previous research has focused heavily on neuroinflammation induced by the activation of the vasculature. Driving this interest is the correlation of cardiovascular disease and vascular risk factors, such as hypertension and diabetes, with AD incidence rates\textsuperscript{6}. Further, injury to the cerebrovasculature leads to the activation and dysfunction of brain endothelial cells\textsuperscript{12}. In the AD brain, vascular activation has detrimental consequences for neuronal viability. Many vascular-derived factors, such as thrombin, are neurotoxic and likely critical in the pathogenesis of AD\textsuperscript{11,13,14}.

Currently, available medications target symptoms, but not disease pathology or progression. The two approved drug treatments for AD are inhibitors of cholinesterase and \textit{N}-methyl-D-aspartate (NMDA) receptors; both exhibit modest beneficial effects on cognition\textsuperscript{5,15}. Significant research has focused on identifying novel disease-modifying drugs, but there have been several failures in the clinic\textsuperscript{16}. Current trends for AD research are now focusing on identifying biomarkers for earlier diagnosis and identifying interventions that aim to modify disease progression\textsuperscript{4,17}. Continued AD research must identify new ways to modify disease progression and pathogenesis to drive the future of pharmaceutical developments.

\textbf{Parkinson’s Disease}

PD is characterized by irregular, uncontrolled movements, frequently presenting as resting tremors or dyskinesias. Pathological hallmarks include the loss of dopaminergic neurons in the substantia nigra and an abundance of \textit{\alpha}-synuclein aggregates, termed Lewy bodies, throughout the brain\textsuperscript{18}. Direct causes of Parkinson’s disease are not known; however, a variety of genetic predispositions, gender, and environmental factors have been identified as contributors. At least 17 genetic mutations have been identified as contributing factors in PD including \textit{\alpha}-synuclein,
parkin, DJ-1, and leucine-rich repeat kinase 2 (LRRK2)\textsuperscript{18–20}. Environmental exposure to pesticides, such as paraquat, and similarly structured chemical 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can also result in symptoms indistinguishable from PD\textsuperscript{18–20}. Interestingly, males are 1.5 times more likely to have PD than females, and incident rates in females increase dramatically after menopause, suggesting a protective role of estrogen\textsuperscript{21,22}.

Pharmaceutical interventions for PD have mainly focused on the replenishment of dopamine to reduce motor impairments. These pharmaceutical classes include catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase type B (MAO-B) inhibitors, dopamine agonists, and levodopa paired with a dopamine decarboxylase inhibitor\textsuperscript{23–25}. Levodopa combination therapy limits the production of dopamine in the periphery and attempts to restore dopamine imbalance in the brain. Levodopa is then converted to dopamine by dopamine decarboxylase, increasing levels of dopamine in the affected brain regions\textsuperscript{26}. Levodopa paired with a dopamine decarboxylase inhibitor is currently the standard of care for PD; however, with prolonged treatment, levodopa becomes less effective, and motor deficits can increase\textsuperscript{26}. The aforementioned therapies are effective in some cases, but new formulations and administration routes are being explored to overcome problems of prolonged efficacy\textsuperscript{23}. Surgical interventions have also been approved as therapies for PD. Deep brain stimulation using high-frequency stimulation in the subthalamic nucleus and globus pallidus internus exhibits improved motor control\textsuperscript{24,25}. Similar to AD, available interventions cannot stop or prevent disease progression; therefore, it is essential to identify and target disease-modifying mechanisms. Current literature proposes the investigation of genetic mutations, mitochondrial function, neuroinflammation, and oxidative stress, among others\textsuperscript{18,26}. 
Neuroinflammation in Alzheimer’s and Parkinson’s Diseases

Neuroinflammation has been recognized as a major factor in AD and PD pathogenesis. While these two diseases present quite differently, the neuroinflammatory response is similar. Integral to the regulation of inflammation in the brain is the neurovascular unit (NVU). Astrocytes, microglia, neurons, pericytes, and endothelial cells collectively create the NVU that maintains normal cerebral blood flow and blood-brain barrier (BBB) functioning. Under normal conditions, microglia, the major immune cells of the brain, work to detect pathogens or tissue damage and elicit a response to clear cellular debris and degenerating cells. However, when microglia are continuously activated by external stimuli such as aggregated protein or foreign pathogens, this response can then exacerbate any present neuronal damage. This toxic microglial inflammatory response includes the release of a variety of inflammatory mediators, such as chemokines, cytokines, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and reactive mediators, namely, reactive oxygen species (ROS) and nitric oxide species (NOS). The chronic production of these inflammatory mediators increases oxidative stress and contributes to neuronal death. Although complex, neuroinflammation plays a major role in neurodegenerative diseases and has been identified as a worthy target for pharmaceutical interventions in neurodegenerative diseases.

Therapeutic Strategies

In recent years, big pharmaceutical companies such as Pfizer have shut down their neuroscience research groups. A major part of this is due to the lack of success in developing drugs to treat neurological diseases. Since 1990, there has been a decline in nervous system drugs, with fewer Phase I trial starts, as well as a greater probability of failure in Phase III. The investigation of new therapeutics for central nervous system diseases has proven to be extremely cost and time ineffective.
Therefore, it is imperative to acknowledge and utilize methods that will reduce both factors. Herein, we investigate two commonly used drug discovery strategies: natural products and repurposing pharmaceuticals.

**Therapeutic Strategy I: Natural Products**

Plant-based approaches to medicine have been utilized for centuries. The generational knowledge of traditional Chinese medicine (TCM) and traditional Indian medicine (Ayurveda) have driven the investigation of natural sources to identify biologically active compounds\textsuperscript{34}. Among these discoveries have come major medical advancements for cancer, hypertension, malaria, and pain, among others\textsuperscript{35}. One of the most commonly known natural product derived pharmaceuticals is aspirin. Willow bark as a pain and fever reliever dates back more than 3,500 years. The active compound, salicylic acid, was initially identified in 1838. Scientists at Bayer then acetylated salicylic acid to create a more stable compound, now known as aspirin\textsuperscript{36}. This story is not unique to aspirin, approximately 51% of all newly approved drugs from 1981 to 2014 were derived from or structurally related to a natural product\textsuperscript{37}. Natural product, *Gingko biloba*, is an example that has been successful in mitigating the cognitive decline in animal models but has been controversial in AD clinical trials\textsuperscript{38-41}. The success of natural products has been instrumental in the foundations of modern medicine and thus should not be ignored as a viable option for future therapeutic developments\textsuperscript{35,42}.

*Mucuna pruriens* is a legume common to southern China and eastern India, used heavily as a food source, and for the treatment of tremors\textsuperscript{43}. Ayurveda traditionally used Mucuna to treat PD, as the beans are naturally high in levodopa\textsuperscript{44}. This use of *Mucuna pruriens* led to further investigation of this medicinal plant. In two clinical trials, *Mucuna pruriens* preparations exhibited more rapid onset and more tolerable profiles as compared to levodopa paired with a dopamine decarboxylase
inhibitor, suggesting potential advantages of the natural product to the common pharmaceutical\textsuperscript{45,46}. Multiple studies suggest that the anti-PD activity of Mucuna is entirely due to the presence of levodopa\textsuperscript{46–49}. However, newer evidence also suggests that there may be bioactive compounds other than levodopa could provide neuroprotection\textsuperscript{50}.

Another interesting class of natural products, namely, polyphenols, exhibits a wide range of bioactive properties including antioxidant, anti-inflammatory, anti-apoptotic and lipid-lowering properties\textsuperscript{51,52}. Interestingly, the Mediterranean diet is characterized by a high intake of polyphenols and has been identified as a beneficial intervention for the management of cardiovascular disease, obesity and neurodegenerative diseases\textsuperscript{53–55}. While polyphenols themselves may exhibit biological effects, it is generally considered that the consumed compounds get metabolized in the colon by microbiota to produce bioactive metabolites\textsuperscript{56–60}. Two common classes of polyphenols: lignans and isoflavones are found primarily in flaxseed and soy, respectively. The common and prototypical dietary lignan, secoisolariciresinol (SECO), is known to be converted to the polyphenol microbial metabolites (PMM) enterodiol (ED) and enterolactone (EL)\textsuperscript{61}. The isoflavones, genistein (GEN) and daidzein (DAI), are metabolized in the gut by intestinal microflora to produce equol (EQ)\textsuperscript{62}. Isoflavones are structurally similar to estrogen, containing 3-phenylchromen-4-one backbone, making them a curious class of compounds for PD research\textsuperscript{63}. Additionally, GEN was identified as a potential nutraceutical for AD due to the ability to inhibit mitochondria-dependent apoptosis, and alleviate β-amyloid neurotoxicity, but failed in clinical trials\textsuperscript{64–66}. Failing in the clinic may have been due to rapid metabolism into metabolites, therefore it would be of interest to examine gut microbial-derived metabolites.

**Therapeutic Strategy II: Repurposing Pharmaceuticals**
Another promising strategy for new therapeutics is to repurpose “old” drugs. Repurposing pharmaceuticals is defined as determining alternative uses beyond the scope of the original indication\textsuperscript{67}. This approach is advantageous as these therapeutics have been extensively studied for safety, pharmacokinetic profiles, bulk manufacturing, and \textit{in vitro} and \textit{in vivo} screening\textsuperscript{67}. This strategy reduces risk, development time and costs, and provides a fast-track to the patient population\textsuperscript{68}. Repurposing pharmaceuticals has been utilized to identify new therapies for cancer, depression, and schizophrenia, among others\textsuperscript{68–70}. Aspirin is again a good example drug, as it has been re-purposed for several alternative therapeutic indications. Aspirin was initially FDA-approved to reduce pain and fevers. Recently, aspirin has been extensively studied for antiproliferative and anticancer activities\textsuperscript{71}. Aspirin is effective in reducing cell viability in multiple subtypes of breast cancer cells\textsuperscript{72}. In colorectal cancer patients, aspirin has shown improved survival rates\textsuperscript{73}. In addition to cancer, aspirin has also been analyzed in combating fungal infections\textsuperscript{74}. Moreover, recent studies have looked at repurposing approved antibiotics to reduce protein aggregation in neurodegenerative diseases\textsuperscript{75–77}. Using pharmaceuticals to target diseases alternative to initial indications has proven a worthy mechanism to identify new therapies and should be continuously explored.

Dabigatran etexilate (Pradaxa®, Boehringer Ingelheim) is a commonly prescribed anticoagulant that directly inhibits thrombin. Vascular activation results in injured endothelial cells which upregulate the production of thrombin both \textit{in vivo} and \textit{in vitro}\textsuperscript{13,78,79}. Elevated levels of thrombin can be neurotoxic through the interaction with protease-activated receptor 1 (PAR-1), leading to the release of reactive oxygen species (ROS) and increases in a large array of inflammatory proteins\textsuperscript{80,81}. Increased levels of both thrombin and PAR-1 have been identified in both AD and PD\textsuperscript{82}. Previous studies have identified that dabigatran treatment mitigates the neurotoxic
effects of thrombin\textsuperscript{13,83,84}. Dabigatran etexilate also provides neuroprotection in a rotenone-induced rat model of PD through nuclear receptor-related \textsuperscript{185}. 

\textbf{Dissertation Objective}

The following dissertation will propose new therapeutic strategies from natural products and pharmaceuticals to reduce neuroinflammation in AD and PD models. Outcomes will provide new insight into the current state for the protection against neuroinflammation.
References

1. Gaugler, J., James, B., Johnson, T., Scholz, K. & Weuve, J. Alzheimer’s disease facts and figures. *Alzheimer's Dement.* 12, 459–509 (2016).

2. Marras, C. *et al.* Prevalence of Parkinson’s disease across North America. *npj Park. Dis.* 4, 21 (2018).

3. Richard M. Ransohoff. How neuroinflammation contributes to neurodegeneration. *Science* 353, 772–777 (2016).

4. Bondi, M. W., Edmonds, E. C. & Salmon, D. P. Alzheimer’s Disease: Past, Present, and Future. *J. Int. Neuropsychol. Soc.* 23, 818–831 (2017).

5. Ballard, C. *et al.* Alzheimer’s disease. *Lancet* 337, 1019–31 (2011).

6. Lane, C. A., Hardy, J. & Schott, J. M. Alzheimer’s disease. *Eur. J. Neurol.* 25, 59–70 (2018).

7. Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. *Nat. Rev. Neurosci.* 16, 358–72 (2015).

8. Gao, Y., Tan, L., Yu, J.-T. & Tan, L. Tau in Alzheimer’s Disease: Mechanisms and Therapeutic Strategies. *Curr. Alzheimer Res.* 15, 283–300 (2018).

9. Akiyama, H. *et al.* Inflammation and Alzheimer’s disease. *Neurobiology of Aging* 21, 383-421 (2000).

10. Osorio, C. *et al.* The post-amyloid era in Alzheimer’s disease: Trust your gut feeling. *Front. Aging Neurosci.* 11, 1–27 (2019).

11. Grammas, P. *et al.* A New Paradigm for the Treatment of Alzheimer’s Disease: Targeting Vascular Activation. *J. Alzheimer’s Dis.* 40, 619–630 (2014).

12. Grammas, P., Martinez, J. & Miller, B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. *Expert Rev. Mol. Med.* 13,
13. Tripathy, D. et al. Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. *Front. Aging Neurosci.* **5**, 1–9 (2013).

14. Grammas, P., Samany, P. & Thirumangalakudi, L. Thrombin and inflammatory proteins are elevated in Alzheimer’s disease microvessels: implications for disease pathogenesis. *J. Alzheimers Dis* **9**, 51–8 (2006).

15. Briggs, R., Kennelly, S. P. & O’Neill, D. Drug treatments in Alzheimer’s disease. *Clin. Med. (Northfield. II).* **16**, 247–53 (2016).

16. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer’s disease: clinical trials and drug development. *Lancet Neurol.* **9**, 702–716 (2010).

17. Fakhoury, M. Microglia and astrocytes in Alzheimer's disease: implications for therapy. *Curr. Neuropharmacol.* **16**, 508–518 (2018).

18. Kalia, L. V. & Lang, A. E. Parkinson’s disease. *Lancet* **386**, 896–912 (2015).

19. Dexter, D. T. & Jenner, P. Parkinson disease: from pathology to molecular disease mechanisms. *Free Radic. Biol. Med.* **62**, 132–144 (2013).

20. Lees, A. J., Hardy, J. & Revesz, T. Parkinson’s disease. *Lancet* **373**, 2055–2066 (2009).

21. Moisan, F. et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. *J. Neurol. Neurosurg. Psychiatry* **87**, 952–957 (2016).

22. Labandeira-Garcia, J. L., Rodriguez-Perez, A. I., Valenzuela, R., Costa-Besada, M. A. & Guerra, M. J. Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. *Front. Neuroendocrinol.* **43**, 44–59 (2016).

23. Dong, J., Cui, Y., Li, S. & Le, W. Current Pharmaceutical Treatments and
Alternative Therapies of Parkinson’s Disease. *Curr. Neuropharmacol.* **14**, 339–355 (2016).

24. Kulisevsky, J., Oliveira, L. & Fox, S. H. Update in therapeutic strategies for Parkinson’s disease. *Curr. Opin. Neurol.* **31**, 439–447 (2018).

25. Pires, A. O. *et al.* Old and new challenges in Parkinson’s disease therapeutics. *Prog. Neurobiol.* **156**, 69–89 (2017).

26. Rane, P. *et al.* Novel targets for Parkinson’s Disease: Addressing different therapeutic paradigms and conundrums. *ACS Chem. Neurosci.* **10**, 44-57 (2018).

27. Kaur, K., Gill, J. S., Bansal, P. K. & Deshmukh, R. Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson’s disease. *J. Neurol. Sci.* **381**, 308–314 (2017).

28. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? *Lancet Neurol.* **8**, 382–397 (2009).

29. Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W. & Zlokovic, B. V. The role of brain vasculature in neurodegenerative disorders. *Nat. Neurosci.* **21**, 1318–1331 (2018).

30. Subhramanyam, C. S., Wang, C., Hu, Q. & Dheen, S. T. Microglia-mediated neuroinflammation in neurodegenerative diseases. *Semin. Cell Dev. Biol.* **94**, 112-120 (2019).

31. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C. & Gage, F. H. Mechanisms Underlying Inflammation in Neurodegeneration. *Cell* **140**, 918–934 (2010).

32. Smith, J. A., Das, A., Ray, S. K. & Banik, N. L. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. *Brain Res. Bull.* **87**, 10–20 (2012).
33. Kesselheim, A. S., Hwang, T. J. & Franklin, J. M. Two decades of new drug development for central nervous system disorders. *Nat. Rev. Drug Discov.* **14**, 815–816 (2015).

34. Patwardhan, B., Warude, D., Pushpangadan, P. & Bhatt, N. Ayurveda and Traditional Chinese Medicine: A Comparative Overview. *Evidence-Based Complement. Altern. Med.* **2**, 465–473 (2005).

35. Cragg, G. M. & Newman, D. J. Natural products: A continuing source of novel drug leads. *Biochim. Biophys. Acta - Gen. Subj.* **1830**, 3670–3695 (2013).

36. Desborough, M. J. R. & Keeling, D. M. The aspirin story – from willow to wonder drug. *Br. J. Haematol.* **177**, 674–683 (2017).

37. Newman, D. J. & Cragg, G. M. Natural Products as Sources of New Drugs from 1981 to 2014. *J. Nat. Prod.* **79**, 629–661 (2016).

38. Kaur, S., Chhabra, R. & Nehru, B. Ginkgo biloba extract attenuates hippocampal neuronal loss and cognitive dysfunction resulting from trimethyltin in mice. *Phytomedicine* **20**, 178–186 (2013).

39. Shi, C., Liu, J., Wu, F. & Yew, D. T. Ginkgo biloba extract in Alzheimer's disease: From action mechanisms to medical practice. *Int. J. Mol. Sci.* **11**, 107–123 (2010).

40. Sharma, M. *et al.* Inflammatory Biomarkers and Cognitive Decline: The Ginkgo Evaluation of Memory Studie. *J AM Geriatr Soc* **64**, 1171–1177 (2016).

41. Spiegel, R. *et al.* Ginkgo biloba extract EGb 761® alleviates neurosensory symptoms in patients with dementia: A meta-analysis of treatment effects on tinnitus and dizziness in randomized, placebo-controlled trials. *Clin. Interv. Aging* **13**, 1121–1127 (2018).

42. Newman, D. J. & Cragg, G. M. Natural Products as Sources of New Drugs from 1981 to 2014. *J. Nat. Prod.* **79**, 629–661 (2016).
43. Lampariello, L. R., Cortelazzo, A., Guerranti, R., Sticozzi, C. & Valacchi, G. The Magic Velvet Bean of Mucuna pruriens. *J. Tradit. Complement. Med.* **2**, 331–339 (2012).

44. Natarajan, K., Narayanan, N. & Ravichandran, N. Review on ‘Mucuna’ - The wonder plant. *Int. J. Pharm. Sci. Rev. Res.* **17**, 86–93 (2012).

45. Katzenschlager, R. *et al.* Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. *J. Neurol. Neurosurg. Psychiatry* **75**, 1672–1677 (2004).

46. Cilia, R. *et al.* Mucuna pruriens in Parkinson Disease A double-blind, randomized, controlled, crossover study. *Neurology* **89**, 1–7 (2017).

47. Manyam, B. V., Dhanasekaran, M. & Hare, T. A. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. *Phyther. Res.* **18**, 706–712 (2004).

48. Kasture, S. *et al.* Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson’s disease. *Neurotox. Res.* **15**, 111–122 (2009).

49. Lieu, C. A., Kunselman, A. R., Manyam, B. V., Venkiteswaran, K. & Subramanian, T. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. *Park. Relat. Disord.* **16**, 458–465 (2010).

50. Poddighe, S. *et al.* Mucuna pruriens(Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson’s disease. *PLoS One* **9**, (2014).

51. Braga, R. *et al.* Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences. *Oxid. Med. Cell. Longev.* (2018).

52. Jung, U. J. & Kim, S. R. Beneficial Effects of Flavonoids Against Parkinson's
Disease. J. Med. Food 21, 421-432 (2018).

53. Gardener, H. & Caunca, M. R. Mediterranean Diet in Preventing Neurodegenerative Diseases. Curr. Nutr. Rep. 7, 10–20 (2018).

54. Castro-Barquero, S., Lamuela-Raventós, R. M., Doménech, M. & Estruch, R. Relationship between Mediterranean Dietary Polyphenol Intake and Obesity. 1–13 (2018).

55. Widmer, R. J., Flammer, A. J., Lerman, L. O. & Lerman, A. The Mediterranean Diet, its components and cardiovascular disease. Am J Med. 128, 229–238 (2015).

56. Yuan, T. et al. Pomegranate’s Neuroprotective Effects against Alzheimer’s Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived Metabolites. ACS Chem. Neurosci. (2015).

57. D’Archivio, M. et al. Bioavailability of the Polyphenols: Status and Controversies. Int. J. Mol. Sci. 11, 1321–1342 (2010).

58. Subedi, L. et al. Equol, a Dietary Daidzein Gut Metabolite Attenuates Microglial Activation and Potentiates Neuroprotection In Vitro. Nutrients 9, 207 (2017).

59. Lewandowska, U., Szewczyk, K., Hrabec, E., Janecka, A. & Gorlach, S. Overview of Metabolism and Bioavailability Enhancement of Polyphenols. J. Agric. Food Chem. 61, 12183–12199 (2013).

60. Marín, L., Miguélez, E. M., Villar, C. J. & Lombó, F. Bioavailability of dietary polyphenols and gut microbiota metabolism: Antimicrobial properties. Biomed Res. Int. (2015).

61. Mukker, J. K., Michel, D., Muir, A. D., Krol, E. S. & Alcorn, J. Permeability and Conjugative Metabolism of Flaxseed Lignans by Caco-2 Human Intestinal Cells. J. Nat. Prod. 77, 29–34 (2014).

62. Setchell, K. D. R. & Clerici, C. Equol: History, Chemistry, and Formation. J.
63. Esch, H. L., Kleider, C. & Scheffler, A. *Isoflavones: Toxicology Aspects and Efficacy*. *Nutraceuticals* **8**, 465-488 (2016).

64. Bang, O. Y. *et al.* Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. *Neurobiol. Dis.* **16**, 21–28 (2004).

65. Ma, H. *et al.* The hydrolyzable gallotannin, penta-O-galloyl-β-glucopyranoside, inhibits the formation of advanced glycation endproducts by protecting protein structure. *Mol. BioSyst.* **11**, 1338–1347 (2015).

66. Qian, Y. *et al.* Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-κB activation in a cerebral ischemia mouse model. *Neurochem. Int.* **60**, 759–767 (2012).

67. Ashburn, T. T. & Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs. *Nat. Rev. Drug Discov.* **3**, 673–683 (2004).

68. Parsons, C. G. CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer’s disease, Parkinson’s disease and spasticity. *Neuropharmacology* **147**, 4–10 (2019).

69. Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S. & Schutjens, M. H. D. B. Drug repositioning and repurposing: terminology and definitions in literature. *Drug Discov. Today* **20**, 1027–1034 (2015).

70. Cragg, G. M., Grothaus, P. G. & Newman, D. J. New horizons for old drugs and drug leads. *J. Nat. Prod.* **77**, 703–723 (2014).

71. Mahdi, J. G., Mahdi, A. J., Mahdi, A. J. & Bowen, I. D. The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. *Cell Prolif.* **39**, 147–155 (2006).

72. Amaral, M. E. A., Nery, L. R., Leite, C. E., de Azevedo Junior, W. F. &
Campos, M. M. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. *Invest. New Drugs* **36**, 782–796 (2018).

73. Frouws, M. A. *et al.* The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. *Cancer Treat. Rev.* **55**, 120–127 (2017).

74. Ogundeji, A. O., Pohl, C. H. & Sebolai, O. M. Repurposing of aspirin and ibuprofen as candidate anti-Cryptococcus drugs. *Antimicrob. Agents Chemother.* **60**, 4799–4808 (2016).

75. Socías, S. B. *et al.* Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. *Prog. Neurobiol.* **162**, 17–36 (2018).

76. González-Lizárraga, F. *et al.* Repurposing doxycycline for synucleinopathies: Remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species. *Sci. Rep.* **7**, 1–13 (2017).

77. Bortolanza, M. *et al.* Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease. *J. Neural Transm.* **125**, 1403–1415 (2018).

78. Yin, X., Wright, J., Wall, T. & Grammas, P. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer’s disease. *Am. J. Pathol.* **176**, 1600–1606 (2010).

79. Luo, J. *et al.* Hypoxia induces angiogenic factors in brain microvascular endothelial cells. *Microvasc. Res.* **83**, 138–145 (2012).

80. Coughlin, S. R. Thrombin signalling and protease-activated receptors. *Nature* **407**, 258–64 (2000).

81. Grammas, P. & Martinez, J. M. Targeting thrombin: An inflammatory neurotoxin in alzheimer’s disease. *J. Alzheimer’s Dis.* **42**, S537–S544 (2014).

82. Sokolova, E. & Reiser, G. Prothrombin/thrombin and the thrombin receptors PAR-I and PAR-4 in the brain: Localization, expression and participation in
neurodegenerative diseases. *Thromb Haemost* **100**, 576–581 (2008).

83. Lee, I.-O., Kratz, M. T., Schirmer, S. H., Baumhakel, M. & Bohm, M. The Effects of Direct Thrombin Inhibition with Dabigatran on Plaque Formation and Endothelial Function in Apolipoprotein E-Deficient Mice. *J. Pharmacol. Exp. Ther.* **343**, 253–257 (2012).

84. Hawkins, B. T., Gu, Y. H., Izawa, Y. & Del Zoppo, G. J. Dabigatran abrogates brain endothelial cell permeability in response to thrombin. *J. Cereb. Blood Flow Metab.* **35**, 985–992 (2015).

85. Kandil, E. A., Sayed, R. H., Ahmed, L. A., Abd El Fattah, M. A. & El-Sayeh, B. M. Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats. *Mol. Neurobiol.* **55**, 4078–4089 (2018).
Levodopa-Reduced *Mucuna pruriens* Seed Extract Shows Neuroprotective Effects against Parkinson’s Disease in Murine Microglia and Human Neuroblastoma Cells, *Caenorhabditis elegans*, and *Drosophila melanogaster*

Shelby L. Johnson $^{1,2,3}$, Hyun Y. Park $^{4,5}$, Nicholas A. DaSilva $^{2,3}$, Dhiraj A. Vattem $^{4,5,*}$, Hang Ma $^{1,2,3,*}$ and Navindra P. Seeram $^{2,3,*}$

Affiliations:

1 School of Biotechnology and Health Sciences, Wuyi University; International Healthcare Innovation Institute (Jiangmen), Jiangmen 529020, China

2 Bioactive Botanical Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA; shelby_johnson@uri.edu (S.L.J); ndasilva@my.uri.edu (N.A.D.)

3 George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA

4 Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA; parkh4@ohio.edu

5 School of Applied Health Sciences and Wellness, Ohio University, Athens, OH 45701, USA

*Correspondence: vattem@ohio.edu (D.A.V.); hang_ma@uri.edu (H.M.); nseeram@uri.edu (N.P.S.); Tel.: +1-740-593-0133 (D.A.V.); +1-401-874-7654 (H.M.); +1-401-874-9367 (N.P.S.)
Abstract

*Mucuna pruriens* (Mucuna) has been prescribed in Ayurveda for various brain ailments including ‘kampavata’ (tremors) or Parkinson’s disease (PD). While Mucuna is a well-known natural source of levodopa (L-dopa), published studies suggest that other bioactive compounds may also be responsible for its anti-PD effects. To investigate this hypothesis, a L-dopa reduced (<0.1%) *M. pruriens* seeds extract (MPE) was prepared and evaluated for its anti-PD effects in cellular (murine BV-2 microglia and human SH-SY5Y neuroblastoma cells), *Caenorhabditis elegans*, and *Drosophila melanogaster* models. In BV-2 cells, MPE (12.5–50 μg/mL) reduced hydrogen peroxide-induced cytotoxicity (15.7–18.6%), decreased reactive oxygen species production (29.1–61.6%), and lowered lipopolysaccharide (LPS)-induced nitric oxide species release by 8.9–60%. MPE (12.5–50 μg/mL) mitigated SH-SY5Y cell apoptosis by 6.9–40.0% in a non-contact co-culture assay with cell-free supernatants from LPS-treated BV-2 cells. MPE (12.5–50 μg/mL) reduced 6-hydroxydopamine (6-OHDA)-induced cell death of SH-SY5Y cells by 11.85–38.5%. Furthermore, MPE (12.5–50 μg/mL) increased median (25%) and maximum survival (47.8%) of *C. elegans* exposed to the dopaminergic neurotoxin, methyl-4-phenylpyridinium. MPE (40 μg/mL) ameliorated dopaminergic neurotoxin (6-OHDA and rotenone) induced precipitation of innate negative geotaxis behavior of *D. melanogaster* by 35.3 and 32.8%, respectively. Therefore, MPE contains bioactive compounds, beyond L-dopa, which may impart neuroprotective effects against PD.

**Keywords:** *Mucuna pruriens*; levodopa; Parkinson’s disease; neuroprotection; *Caenorhabditis elegans; Drosophila melanogaster*
Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disease that leads to impaired motor function and is characterized by a loss of dopaminergic neurons in the substantia nigra and is second only to Alzheimer’s disease in its prevalence [1]. The etiology and pathophysiology of PD are not very well understood and have consequently stifled the development of effective therapeutic interventions for PD. Accumulating evidence suggests that elevated oxidative stress and neuroinflammation associated with microgliosis and intracellular aggregation of α-synuclein molecules may be responsible for dopaminergic neuronal atrophy and ultimately the clinical manifestation of PD [2–4].

*Mucuna pruriens*, commonly known as Mucuna or velvet bean, is native to eastern India and western regions of China. Mucuna seeds, a rich source of naturally occurring levodopa (L-dopa; 4–7% in Mucuna seeds) [5], have been used traditionally as an effective remedy for several brain related maladies, including reducing tremors (as seen in PD), as documented in the ancient treatise of Ayurveda, the Indian traditional system of medicine [6]. The lack of effective pharmaceutical treatments has stimulated research interest in Mucuna as a PD therapeutic agent in several animal studies and a limited number of human clinical trials [7–9]. For example, Mucuna, at a dosage of 17.5 mg/kg, improved motor function and reduced dyskinesia in patients with advanced PD with fewer adverse effects as compared with the conventional treatment of L-dopa paired with a dopamine decarboxylase inhibitor, namely Carbidopa [9]. Mucuna has also been reported to show protective effects against PD in rodent models by increasing the activity of brain mitochondrial complex-I [10] and reducing motor dysfunction [11,12]. While several studies have attributed the anti-PD activities to naturally occurring high levels of L-dopa in Mucuna, emerging evidence suggests that other bioactive compounds besides L-dopa may also have
neuroprotective effects. For example, a Mucuna methanolic extract (0.1% dosage) containing low levels of L-dopa (0.01%) showed anti-PD effects including improvements of motor function and olfactory response in a *Drosophila melanogaster* genetic model of PD [13]. The anti-PD effects of the Mucuna methanolic extract were superior to that of the treatment of L-dopa (0.01%) alone in the aforementioned *D. melanogaster* model, suggesting that the overall anti-PD effects of Mucuna were a result of other compounds beyond L-dopa alone [13].

Our group has previously reported on the development of a neuroprotective potential algorithm for several Ayurvedic botanical extracts, among which *M. pruriens* ranked in the top four [14]. Given our group’s research interest in this medicinal plant, and to explore the role of its ‘non-L-dopa’ bioactives against PD, we prepared a *M. pruriens* seed extract (MPE) containing low amounts of L-dopa (<0.1%) with the following objectives: (1) to evaluate the antioxidant and anti-inflammatory effects of MPE in murine microglia (BV-2) and human neuroblastoma (SH-SY5Y) cells; (2) to assess the neuroprotective effects of MPE against neurotoxin-induced cytotoxicity in cellular PD models; and (3) to evaluate the neuroprotective effects of MPE using *Caenorhabditis elegans* and *D. melanogaster* models of chemically induced PD.
Materials and Methods

Chemicals

Dimethylsulfoxide (DMSO), levodopa (L-dopa), Resveratrol (Resv), lipopolysaccharide (LPS), 2’,7’-dichlorofluorescin diacetate (DCF-DA), hydrogen peroxide (H$_2$O$_2$), 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenylpyridinium (MPP$^+$), and rotenone were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM)/F-12, phenol red-free DMEM medium and trypsin-versene were purchased from Life Technologies (Grand Island, NY, USA).

Preparation of Mucuna pruriens Seeds Extract (MPE)

*Mucuna pruriens* seeds (3–7% L-dopa) were botanically authenticated and generously provided by Verdure Sciences (Noblesville, IN, USA). *Mucuna pruriens* seeds were authenticated by Dr V. Singh (Pharmanza, Gujarat, India) with voucher specimen (No. PHPL/HB/013) deposited in the Heber-Youngken Garden and Greenhouse at the College of Pharmacy, the University of Rhode Island, RI, USA. Briefly, the ground *M. pruriens* seeds (150 g) were extracted with sonication in methanol (1000 mL) in an ultrasonic bath (Bransonic 8510; Branson Ultrasonics Corp. Danbury, CT, USA) for 0.5 h and macerated in methanol at room temperature for 24 h to afford a crude methanol extract (6.5 g), which was dried *in vacuo* (in a water bath at 35 °C); reconstituted in water; and then partitioned sequentially in *n*-hexanes, ethyl acetate, and butanol with details as follows. The dried crude extract (6.5 g) was reconstituted in distilled water (250 mL) and sequentially partitioned with *n*-hexanes, ethyl acetate, and butanol (250 mL × 3 for each solvent). Each of these fractions, namely, hexanes (0.2 g), ethyl acetate (0.3 g), butanol (2.9 g), and the
remaining water portion (3.0 g), were dried in vacuo (in a water bath at 35 °C) to afford respective extracts. The levels of L-dopa were quantified in each dried extract (described below) and the extract with the lowest level of L-dopa, namely, MPE (the *M. pruriens* ethyl acetate extract; see Table 1), was selected for further biological evaluation.

**Quantification of L-dopa by Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS)**

L-dopa was quantified by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI–MS/MS) using methods and parameters published by our group and others with some modifications [15–19]. L-dopa quantifications were performed on a prominence ultra-fast liquid chromatography (UFLC) system (Shimadzu, Marlborough, MA, USA) coupled with a QTRAP 4500 system (Applied Biosystems/MDS Sciex, Framingham, MA, USA) with data acquired using Analyst 1.6.3 software and processed using MultiQuant 3.0.1 software (Sciex, Framingham, MA, USA). The UFLC system consisted of three LC-20AD pumps, a DGU-20A degassing unit, SIL-20AC auto sampler, CTO-20AC column oven, and CBM-20A communication bus module. Chromatographic separation was performed using a 100 mm × 4.6 mm i.d., 5 μm, XBridge C18 column (Waters, Milford, MA, USA). The mobile phase consisted of A (water containing 0.1% (v/v) formic acid) and B (methanol containing 0.1% (v/v) formic acid) with a gradient elution of 1% B from 0 to 10 min, and 1–4% B from 10 to 20 min. The flow rate was 0.5 mL/min and the injection volume was 10 μL. The column temperature was maintained at 40 °C. The MS operated in electrospray ionization (ESI) in positive mode with multiple reaction monitoring (MRM). Nitrogen was used as the source gas in all cases. Parameters were optimized as follows: IonSpray voltage, 4500 V; nebulizer gas, 40 psi; auxiliary
heater gas, 45 psi; curtain gas, 20 psi; turbo gas temperature, 300 °C. Using an authentic L-dopa standard (purchased from Sigma-Aldrich Chemical Co.; St. Louis, MO, USA), L-dopa was analyzed by the multiple reaction monitor (MRM) mode using ion transition at m/z values of 198/152. All of the analyses of the standard and extracts were performed in triplicates (see LC-ESI-MS/MS spectra in the Supplementary Materials; Figure S1). The calibration curve (y = 5006.29x – 13189.13; R = 0.99825) was acquired by plotting the peak area against the nominal concentrations of L-dopa. The linearity was in the range of 10–1000 ng/mL. The presence of L-dopa in Mucuna extracts was identified as a peak with a retention time of 3.95 min under the ion transition 198/152. The percentage of L-dopa in the different Mucuna extracts was calculated as follows: (ng/mL of L-dopa in extract)/(µg/mL of extract injected) × 100%.

Cell Culture

Murine microglia (BV-2) cells were kindly provided by Dr. Grace Y. Sun (University of Missouri at Columbia, MO, USA) and human neuroblastoma (SH-SY5Y) cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained at 37 °C in 5% CO₂ with high glucose (4.5 g/L) DMEM/F-12 accompanied with 10% heat inactivated fetal bovine serum, and 1% P/S (100 U/mL penicillin, 100 mg/mL streptomycin) (Life Technologies, Gaithersburg, MD, USA). MPE was dissolved in distilled water to obtain a 10 mg/mL stock solution and further diluted in serum free media for treatments. Resv (used as a positive control for the cellular based assays) was dissolved in DMSO (10 mM) and diluted in media to the desired concentration. Control cells were treated with 0.1% DMSO in serum free media.
Cell Viability

BV-2 and SH-SY5Y cells were seeded in white walled 96-well plates at $1 \times 10^5$ cells/mL in serum free media. MPE (12.5, 25, and 50 μg/mL) were evaluated for cytotoxicity effects in BV-2 and SH-SY5Y cells. After 24 h, cell viability was determined using Cell Titer Glo 2.0 (CTG; Promega, Madison, WI, USA) according to methods previously reported by our group [14,20]. MPE was then evaluated for its cellular protective effects against several oxidative insults as follows. Cells were pretreated with MPE (12.5, 25, and 50 μg/mL), Resv (20 μM), or solvent control (0.1% DMSO) for either 1 h (in BV-2 cells) or 2 h (in SH-SY5Y cells). Cellular oxidative stress was induced in BV-2 and SH-SY5Y with H$_2$O$_2$ (100 μM), SH-SY5Y with 6-OHDA (25 μM), and MPP$^+$ (2 mM). Cellular viability of BV-2 and SH-SY5Y cells after treatment were determined at 6 and 24 h, respectively, by the aforementioned CTG assay.

Determination of Hydrogen Peroxide (H$_2$O$_2$)-Induced Reactive Oxygen Species (ROS) in Murine Microglia BV-2 Cells

The production of H$_2$O$_2$-induced reactive oxygen species (ROS) in BV-2 cells was determined by a fluorescent probe (DCF-DA) using previously reported method with modifications [22]. BV-2 microglial cells were seeded in a black 96-well plate at $1 \times 10^5$ cells/mL in serum free media. Cells were allowed to attach for 24 h and pretreated with MPE (12.5, 25, and 50 μg/mL), Resv (20 μM), or solvent control (0.1% DMSO) for 1 h. Next, DCF-DA (20 μM) was added to each well and incubated for 25 min. Cells were then washed with PBS and incubated with H$_2$O$_2$ (100 μM) for 6 h. The fluorescence signal of each cell was measured at excitation and emission wavelengths of 495 nm and 529 nm, respectively, using a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, USA).
Measurement of Lipopolysaccharide (LPS)-Induced Nitric Oxide Species (NOS) in Murine Microglia BV-2 Cells

The production of total nitric oxide species (NOS) was determined using the Griess reagent as previously reported by our group [14,20]. BV-2 cells were seeded in clear 24-well plates at $1 \times 10^5$ cells/mL in serum free media. Cells were treated with MPE (12.5, 25, and 50 μg/mL), Resv (20 μM), or solvent control (0.1% DMSO) for 1 h. The cells were exposed to inflammatory stress induced by treating with LPS (1 μg/mL) for 24 h. Next, culture media from each well were transferred to a 96-well plate and measured for total NOS using the Griess reagent kit (Promega, Fitchburg, WI, USA). Absorbance values were recorded using the SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, USA) at 535 nm.

Non-Contact Co-Culture Assay with BV-2 and SH-SY5Y Cells

The non-contact co-culture assay was performed according to protocols previously reported by our group [21]. Briefly, SH-SY5Y cells were seeded in white wall and clear bottom 96-well plates and allowed to adhere for 24 h. BV-2 cells were plated in 24 well plates and treated with MPE (12.5, 25, and 50 μg/mL), Resv (20 μM), or solvent control (0.1% DMSO), followed by LPS (1 μg/mL) treatment for 24 h. Media from each treatment was collected and centrifuged at 15,000 rpm for 10 min. After centrifugation, BV-2 cell supernatant was used to treat SH-SY5Y cells for 24 h. Cellular viability of SH-SY5Y cells was determined using the CTG assay.

1-Methyl-4-Phenylpyridinium (MPP+) Induced Dopaminergic Neurotoxicity in C. elegans

Wild type C. elegans (N2) were maintained on nematode growth media culture plates at 20 °C and age synchronized as previously reported by our group [21]. Then,
40 μL of age synchronized L1 worms washed in S-complete were transferred to a 96-well microplate (approximately 20 worms/well) with *Escherichia coli* OP50 (5 mg/mL), MPP⁺ (750 μM), and MPE (20 or 40 μg/mL) to a final volume of 50 μL. S-complete media was used for control groups. Live worms were counted every 12 h post treatment until no live worms remained.

*D. melanogaster Strains and Maintenance*

Wild type STR-5 flies were obtained from the Bloomington Stock Center (Department of Biology, Indiana University, Bloomington, IN, USA). Strains were reared on Formula 4-24® Instant *Drosophila* Medium (Carolina Biological Supply, Burlington, NC, USA) and reared on Bloomington Formulation (Genesee Scientific, San Diego, CA, USA) at 25 °C with 75% humidity and a 12-hour light/dark cycle [23]. Approximately 40–50 mating pairs were transferred into flasks and allowed to lay eggs. After nine days, newly eclosed male flies were collected over a period of three days and used in further experiments.

*Negative Geotaxis (Climbing) Assay in D. melanogaster*

Newly eclosed wild type (STR-5) male flies were randomly separated into 10 groups of 50 flies each and transferred to control flasks (media only) or in treatment flasks (media + 40 μg/mL MPE). To induce neurotoxicity, every four days, flies were starved in empty vials for 24 h and transferred into vials containing a filter paper saturated with 1 mL of 10% sucrose (blank), 6-OHDA (1 mM), or rotenone (500 μM). After 24 h, the flies were transferred into vials with a fresh supply of their respective diets and used for climbing assay on day 10 post-eclosion. Flies from control and treatment groups were then tapped into the bottom of graduated cylinder (diameter: 2.7 cm, height: 25 cm) superimposed with a ruler and allowed to climb for 10 s. Flies
were photographed (Canon, Inc, Tokyo, JP, EOS 50D; 15.1 MP Digital SLR) at $t_0$ and $t_{10}$ seconds to calculate the climbing distance [24].

**Statistical Analyses**

All data are presented as mean ± standard errors of three separate biological samples. Analyses of cellular data were conducted by analysis of variance (ANOVA) followed by Dunnett's test for multiple comparisons of group means. The Kaplan–Meier method was used to compare the survival curves of *C. elegans* and the survival differences were tested for statistical significance using the log rank test (Mantel Cox). For the *D. melanogaster* climbing assay, Welch's *t*-test was used to compare the different treatment groups and generate *p* values (alpha = 0.05). Significance compared with control group is presented as $p \leq 0.05$ (#), $p \leq 0.001$ (###), and $p \leq 0.0001$ (####). Significance for all tests compared with toxic treatment was defined as follows: $p \leq 0.05$ (*), $p \leq 0.01$ (**), $p \leq 0.001$ (***) and $p \leq 0.0001$ (****). GraphPad Prism software 6.0 (GraphPad Software, Inc., San Diego, CA, USA) was used to calculate statistics for both the in vitro and in vivo analyses.
Results and Discussion

Preparation of Levodopa (L-dopa)-Reduced Mucuna pruriens Extract (MPE)

*Mucuna pruriens* is a medicinal plant that is well known to naturally contain L-dopa (4–7%) [5], which might be attributed to its neuroprotective effects against PD [6]. However, the presence of other phytochemicals in *M. pruriens*, including polyphenols (tannins, flavonoids, gallic acid, phenolic acids), saponins, terpenoids, alkaloids, and fatty acids, have been reported with various pharmacological activities (see Supplementary Materials; Figure S2 and Table S1) [6,25–29]. Recent studies also suggest that phytochemicals apart from L-dopa may also contribute to the overall neuroprotective activities of *M. pruriens* [13,30]. Therefore, in this study, we prepared a *M. pruriens* seed extract (MPE) containing reduced L-dopa levels (<0.1%), which was subsequently evaluated for its neuroprotective effects using a panel of in vitro and in vivo assays. The seeds of *M. pruriens* were extracted/solvent-solvent partitioned in varying solvents to yield extracts, which were evaluated for L-dopa content by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI–MS/MS). As shown in Table 1, the L-dopa levels in the initial methanol *M. pruriens* seeds extract was 28.0%, which was significantly reduced to 0.03% in the ethyl acetate *M. pruriens* extract (MPE). As even this low level (0.03%) of L-dopa could impart biological effects, we evaluated a pure L-dopa solution (<0.1%) in several of the in vitro assays. Our preliminary data showed that the MPE, but not this pure L-dopa was active in these assays (data shown in Supplementary Materials Figures S5 and S6). Therefore, this MPE extract was selected for further evaluation of its neuroprotective effects in a panel of cell-based and in vivo bioassays as described below.
MPE Reduces Hydrogen Peroxide (H₂O₂)-Induced Toxicity and Reactive Oxygen Species (ROS) Production in Microglia BV-2 Cells

Microglia are the native immune cells of the central nervous system (CNS) that undergo activation and proliferation to carry out phagocytosis, release inflammatory cytokines, and produce ROS and reactive nitrogen species (RNS) in response to injury and/or infection. Unresolved inflammation and excessive oxidant production by microglia are lethal to both neuronal and non-neuronal cells in the CNS and have been associated with PD. All of the Mucuna extracts including the crude methanol, hexanes, ethyl acetate (MPE), butanol, and water extracts (at 25 µg/mL) were evaluated for their protective effects against H₂O₂-induced toxicity in BV-2 cells. Our data showed that among the extracts, only the MPE significantly increased the viability of BV-2 cells exposed to H₂O₂ (see Supplementary Materials Figure S3A). Therefore, we evaluated the effects of MPE on oxidative stress induced by H₂O₂ in microglia BV-2 cells. MPE (12.5, 25, and 50 µg/mL) was non-toxic to BV-2 cells with cell viability greater than 90.3% at 24 h (Figure 1A). As shown in Figure 1B, the cell viability of H₂O₂-treated BV-2 cells decreased by 39.2%, as compared with the control group. Although MPE, at concentrations of 12.5, 25, and 50 µg/mL, showed a trend to ameliorate the H₂O₂-induced cytotoxicity in BV-2 cells, only MPE at a concentration of 25 µg/mL significantly increased the cell viability of H₂O₂-treated BV-2 cells, by 18.6%. The protective effects of MPE against the production of ROS by H₂O₂ in BV-2 cells were then evaluated. As shown in Figure 1C, the production of ROS in H₂O₂-treated BV-2 cells was elevated by 3.29-fold as compared with the control cells. MPE (12.5, 25, and 50 µg/mL) reduced the H₂O₂-induced production of ROS by 35.5, 29.1, and 61.6%, respectively, compared with the H₂O₂-treated BV-2 cells. Resveratrol (Resv; 20 µM), used as the positive control, reduced the H₂O₂-induced production of...
ROS by 44.52%. These results are in agreement with our previous observation, wherein an *M. pruriens* water extract increased viabilities of murine BV-2 microglia and differentiated human SH-SY5Y neuronal cells that exposed to H₂O₂ [14]. Moreover, studies from other research groups also reported that *Mucuna* seeds powder (300 mg/kg/BW in diet) reduced oxidative stress in rodent sperm cells [31].

*MPE Reduces Lipopolysaccharide (LPS)-Induced Nitric Oxide Species (NOS) Production in Microglia BV-2 Cells and Protects SH-SY5Y Cells in a Co-Culture Model*

Elevated production of NOS leading to massive neuronal death has been implicated in PD [32]. All of the aforementioned *Mucuna* extracts (at 25 µg/mL) were evaluated for their protective effects against LPS-induced NO production in BV-2 cells. Among the extracts, MPE showed the highest ability to reduce NO production in BV-2 cells exposed to LPS (see Supplementary Materials Figure S3B). Therefore, MPE was evaluated for its protective effects against neuroinflammation induced by LPS in BV-2 cells and in a non-contact co-culture model with SH-SY5Y neuroblastoma cells [21]. As shown in Figure 2A, LPS increased the NOS production in BV-2 cells by 4.46-fold as compared with the control group (control 8.987 µM vs. LPS 40.06 µM). MPE (12.5, 25, and 50 µg/mL) reduced the NOS production in LPS-stimulated BV-2 cells by 8.9, 37.8, and 60.1%, respectively, as compared with the cells treated with LPS alone. Resv (positive control; 20 µM), also reduced the NOS production by 43.2% in the LPS-treated BV-2 cells and was similar to our previous observation [21]. In the non-contact co-culture model (Figure 2B), conditioned media collected from BV-2 cells treated with LPS alone reduced the cell viability of SH-SY5Y cells by 43.1%. The conditioned media from treatment of LPS and MPE (12.5, 25 and 50 µg/mL) significantly increased the cellular viability of SH-SY5Y cells by 19.4,
23.2%, and 40.1%, respectively, as compared with the cells treated with media from LPS-treated BV-2 cells. The positive control, Resv (20 μM), also increased the cell viability of SH-SY5Y cells by 29.3%. Our results support other studies on Mucuna reporting a reduction in nitrite levels induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the nigrostriatal region of Parkinsonian mice brain [33].

MPE Reduces Oxidative Stress Induced Cytotoxicity in SH-SY5Y Cells

Several neurotoxins, including 6-OHDA and MPP, induce oxidative cytotoxicity in dopaminergic neurons by multiple mechanisms and thus are used to model PD [2,34,35]. The protective effects of MPE were evaluated in SH-SY5Y neuroblastoma cells against oxidative stress induced neurotoxicity. MPE (12.5, 25, and 50 μg/mL) did not induce cytotoxicity of SH-SY5Y cells after 24 h incubation (viability >90%) in the CTG assay (Figure 3A). Toxicity was induced in SH-SY5Y neuroblastoma by treatment with 6-OHDA, H₂O₂, and MPP⁺ (25 μM, 100 μM, and 2 mM, respectively). Treatment of 6-OHDA significantly reduced the viability of SH-SY5Y cells by 71.9% as compared with the control group, while MPE (12.5, 25, and 50 μg/mL) reduced 6-OHDA-induced cell death of SH-SY5Y cells by increasing cell viability compared with the 6-OHDA treated group by 11.9%, 38.5%, and 23.9%, respectively (Figure 3B). Treatment of H₂O₂ reduced SH-SY5Y cells viability by 65.1% as compared with control, while MPE (at higher concentrations of 25 and 50 μg/mL) showed moderate protective effects by increasing SH-SY5Y cell viability compared with cell viability of the H₂O₂ treated group by 19.5% and 16.3%, respectively (Figure 3C). MPP⁺ treatment significantly reduced the viability of SH-SY5Y cells by 46.7% as compared with control (Figure 3D); however, MPE showed no protective effects. Our findings obtained from these cellular PD models are in agreement with previously reported neuroprotective effects of Mucuna in neurotoxins-induced PD animal models. For
example, *Mucuna* treatment reduced 6-OHDA-induced L-dopa depletion in nigrostriatal tract of rats with PD symptoms [10,33].

**MPE Reduces Lethality of MPP⁺ Induced Dopaminergic Neurotoxicity in C. elegans**

The neurotoxin, MPTP, is metabolized to MPP⁺ by monoamine oxidase-B and is subsequently taken up by dopaminergic neurons, where it inhibits mitochondrial complex I, resulting in ATP depletion to induce neuronal death [35]. Therefore, we evaluated the effects of MPE against MPP⁺ dopaminergic neurotoxicity in wild type *C. elegans*. The effects of MPE in MPP⁺ induced neurotoxic paralysis and lethality in *C. elegans* were evaluated at concentrations of 20 and 40 μg/mL (IC₁₀ = 42.1 μg/mL). The median and maximum survival of worms after exposure to 750 μM MPP⁺ was 72 h (Table 2).

Treatment of MPP⁺ significantly reduced the median and maximum survival by 3.2-fold (72 h) and 3.5-fold (72 h), respectively, compared with worms in the control group (Figure 4A). MPE at 20 μg/mL significantly increased ($p < 0.001$) the median and maximum survival by 1.3-fold (96 h) and 1.9-fold (138 h), respectively, compared with worms treated with MPP⁺ alone (Figure 4B). MPE at 40 μg/mL significantly increased the mean and maximum survival in *C. elegans* by 1.8-fold (132 h) and 2.25-fold (162 h) respectively, compared with worms treated with MPP⁺ alone (Figure 4C and Table 2).

**MPE Abrogates Chemically Induced Neurotoxicity in D. melanogaster**

Changes in several behavioral phenotypes of *D. melanogaster* in response to genetically or chemically induced neurotoxicity have been exploited extensively to evaluate potential neuroprotective effects of therapeutics [36]. As MPE was significantly more neuroprotective at 40 μg/mL in reducing MPP⁺ induced
dopaminergic neurotoxicity in C. elegans (Figure 4), we used this dosage to determine its effect on climbing behavior (negative geotaxis) in D. melanogaster neurotoxin induced PD model. The two neurotoxins (6-OHDA and rotenone) used in our study induce a PD-like phenotype in D. melanogaster characterized by several behavioral changes including a muted innate negative geotaxis response due to locomotor defects. The aforementioned toxins generally injure dopamine neurons and cause behavioral defects including climbing, which can be measured by negative geotaxis assay. Similar to MPP⁺, rotenone is another mitochondrial complex I inhibitor that causes ATP impairment and ROS production and induces neuronal death [35]. In our study, D. melanogaster were exposed to 6-OHDA and rotenone to induce PD like phenotype. After 10 days, flies exposed to neurotoxins showed a highly muted climbing ability compared with control group. This loss of negative geotaxis ability was significantly ameliorated when flies were pre-treated with MPE.

The median climbing distance in 6-OHDA treated flies and rotenone treated flies was 18.6% (8.7 cm; \( p \leq 0.05 \)) and 37.8% (6.2 cm, \( p \leq 0.001 \)) lower than in control flies (10.95 cm), respectively (Figure 5). Treatment of MPE alone significantly increased the climbing distance in flies by 42.5% (15.9 cm) compared with the control group (Figure 5). Pre-treatment with MPE abrogated the effect of neurotoxins on climbing behavior. In the MPE + 6-OHDA treated flies, the median climbing distance was 54.5% (13.95 cm) higher as compared with flies that were treated with 6-OHDA alone (Figure 5). In the MPE + rotenone treated flies, this was 48.7% (9.9 cm) higher than in flies that were exposed to rotenone only without any MPE pre-treatment (Figure 5). Our results on the neuroprotective effects of MPE on neurotoxin induced PD models using C. elegans and D. melanogaster support previous studies with Mucuna in rodent models of PD using MPTP [33] and 6-OHDA [25] and provide further evidence on the neuroprotective effects of non-L-dopa bioactives in MPE.
Conclusions

In summary, we developed a L-dopa reduced *Mucuna pruriens* extract (MPE) and evaluated its neuroprotective effects in murine microglia BV-2 and neuroblastoma SH-SY5Y cells. MPE treatment decreased BV-2 and SH-SY5Y cytotoxicity induced by oxidative stress and inflammation. In addition, MPE ameliorated dopaminergic neurotoxin-induced lethality in SH-SY5Y (6-OHDA), *C. elegans*, and recovered climbing ability *D. melanogaster* models for PD. Taken the data from the in vitro and in vivo experiments together, MPE showed neuroprotective effects in our PD models. Studies on the anti-PD effects of purified compounds isolated from MPE and their potential mechanism/s of action will be pursued by our group in the future.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/9/1139/s1, Figure S1: LC-ESI-MS/MS spectra for quantifications of L-dopa in Mucuna pruriens extracts, Figure S2: HPLC-DAD chromatograms of Mucuna pruriens extracts, Figure S3: Effects of Mucuna pruriens extracts on the cell viability and LPS-induced NO production in murine BV-2 microglia, Figure S4: Morphology of BV-2 murine microglia treated with H2O2+MPE, H2O2+0.07% L-dopa, LPS+MPE, and LPS+0.07% L-dopa, Figure S5: Effects of MPE and 0.07% L-dopa on H2O2-induced toxicity in murine BV-2 microglia, Figure S6: Effects of MPE and 0.07% L-dopa on LPS-induced NO production in murine BV-2 microglia, Table S1: Chemical constituents of Mucuna pruriens.

Author Contributions: H.M., N.P.S., and D.A.V., conceived and designed the experiments; S.L.J., H.Y.P., and N.A.D., performed the experiments; S.L.J., H.Y.P., H.M., D.A.V., and N.P.S. analyzed the data. D.A.V. and N.P.S. contributed reagents and materials; S.L.J., H.M., H.Y.P., D.A.V., and N.P.S wrote the paper. All authors read and approved the final manuscript.

Funding: This research received no external funding.

Acknowledgments: S.L.J. was supported by a fellowship from the George and Anne Ryan Institute for Neuroscience. Mucuna pruriens seeds were generously provided by Verdure Sciences (Noblesville, IN, USA). Spectroscopic data were obtained from instruments located in the Rhode Island-IDeA Network for Excellence in Biomedical Research core facility supported by Grant # P20GM103430 from the National Institute of General Medical Sciences of the National Institutes of Health.

Conflicts of Interest: The authors declare no conflict of interest.
Table 1. Levodopa (L-dopa) content for each *Mucuna pruriens* seed extracts as determined by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).

| Extract     | Yield (%; w/w) | L-dopa Content (%; w/w) |
|-------------|----------------|-------------------------|
| methanol    | 100            | 28.0                    |
| hexanes     | 3.1            | 0.54                    |
| ethyl acetate| 4.7            | 0.03                    |
| butanol     | 45.3           | 10.05                   |
| water       | 46.9           | 21.39                   |
Figure 1. Effects of *Mucuna Pruriens* Seeds Extract (MPE) (12.5, 25, 50 μg/mL) on cellular viability and reactive oxygen species (ROS) levels in BV-2 cells. Effects on BV-2 cellular viability by MPE alone (A); by MPE after H$_2$O$_2$-induced BV-2 cell toxicity (B); and on ROS levels after BV-2 cell exposure to H$_2$O$_2$ (C). All data expressed as mean ± standard error ($n=3$), significance was reported by analysis of variance (ANOVA) followed with Dunnett multiple comparison testing, as compared with control $p \leq 0.001$ (###), and $p \leq 0.0001$ (####); as compared with toxic agent, $p \leq 0.05$ (*), $p \leq 0.01$ (**), $p \leq 0.001$ (**), and $p \leq 0.0001$ (****). Resv—Resveratrol.
Figure 2. Effects of MPE (12.5, 25, 50 μg/mL) on production of nitric oxide in BV-2 microglia and resulting influence in non-contact co-culture in SH-SY5Y neuroblastoma. Effects on levels of nitric oxide produced in BV-2 induced with lipopolysaccharide (LPS) (A), and on SH-SY5Y cell viability after co-culture with BV-2 LPS-induced media (B). All data expressed as mean ± standard error (n = 3), significance was reported by ANOVA followed with Dunnett multiple comparison testing, as compared with control p ≤ 0.0001 (#####); as compared with toxic agent, p ≤ 0.01 (**), p ≤ 0.001 (***) and p ≤ 0.0001 (****).
Figure 3. Effects of MPE (12.5, 25, and 50 μg/mL) on cellular viability of SH-SY5Y human neuroblastoma cells against toxic models of Parkinson’s disease. Effects of MPE (12.5, 25, and 50 μg/mL) alone on SH-SY5Y cell viability (A), of MPE after 6-OHDA-induced toxicity (B), of MPE against H$_2$O$_2$-induced toxicity (C), and of MPE against MPP$^+$ induced toxicity (D). Data shown as mean ± standard error ($n$ = 3), significance was reported by ANOVA and subsequent Dunnett multiple as compared with control $p \leq 0.001$ (####), and $p \leq 0.0001$ (#####); as compared with toxic agent, $p \leq 0.05$ (*), and $p \leq 0.01$ (**).
Table 2. Survival (median and maximum) of *C. elegans* (N2), as compared with 1-methyl-4-phenylpyridinium (MPP\(^+\)) treatment (750 \(\mu\)M). MPE treatment at both 20 and 40 \(\mu\)g/mL significantly increased survival, as determined by log rank test (Mantel Cox), \(n > 100\), \(p \leq 0.05\) (*), \(p \leq 0.001\) (***)

| Survival (h) | MPP\(^+\) | MPP\(^+\) + MPE (20 \(\mu\)g/mL) | MPP\(^+\) + MPE (40 \(\mu\)g/mL) |
|--------------|-----------|---------------------------------|---------------------------------|
| Median       | 72        | 96 *                            | 138 ***                         |
| Maximum      | 72        | 132 *                           | 162 ***                         |
Figure 4. Effects of MPE (20 and 40 μg/mL) on lifespan of *C. elegans* after MPP⁺ exposure. MPP⁺ at concentration of 750 μM reduces *C. elegans* lifespan, as compared with control group (A). MPE at concentrations 20 μg/mL (B) and 40 μg/mL (C) increase *C. elegans* lifespan, as compared with toxic MPP⁺ exposure (750 μM). Survival curves of *C. elegans* were statistically analyzed by log rank test (Mantel Cox), as compared with MPP⁺ treatment (*n* > 100).
Figure 5. Effects of MPE on negative geotaxis in *Drosophila melanogaster*. Effects of MPE (40 μg/mL) alone on climbing ability, by MPE after 6-OHDA (1 mM) exposure, and on MPE climbing ability after rotenone exposure (500 μM). Significance was determined as compared with control and $p \leq 0.05$ (#) and $p \leq 0.0001$ (####); compared with toxic treatment using Welch’s t-test with three replicates of $n > 40$, $p \leq 0.0001$ (***)
References

1. Abushouk, A.I.; Negida, A.; Ahmed, H.; Abdel-Daim, M.M. Neuroprotective mechanisms of plant extracts against MPTP induced neurotoxicity: Future applications in Parkinson’s disease. *Biomed. Pharmacother.* **2017**, *85*, 635–645, doi:10.1016/j.biopha.2016.11.074.

2. Dexter, D.T.; Jenner, P. Parkinson disease: From pathology to molecular disease mechanisms. *Free Radic. Biol. Med.* **2013**, *62*, 132–144, doi:10.1016/j.freeradbiomed.2013.01.018.

3. Kim, S.W.; Ko, H.S.; Dawson, V.L.; Dawson, T.M. Recent advances in our understanding of Parkinson’s disease. *Drug Discov. Today Dis. Mech.* **2005**, *2*, 427–433, doi:10.1016/j.ddmec.2005.11.015.

4. Tapias, V.; Cannon, J.R.; Greenamyre, J.T. Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson’s disease. *Neurobiol. Aging* **2014**, *35*, 161–169, doi:10.1016/j.neurobiolaging.2013.10.077.

5. Lampariello, L.R.; Cortelazzo, A.; Guerranti, R.; Sticozzi, C.; Valacchi, G. The magic velvet bean of *Mucuna pruriens*. *J. Tradit. Complement. Med.* **2012**, *2*, 331–339, doi:10.1016/S2225-4110(16)30119-5.

6. Natarajan, K.; Narayanan, N.; Ravichandran, N. Review on “Mucuna”—The wonder plant. *Int. J. Pharm. Sci. Rev. Res.* **2012**, *17*, 86–93.

7. Katzenschlager, R.; Evans, A; Manson, A; Patsalos, P.; Ratnaraj, N.; Watt, H.; Timmermann, L.; Van der Giessen, R.; Lees, A *Mucuna pruriens* in Parkinson’s disease: A double blind clinical and pharmacological study. *J. Neurol. Neurosurg. Psychiatry* **2004**, *75*, 1672–1677, doi:10.1136/jnnp.2003.028761.

8. Nagashima, Y.; Kondo, T.; Sakata, M.; Koh, J.; Ito, H. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson’s disease.
disease—In relation to the effects of *Mucuna pruriens*. *J. Neurol. Sci.* 2016, 361, 229–234, doi:10.1016/j.jns.2016.01.005.

9. Cilia, R.; Laguna, J.; Cassani, E.; Cereda, E.; Pozzi, N.G.; Isaias, I.U.; Contin, M.; Barichella, M.; Pezzoli, G. Mucuna pruriens in Parkinson Disease A double-blind, randomized, controlled, crossover study. *Neurology* 2017, 89, 1–7, doi:10.1212/WNL.0000000000004175.

10. Manyam, B.V.; Dhanasekaran, M.; Hare, T.A. Neuroprotective effects of the antiparkinson drug *Mucuna pruriens*. *Phyther. Res.* 2004, 18, 706–712, doi:10.1002/ptr.1514.

11. Kasture, S.; Pontis, S.; Pinna, A.; Schintu, N.; Spina, L.; Longoni, R.; Simola, N.; Ballero, M.; Morelli, M. Assessment of symptomatic and neuroprotective efficacy of *Mucuna pruriens* seed extract in rodent model of Parkinson’s disease. *Neurotox. Res.* 2009, 15, 111–122, doi:10.1007/s12640-009-9011-7.

12. Lieu, C.A.; Kunselman, A.R.; Manyam, B.V.; Venkiteswaran, K.; Subramanian, T. A water extract of *Mucuna pruriens* provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. *Park. Relat. Disord.* 2010, 16, 458–465, doi:10.1016/j.parkreldis.2010.04.015.

13. Poddighe, S.; De Rose, F.; Marotta, R.; Ruffilli, R.; Fanti, M.; Secci, P.P.; Mostallino, M.C.; Setzu, M.D.; Zuncheddu, M.A.; Collu, I.; et al. *Mucuna pruriens* (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 *Drosophila melanogaster* genetic model of Parkinson’s disease. *PLoS ONE* 2014, 9, e110802, doi:10.1371/journal.pone.0110802.

14. Liu, W.; Ma, H.; Dasilva, N.A.; Rose, K.N.; Johnson, S.L.; Zhang, L.; Wan, C.; Dain, J.A.; Seeram, N.P. Development of a neuroprotective potential algorithm for medicinal plants. *Neurochem. Int.* 2016, 100, 164–177, doi:10.1016/j.neuint.2016.09.014.
15. Liu, Y.; Seeram, N.P. Liquid chromatography coupled with time-of-flight tandem mass spectrometry for comprehensive phenolic characterization of pomegranate fruit and flower extracts used as ingredients in botanical dietary supplements. J. Sep. Sci. 2018, doi:10.1002/jssc.201800480.

16. Liu, Y.; Siard, M.; Adams, A.; Keowen, M.L.; Miller, T.K.; Garza, F.; Andrews, F.M.; Seeram, N.P. Simultaneous quantification of free curcuminoids and their metabolites in equine plasma by LC-ESI–MS/MS. J. Pharm. Biomed. Anal. 2018, 154, 31–39, doi:10.1016/j.jpba.2018.03.014.

17. Li, C.; Seeram, N.P. Ultra-fast liquid chromatography coupled with electrospray ionization time-of-flight mass spectrometry for the rapid phenolic profiling of red maple (Acer rubrum) leaves. J. Sep. Sci. 2018, 41, 2331–2346, doi:10.1002/jssc.201800037.

18. Eisenhofer, G.; Brown, S.; Peitzsch, M.; Pelzel, D.; Lattke, P.; Glöckner, S.; Stell, A.; Prejblisz, A.; Fassnacht, M.; Beuschlein, F.; et al. Levodopa therapy in Parkinson’s disease: Influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann. Clin. Biochem. 2014, 51, 38–46, doi:10.1177/0004563213487894.

19. Vilhena, R.O.; Pontes, F.L.; Marson, B.M.; Ribeiro, R.P.; Carvalho, K.A.T. de; Cardoso, M.A.; Pontarolo, R. A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2014, 967, 41–49, doi:10.1016/j.jchromb.2014.06.030.

20. Ma, H.; Johnson, S.L.; Liu, W.; Dasilva, N.A.; Meschwitz, S.; Dain, J.A.; Seeram, N.P. Evaluation of polyphenol anthocyanin-enriched extracts of blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry for free radical...
scavenging, reactive carbonyl species trapping, anti-glycation, anti-β-amyloid aggregation, and microglial neuroprotective effects. *Int. J. Mol. Sci.* 2018, 19, 416, doi:10.3390/ijms19020461.

21. Ma, H.; DaSilva, N.A.; Liu, W.; Nahar, P.P.; Wei, Z.; Liu, Y.; Pham, P.T.; Crews, R.; Vattem, D.A.; Slitt, A.L.; et al. Effects of a standardized phenolic-enriched maple syrup extract on β-amyloid aggregation, neuroinflammation in microglial and neuronal cells, and β-amyloid induced neurotoxicity in *Caenorhabditis elegans*. *Neurochem. Res.* 2016, 41, 2836-2841, doi:10.1007/s11064-016-1998-6.

22. Zhao, L.; Chen, J.; Su, J.; Li, L.; Hu, S.; Li, B.; Zhang, X.; Xu, Z.; Chen, T. In vitro antioxidant and antiproliferative activities of 5-hydroxymethylfurfural. *J. Agric. Food Chem.* 2013, 61, 10604–10611, doi:10.1021/jf403098y.

23. Ormerod, K.G.; LePine, O.K.; Abbineni, P.S.; Bridgeman, J.M.; Coorssen, J.R.; Mercier, A.J.; Tattersall, G.J. *Drosophila* development, physiology, behavior, and lifespan are influenced by altered dietary composition. *Fly (Austin)* 2017, 11, 153–170, doi:10.1080/19336934.2017.1304331.

24. Nichols, C.D.; Becnel, J.; Pandey, U.B. Methods to assay *Drosophila* behavior. *J. Vis. Exp.* 2012, 3–7, doi:10.3791/3795.

25. Kasture, S.; Mohan, M.; Kasture, V. *Mucuna pruriens* seeds in treatment of Parkinson’s disease: Pharmacological review. *Orient. Pharm. Exp. Med.* 2013, 13, 165–174, doi:10.1007/s13596-013-0126-2.

26. Sridhar, K.R.; Bhat, R. Agrobotanical, nutritional and bioactive potential of unconventional legume—*Mucuna*. *Livest. Res. Rural Dev.* 2007, 19:1-31. Available online: [http://www.lrrd.org/lrrd19/9/srid19126.htm](http://www.lrrd.org/lrrd19/9/srid19126.htm) (Accessed on: 03.08.2018)
27. Damodaran, M.; Ramaswamy, R. Isolation of l-3:4-dihydroxyphenylalanine from the seeds of *Mucuna pruriens*. *Biochem. J.* 1937, 31, 2149–2152, doi:10.1042/bj0312149.

28. Misra, L.; Wagner, H. Lipid derivatives from *Mucuna pruriens* seeds. *Indian J. Chem.* 2006, 45, 801–804.

29. Janardhanan, K.; Gurumoorthi, P.; Pugalenthi, M. Nutritional Potential of Five Accessions of a South Indian Tribal Pulse, *Mucuna pruriens* var utilis I. The effect of processing methods on the content of L-Dopa, phytic acid, and oligosaccharides. *Trop. Subtrop. Agroecosystems* 2003, 1, 141–152, doi:10.1016/j.theriogenology.2015.06.019.

30. Lieu, C.A.; Venkiteswaran, K.; Gilmour, T.P.; Rao, A.N.; Petticofer, A.C.; Gilbert, E.V.; Deogaonkar, M.; Manyam, B.V.; Subramanian, T. The antiparkinsonian and antidyskinetic mechanisms of *Mucuna pruriens* in the MPTP-treated nonhuman primate. *Evid. Based Complement Altern. Med.* 2012, 2012, doi:10.1155/2012/840247.

31. Singh, A.P.; Sarkar, S.; Tripathi, M.; Rajender, S. *Mucuna pruriens* and its major constituent L-DOPA recover spermatogenic loss by combating ROS, loss of mitochondrial membrane potential and apoptosis. *PLoS ONE* 2013, 8, e54655, doi:10.1371/journal.pone.0054655.

32. Yuste, J.E.; Tarragon, E.; Campuzano, C.M.; Ros-Bernal, F. Implications of glial nitric oxide in neurodegenerative diseases. *Front. Cell. Neurosci.* 2015, 9, 1–13, doi:10.3389/fncel.2015.00322.

33. Yadav, S.K.; Prakash, J.; Chouhan, S.; Westfall, S.; Verma, M.; Singh, T.D.; Singh, S.P. Comparison of the neuroprotective potential of *Mucuna pruriens* seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
induced PD mice model. *Neurochem. Int.* **2014**, *65*, 1–13, doi:10.1016/j.neuint.2013.12.001.

34. Shimohama, S.; Sawada, H.; Kitamura, Y.; Taniguchi, T. Disease model: Parkinson’s disease. *Trends Mol. Med.* **2003**, *9*, 360–365, doi:10.1016/S1471-4914(03)00117-5.

35. Dauer, W.; Przedborski, S. Parkinson’s Disease: Mechanisms and Models. *Neuron* **2003**, *39*, 889–909, doi:10.1016/S0896-6273(03)00568-3.

36. Muñoz-Soriano, V.; Paricio, N. Drosophila models of Parkinson’s disease: Discovering relevant pathways and novel therapeutic strategies. *Parkinsons. Dis.* **2011**, *2011*, 520640, doi:10.4061/2011/520640
CHAPTER 1
MANUSCRIPT 2

Submitted: 4 November 2019

Chemistry of Natural Products

Isolation and identification of compounds from *Mucuna pruriens* seeds

Shelby L. Johnson $^{1,2\dagger}$, Yu Lu $^{3\dagger}$, Hang Ma $^{1,2}$, Navindra P. Seeram $^{1,2\ast}$, and Tao Yuan$^{3\ast}$

Affiliations:

1. Bioactive Botanical Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA
2. George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA
3. The Laboratory of Effective Substances of Jiangxi Genuine Medicinal Materials, College of Life Sciences, Jiangxi Normal University, Nanchang 330022 China

$\dagger$Equal contribution

*Corresponding authors: nseeram@uri.edu; yuantao@ms.xjb.ac.cn
Abstract

*Mucuna pruriens*, known to naturally contain levodopa, is used as a traditional medicine in Ayurveda to treat symptoms of Parkinson’s disease (PD). Our group has previously reported that a levodopa-reduced *M. pruriens* ethyl acetate (MPEA) seed extract showed neuroprotective effects against PD in several *in vitro* and *in vivo* models but its chemical constituents remain unknown. Herein, a phytochemical investigation of MPEA led to the isolation and identification of phaseic acid (1), cis- and trans-dihydrophaseic acid (2 and 3), gancidin W (4), maculosin (5), levodopa (6), 2,6-dihydroxybenzoic acid (7), and protocatechuic acid (8). All of the compounds, apart from levodopa, are being reported from *Mucuna pruriens* for the first time. Compounds 3-8 were evaluated for their neuroprotective effects in human SH-SY5Y neuroblastoma cells.

**Keywords:** *Mucuna pruriens*, Parkinson’s disease, neuroprotection, levodopa
Body

*Mucuna pruriens* L., belonging to the family Fabaceae, and commonly known as Mucuna or velvet bean, is a medicinal plant which naturally contains levodopa [1]. The seeds of this medicinal plant have been used traditionally to treat brain disorders associated with Parkinson’s disease (PD) in the Indian traditional system of medicine, Ayurveda. Although levodopa is believed to be the major constituent in Mucuna responsible for its neuroprotective effects against PD symptoms [1,2], increasing evidence suggests that other phytochemicals may also contribute to the anti-PD effects of this natural product [3–5].

Our group has previously reported that a levodopa-reduced *M. pruriens* ethyl acetate (MPEA) seeds extract showed neuroprotective effects against PD in several *in vitro* and *in vivo* models including murine BV-2 microglia and human SH-SY5Y neuroblastoma cells, *Caenorhabditis elegans*, and *Drosophila melanogaster* [6]. However, the phytochemical constituents of this MPEA remain unknown. Herein, we report the isolation and identification of eight compounds from this MPEA including phaseic acid (1) [7], cis-dihydrophaseic acid (2) [7], trans-dihydrophaesic acid (3) [7], gancidin W (4)[8], maculosin (5) [9], levodopa (6) [10], 2,6-dihydroxybenzoic acid (7) [11], and protocatechuic acid (8) [11]. While levodopa (6) has been previously reported from *Mucuna pruriens* [12], this is the first report of the isolation and identification of compounds 1-5, 7, and 8 from *M. pruriens*.

Due to limited quantities, only isolates 3-8 (at non-toxic concentrations of 10 and 20 μM) were evaluated for their neuroprotective effects in human neuroblastoma SH-SY5Y cells. The SH-SY5Y cells were pretreated with compounds 3-8 for 1 h after which neurotoxicity was induced with known neurotoxic agents, 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP⁺). Although MPEA was previously
reported to show anti-PD effects in several *in vitro* and *in vivo* PD models [6], the purified isolates alone (at these test concentrations) were not effective in the SH-SY5Y cells. It is possible that the complex matrix of constituents present *in toto* in MPEA may exert their neuroprotective effects in an additive, synergistic and/or complementary manner. However, further studies would be required to confirm this which will be pursued by our group in the future. In summary, the isolation and identification of eight phytochemicals from a *M. pruriens* ethyl acetate seeds extract are reported here. Also, this is the first report of compounds 1-5, 7, and 8 from *M. pruriens*. 
Experimental

General Experimental

The $^1$H and $^{13}$C nuclear magnetic resonance spectroscopic experiments were conducted on a Varian 400 MHz instrument. Deuterated methanol (CD$_3$OD) was used as solvent for the NMR experiments. Solvents were either ACS or HPLC grade purchased from Tansoole (Shanghai, China) or Sigma-Aldrich (St. Louis, MO, USA). Column chromatographic experiments were conducted on a C18 column with reverse-phased silica gel (12 nm, S-50 µm, YMC) and pre-coated silica gel GF254 plates (Qingdao Marine Chemical Plant, Qingdao, People’s Republic of China).

Plant Material

*Mucuna pruriens* seeds were kindly provided by Verdure Sciences (Noblesville, IN, USA) and voucher specimen (No. PHPL/HB/013) are deposited in the Heber Youngken Herbarium and Greenhouse at the College of Pharmacy, the University of Rhode Island, RI, USA.

Extraction and Isolation

*M. pruriens* seeds were extracted with methanol to obtain a crude extract. The crude extract was suspended in distilled water and successively partitioned with petroleum ether, ethyl acetate, and *n*-butanol for 3 times to afford corresponding extract after solvent removal. The ethyl acetate extract was subjected to a silica gel column and eluted with dichloromethane and methanol (10:1, 8:1, 6:1, 4:1, 2:1, and 1:1; v/v) to obtain 6 fractions (Fr 1-6). Fraction 1 was purified by LH20 column to afford 7 fractions. Fraction 1 was purified by a C18 ODS column chromatography to obtain sub-fractions (Fr 1A1-1A7). Fraction 1A2 was further purified by reversed-phase semi-preparative HPLC with MeOH/0.1 % aqueous TFA (40:60; v/v) to afford compounds 4 and 2 (Rt = 12 and 14 min, respectively). Fraction 3 was purified by semi-preparative HPLC with MeOH/0.1 % aqueous TFA (20:80 – 16:84; v/v) to afford
compound 5 (Rt = 14.3 min). Fraction 2 was separated by LH20 column to afford 8 subfractions (Fr2A1-2A8). Fraction 2A2 was purified by HPLC with MeOH/0.1 % aqueous TFA (30:70 – 43:57; v/v) to obtain compounds 3 and 1 (Rt = 12.5 and 14.1 min, respectively). Fraction 2A6 was purified by HPLC with MeOH/0.1 % aqueous TFA (11:89 – 37.8:62.2; v/v) to obtain compounds 6, 7, and 8 (Rt = 10.3, 15.5, and 23.6 min, respectively).

Cell Culture

Human neuroblastoma (SH-SY5Y) cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained as previously described [6]. Compounds were dissolved in DMSO to achieve stock solutions (10 mM) and were further diluted to desired concentrations in serum free media for cell treatments. Cell viability was evaluated after 24 h of treatment of test compounds using a Cell Titer Glo 2.0 (CTG; Promega, Madison, WI, USA) assay. The neuroprotective effects of selected test compounds (at 10 and 20 µM) were evaluated against neurotoxic agents including 6-hydroxydopamine (6-OHDA; 25 µM), and 1-methyl-4-phenylpyridinium (MPP⁺; 2 mM) using a previously described method [6].
Acknowledgments

Spectroscopic data were acquired from instruments located at the University of Rhode Island in the RI-INBRE core facility obtained from Grant # P20GM103430 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). S.J. was supported by a fellowship from the George and Anne Ryan Institute for Neuroscience.
Figure 1: Chemical structures of compounds 1-8 from *Mucuna pruriens* ethyl acetate (MPEA) seeds extract.
Figure 2: Evaluation of single isolated compounds in human neuroblastoma (SH-SY5Y). Cell viability of each compound was assessed after 24h (A), exposure to 6-OHDA (B) and exposure to MPP⁺ (C). All data expressed as mean ± standard error (n = 4), significance reported by analysis of variance (ANOVA) followed by Dunnett multiple comparison tests, as compared to toxic agent p ≤ 0.0001 (****).
Table 1: NMR of isolated compounds were compared to published literature to confirm structure and name of compounds.

| Compound Number | Compound Name                  | Publication |
|-----------------|--------------------------------|-------------|
| 1               | Phaseic acid                   | [7]         |
| 2               | Cis-dihydrophaseic acid        | [7]         |
| 3               | Trans-dihydrophaesic acid      | [7]         |
| 4               | Gancidin W                     | [8]         |
| 5               | Maculosin                      | [9]         |
| 6               | Levodopa                       | [10]        |
| 7               | 2,6-Dihydroxybenzoic acid      | [11]        |
| 8               | Protocatechuic acid            | [11]        |
References

1. L.R. Lampariello, A. Cortelazzo, R. Guerranti, C. Sticozzi, and G. Valacchi, J. Tradit. Complement. Med., 2, 331 (2012).

2. S. Kasture, M. Mohan, and V. Kasture, Orient. Pharm. Exp. Med., 13, 165 (2013).

3. C.A. Lieu, A.R. Kuselman, B.V. Manyam, K. Venkiteswaran, and T. Subramanian, Park. Relat. Disord. 16, 458 (2010).

4. C.A. Lieu, K. Venkiteswaran, T.P. Gilmour, A.N. Rao, A.C. Petticoffer, E.V. Gilbert, M. Deogaonkar, B.V. Manyam, and T. Subramanian, Evidence-based Complement. Altern. Med, (2012).

5. S. Poddighe, F. De Rose, R. Marotta, R. Ruffilli, M. Fanti, P.P. Secci, M.C. Mostallino, M.D. Setzu, M.A. Zuncheddu, I. Collu, P. Solla, F. Marrosu, S. Kasture, E. Acquas, and A. Liscia, PLoS One, 9, (2014).

6. S.L. Johnson, H.Y. Park, N.A. Dasilva, D.A. Vattem, H. Ma, and N.P. Seeram, Nutrients, 10, (2018).

7. B.V. Milborrow, Phytochemistry, 14, 1045 (1975).

8. N.M. Zin, M.S. Baba, A.H. Zainal-Abidin, J. Latip, N.W. Mazlan, and R. Edrada-Ebel, Drug Des. Devel. Ther., 11, 351 (2017).

9. A.C. Stierle, J.H. Cardellina, and G.A. Strobel, Proc. Natl. Acad. Sci., 85, 8008 (1988).

10. Z. Talebpour, S. Haghgoo, and M. Shamsipur, Anal. Chim. Acta, 506, 97 (2004).

11. N. Syafni, D.P. Putra, and D. Arbain, Indones. J. Chem., 12, 273 (2012).

12. M. Damodaran, and R. Ramaswamy, Biochem. J., 31, (1937).
CHAPTER 2
MANUSCRIPT 3
Published: 19 April 2019

Metabolites 2019, 9, 78; doi:10.3390/metabo9040078

Polyphenol Microbial Metabolites Exhibit Gut and Blood–Brain Barrier Permeability and Protect Murine Microglia against LPS-Induced Inflammation

Shelby L. Johnson 1,2, Riley D. Kirk 2, Nicholas A. DaSilva 2, Hang Ma 1,2, Navindra P. Seeram 1,2,* and Matthew J. Bertin 2,*

Affiliations:
1 George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA; shelby_johnson@uri.edu (S.L.J.); Hang_ma@uri.edu (H.M.)
2 Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA; rileykirk@uri.edu (R.D.K.); nickdasilva91@gmail.com (N.A.D.)

* Correspondence: nseeram@uri.edu (N.P.S.); mbertin@uri.edu (M.J.B.); Tel. 401-874-9367 (N.P.S.); Tel.: 401-874-5016 (M.J.B.)
Abstract

Increasing evidence supports the beneficial effects of polyphenol-rich diets, including the traditional Mediterranean diet, for the management of cardiovascular disease, obesity and neurodegenerative diseases. However, a common concern when discussing the protective effects of polyphenol-rich diets against diseases is whether these compounds are present in systemic circulation in their intact/parent forms in order to exert their beneficial effects in vivo. Here, we explore two common classes of dietary polyphenols, namely isoflavones and lignans, and their gut microbial-derived metabolites for gut and blood–brain barrier predicted permeability, as well as protection against neuroinflammatory stimuli in murine BV-2 microglia. Polyphenol microbial metabolites (PMMs) generally showed greater permeability through artificial gut and blood–brain barriers compared to their parent compounds. The parent polyphenols and their corresponding PMMs were evaluated for protective effects against lipopolysaccharide-induced inflammation in BV-2 microglia. The lignan-derived PMMs, equol and enterodiol, exhibited protective effects against nitric oxide production, as well as against pro-inflammatory cytokines (IL-6 and TNF-α) in BV-2 microglia. Therefore, PMMs may contribute, in large part, to the beneficial effects attributed to polyphenol-rich diets, further supporting the important role of gut microbiota in human health and disease prevention.

Keywords: polyphenol; gut microbial metabolites; permeability; equol; enterodiol; enterolactone; inflammation
Introduction

In the United States, obesity is a growing epidemic. There have been many studies that link obesity to an increased risk of developing other diseases, such as cardiovascular disease, diabetes, and Alzheimer’s disease [1]. A quantitative systematic review estimated that the United States spent $113.9 billion dollars total, or 4.8% of all healthcare spending in 2008 on overweight and obesity care [2]. The standard American diet consisting of high levels of saturated fat, sodium and sugars, contributes to these staggering obesity numbers [3]. People abiding by alternative diets in countries such as Greece and Italy exhibit decreased risks of obesity as well as confounding diseases such as metabolic syndrome [4].

Increasing evidence supports the beneficial effects of a traditional Mediterranean diet in the management of cardiovascular disease, obesity and most recently, neurodegenerative diseases [5]. The Mediterranean diet is characterized by high intake of polyphenols and unsaturated fats, with most of the beneficial effects from this diet being attributed to the high polyphenol intake [6,7]. There has been an increased interest in polyphenols for the treatment of neurodegenerative diseases as they exhibit the ability to cross the blood–brain barrier (BBB) and have a wide range of bioactive properties including antioxidant, anti-inflammatory, anti-apoptotic and lipid-lowering properties [8,9].

Polyphenols are a large class of secondary metabolites produced via the shikimate-derived phenylpropanoid or polyketide pathways, and they are characterized by the presence of two or more benzene rings bearing hydroxyl group(s) and lack any nitrogenous functional group in their core structure [10]. Polyphenols are further divided into several subclasses including stilbenes, flavonoids, lignans, and phenolic acids [11]. Although polyphenols exhibit biological effects in a variety of assays, their poor bioavailability, extensive phase-2 metabolism,
and whether they achieve physiologically relevant concentrations as their intact/parent forms to exert their protective effects, have been questioned. Rather, a growing consensus is that dietary polyphenols are metabolized by microbiota in the colon to yield bioactive gut microbial metabolites [12–16]. Herein, two common classes of dietary polyphenols were investigated, isoflavones and lignans, as well as their known polyphenol microbial metabolites (PMMs).

The isoflavones, genistein (GEN) and daidzein (DAI), are two soy-derived polyphenols that have been extensively studied for their bioactivities. Structurally similar to estrogen, isoflavones are comprised of a 3-phenylchromen-4-one backbone, modified by glycosides, O-substituents, and prenylated derivatives [17]. They exhibit the ability to serve as antioxidants, alleviate oxidative stress, and reduce the risk of hormone-dependent cancers [18–20]. GEN has been identified as a potential nutraceutical for Alzheimer’s disease as it exhibits the ability to inhibit mitochondria-dependent apoptosis, and alleviate β-amyloid neurotoxicity, providing neuroprotection [21–23]. DAI also shows pro-apoptotic and neurotoxic effects against glutamate treatment in mouse hippocampal and cerebral cell cultures [24]. When metabolized in the gut by intestinal microflora, these isoflavones are converted into equol (EQ) (Figure 1) [25]. EQ has exhibited bioactive properties in cardiovascular disease, bone health, and cancers [26]. A recent study identified EQ as protective against oxidative stress in microglia, through the downregulation of neuronal apoptosis, and increased neurite growth [14].

Lignans often have complex structures made up of C6 and C3 units [27]. In plant tissues, lignans are often found as dimers and can be in the free state or sugar bound [28]. Data suggests a lignan-rich diet has numerous benefits such as prevention of hormone-dependent tumors, decrease in plasma cholesterol and glucose profiles, and delaying type 2 diabetes [29–31]. The common and prototypical dietary lignan,
secoisolariciresinol (SECO), is known to be deglycosylated by bacteria and converted to the PMMs enterodiol (ED) and enterolactone (EL) (Figure 1) [32].

A common question regarding dietary polyphenols is whether they are present in systemic circulation in physiologically relevant concentrations to exert their biological effects. Polyphenol concentrations in the blood generally range from 0.1–1.0 μM [33]. However, certain phenolic metabolites such as pyrogallol sulfate and catechol sulfate reached plasma concentrations ranging from 5–20 μM, while their parent compounds were undetected [34]. Absorption through the GI tract is complex as the pH changes as compounds traverse through the stomach to the intestines, which changes the bioavailability of substances [35]. The high-throughput parallel artificial membrane permeability assay (PAMPA) is used to determine permeability properties related to the transcellular in vivo absorption process of large compound libraries [36]. PAMPA has become a robust, versatile method for predicting passive permeability of compounds through the gastrointestinal (GI) track, the BBB, and skin [37,38]. A major concern for the development of pharmaceuticals for CNS-related diseases is the ability of compounds to cross the BBB, therefore it is of high importance to evaluate this ability early in drug discovery [39]. The BBB is a lining of endothelial cells that protects the brain from the peripheral nervous system [40]. PAMPA uses a combination of phospholipids specific to the membrane being tested along with a microfiber filter to simulate the biological membrane [41].

Herein, we propose that certain PMMs derived from gut microflora metabolism of their parent polyphenols are gut and BBB permeable and may provide protection against neuroinflammatory stress. To explore this hypothesis, we first performed in silico screening for gut and BBB permeability and then PAMPA of the parent polyphenols and their respective PMMs. Neuroprotective activity for all of the compounds was then assessed by evaluating the levels of nitric oxide species (NOS)
and inflammatory cytokines against LPS-induced inflammation in BV-2 murine microglia.
Materials and Methods

Compounds and Chemicals

Dimethylsulfoxide (DMSO) and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Daidzein (DAI), (±) enterodiol (ED) (Cat# 45198-5MG-F), (±) enterolactone (EL) (Cat# 45199-1MG-F), genistein (GEN) and (±) secoisolariciresinol (SECO) (Cat# 60372-5MG-F) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). S-Equol was purchased from Chembest (Shanghai, China). Antipyrine, corticosterone, ketoprofen, ranitidine, theophylline and verapamil were purchased as PAMPA controls from Pion, Inc (Billerica, MA, USA).

In Silico ADME Predictors

The in silico tool SwissADME was used as a measure to predict BBB and gut permeability. Predicted permeability was assessed for each individual compound and control, as previously explained [56].

Parallel Artificial Membrane Permeability Assay (PAMPA)

Parallel Artificial Membrane Permeability Assay was performed to analyze both blood–brain barrier (BBB) and gut passive permeability. All materials for PAMPA were purchased from Pion, Inc (Billerica, MA, USA). Both the gut and BBB assays were performed according to the manufacturer’s instructions. Briefly, test compounds and standards were prepared at 10 mM concentrations in DMSO. For the gut assay, Prisma HT buffer was adjusted to pHs 5, 6.2, and 7.4 by adding 0.5 M NaOH. In the deepwell plate provided by Pion, 1 mL of each pH-adjusted buffer was added to separate wells. For each pH, 5 µL of the sample was added to the 1 mL of buffer then mixed thoroughly with a pipette, diluting the sample to a final concentration of 50 µM.
Next, 200 µl of the diluted sample was added to the donor (bottom) plate from the Pion sandwich assay, 5 µL of GIT lipid matrix was added to the membrane on the bottom of the acceptor plate, and 200 µL of acceptor sink buffer was added in each well of the acceptor plate. The sandwich was assembled, and the plate incubated at room temperature for 4 h undisturbed. In BBB assays, compounds (10 mM) were diluted to final concentrations of 50 µM in Prisma HT Buffer (pH = 7.4). The PAMPA sandwich was created with the donor (bottom), BBB artificial membrane, and brain sink buffer as the acceptor (top). The assay was performed for 1 h at room temperature with shaking (60 µm) using the manufacturer-supplied GIT Box. After incubation, the UV profiles of the donor and acceptor plates were read on the SpectraMax plate reader connected to the PAMPA software. PAMPA software calculated the –log Pε values for each compound and standard using the UV profiles of the donor and acceptor plates. Standards were all within 0.25 units of the expected value provided by PAMPA and each sample was averaged with 4 replicates.

Cell Culture Conditions

Murine microglia (BV-2) were generously provided by Dr. Grace Sun of the University of Missouri at Columbia. Cells were maintained in DMEM/F12 (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% (v/v) sterile filtered and heat inactivated Fetal Bovine Serum in addition to 1% (v/v) Penicillin/Streptomycin Antibiotic Solution (Life Technologies, Gaithersburg, MD, USA). Cells were incubated at approximately 65% relative humidity at 37 °C under atmospheric oxygen and 5% CO2. Cells were passaged using Trypsin-EDTA (Life Technologies, Gaithersburg, MD USA), enumerated, and checked for viability using Trypan blue (Sigma Aldrich, St. Louis, MO, USA) dye exclusion. DMSO (Sigma
Aldrich, St. Louis, MO, USA) was used to dissolve compounds and did not exceed 0.1% when incubated with cells.

**Cell Viability**

The cytotoxicity of each compound was determined in BV-2. Briefly, cells were seeded in 96 white-walled, clear bottom plates at 100,000 cells/mL. Cells were allowed to adhere for 24 h. Compounds were prepared to 10 mM in DMSO, then diluted in serum-free media to yield concentrations of 20 and 10 μM. Cells were treated with prepared concentrations of each compound for 24 h. Cellular viability was determined as a percentage of control (DMSO) by Cell Titer Glo 2.0 (CTG; Promega, Madison, WI, USA), read for luminescence on the SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, USA).

**LPS Stimulation of Murine Microglia BV-2 Cells**

As previously published, BV-2 cells were seeded at a density of 100,000 cells/mL in 24-well plates [57]. After reaching a confluency of 85%, cells were exposed to either DMSO, SECO (10 μM), ED (10 μM), EL (10 μM), GEN (20, 10 μM), DAI (20, 10 μM), or EQ (20, 10 μM), for 1 h prior to incubation of LPS (1 μg/mL) for 23 h. Media were collected, aliquoted for nitric oxide and cytokine analysis.

**Quantification of Nitric Oxide**

Nitric Oxide (NO) was detected in BV-2 culture media following the stimulation of LPS for 24 h from the previously described experiment by way of the Griess Assay (Promega, Madison WI), according to the manufacturer’s protocol.

**Measurement of IL-6 and TNF-α**
IL-6 and TNF-α were measured from BV-2 media using Enzyme Linked Immunosorbent Assay (ELISA) provided by Biolegend (San Diego, CA, USA) [57].

**Statistical Analysis**

All data are reported as mean ± standard errors of at least three independent biological samples. The analysis of all cellular data was conducted by ANOVA followed by Dunnett’s test or Tukey’s test for multiple comparisons of group means. The significance of the toxic agent compared to the control group is presented as \( p \leq 0.001 \) (###) and \( p \leq 0.0001 \) (####). The significance for tests compared to toxic treatment was defined as: \( p \leq 0.03 \) (*), \( p \leq 0.002 \) (**), \( p \leq 0.0002 \) (***), and \( p \leq 0.0001 \) (****). GraphPad Prism software 7.0 (GraphPad Software, Inc., San Diego, CA, USA) was used for all statistical analysis calculations and graphical representations.
Results

SwissADME Predicts Polyphenol Microbial Metabolites Are Highly Gut and BBB Permeable

Utilizing SwissADME in silico modeling, BBB and gut permeability were predicted (Table 1). All six of the compounds (parent polyphenols and their corresponding PMMs; Figure 1) were identified as having high gut absorbance. The positive PAMPA gut controls, verapamil, ranitidine, ketoprofen and antipyrine, all exhibited high gut permeability in the SwissADME predictor. ED, DAI and EQ were predicted to have BBB permeability. The PAMPA BBB controls, both BBB permeable and impermeable, were additionally screened in SwissADME, predicting passive permeability for verapamil and corticosterone, but no BBB passive permeability by theophylline. After this predictive measure, compounds were experimentally evaluated for passive permeability in the gut and BBB.

SECO, GEN, DAI, EL, and EQ Exhibit High Permeability through PAMPA Gut

Compounds were evaluated for their permeability through simulation membranes of the gut using PAMPA at pHs 5.0, 6.2, and 7.4 (Figure 2). Verapamil was used as the highly permeable control, ranitidine as the low permeability, and antipyrine was used as an intermediate control. Ketoprofen was used as a pH-dependent control. At pH 5, EL showed the highest permeability with a -log $P_e$ value of 4.27 ± 0.05, closely followed by EQ at 4.35 ± 0.11. At pH 6.2, EQ showed the highest permeability with a -log $P_e$ value of 4.20 ± 0.02 followed by EL at 4.37 ± 0.02. At pH 7.4, the same trend followed as pH 6.2. SECO showed moderate permeability at all pHs tested, and DAI was most permeable at pHs 5 and 6.2. Parent compounds showed high permeability
in all three pH treatments, while the metabolite ED showed the lowest permeability of all test compounds in all three pH treatments tested (Figure 2).

**GEN, EL, and EQ Show BBB Passive Permeability in PAMPA Assay**

Isoflavones and lignans were evaluated for BBB penetration through PAMPA experiments (Figure 3). Verapamil, corticosterone and theophylline were controls for high, intermediate and low permeability, respectively, and yielded similar permeability measures as previously reported [35,39]. EL and EQ exhibited high permeability, with \(-\log P_e\) values of 3.97 ± 0.14 and 3.52 ± 0.20, respectively. Intermediate BBB permeability was seen for both GEN and DAI, with \(-\log P_e\) values of 4.26 ± 0.16 and 4.53 ± 0.13, respectively. SECO and ED exhibited low permeability through the BBB.

**Isoflavones and Lignans Show No Cytotoxicity in Murine Microglia**

Isoflavones were administered at 20 μM, while lignans were dosed at 10 μM. Parent polyphenols and PMMs were evaluated for cytotoxicity in murine microglia after a 24 h incubation period (Figure 4A,5A). There were no significant reductions in cellular viability at each of the test concentrations, thus indicating nontoxic levels.

**Isoflavones Reduce NOS Production**

Isoflavones were evaluated for their ability to reduce nitric oxide production after LPS induction, as determined by the Griess Reagent (Figure 4B). Cells treated with LPS produced 41.5 ± 5.6 μM NOS, significantly more than the control (0.4 ± 0.02 μM). GEN significantly reduced nitric oxide at both 20 and 10 μM by 68% and 38%, respectively as compared to LPS alone. At 20 μM, DAI and EQ also significantly reduced nitric oxide compared to LPS by 24 and 22%, respectively.

**Isoflavones Reduce Pro-Inflammatory Cytokine Release**
TNF-α was increased significantly to 687.7 ± 8.0 pg/mL after LPS stimulation, compared to the unstimulated control, 115.4 ± 2.8 pg/mL (Figure 4C). All three isoflavones significantly reduced TNF-α production compared to the LPS-induced treatment. GEN reduced TNF-α, by 29.1% and 16.6% at concentrations of 20 and 10 μM, respectively. DAI and EQ exhibited similar, albeit less potent, protective abilities at both the high (20 μM) and low (10 μM) concentrations (Figure 4C). IL-6 production was significantly increased by LPS (103.7 ± 3.6 pg/mL) compared to the control (0.6 ± 0.05 pg/mL) (Figure 4D). All isoflavones were able to significantly reduce IL-6 production compared to the LPS-induced treatment. GEN was the most effective, reducing IL-6 production by 80.4 and 34.0% at 20 and 10 μM, respectively (Figure 4D).

ANOVA followed by Tukey’s post hoc test was used to determine significant differences amongst test compounds and anti-inflammatory potential. The 20 μM dose of GEN resulted in significantly reduced concentrations of NOS, TNF-α, and IL-6 compared to all other test compounds and concentrations (Tables S1–S3 in supplementary files), clearly showing GEN as the most potent anti-inflammatory metabolite of the isoflavones and PMMs tested.

*Lignans Limit NOS Production*

Nitric oxide concentrations for vehicle-treated microglia were approximately 11.97 μM ± 0.07, whereas LPS stimulation increased this concentration to 51.01 μM ± 1.23. SECO, ED and EL decreased nitric oxide release by approximately 9.13 (46.35 μM ± 0.22), 8.54 (46.65 μM ± 0.36) and 30.07% (35.67 μM ± 0.74), respectively (Figure 5B).

*SECO, ED and EL Significantly Reduce IL-6 and TNF-α*
As expected, IL-6 and TNF-α concentrations were elevated in LPS-treated microglia with concentrations of 665.7 pg/mL ± 5.8, and 518.4 pg/mL ± 8.8, respectively (Figure 5C, 5D). IL-6 concentration decreased by 1.05% (672.8 pg/mL ±13.9) in samples treated with SECO. ED and EL pre-treated conditions decreased the release of IL-6 by approximately 3.74% (690.6 pg/mL ± 5.30) and 26.41% (489.9 pg/mL ± 11.31), respectively. With respect to TNF-α, SECO, ED and EL reduced cytokine release by 3.97% (497.8 pg/mL ± 12.42), 0.5% (515.8 pg/mL ± 7.12) and 29.47% (365.6 pg/mL ± 4.91), respectively. Like GEN above, EL showed significantly greater reduction of inflammatory cytokines when compared to SECO and EL (Tables S4-S6).
Discussion

The overall health of humans and communities depends on many factors including genetics, various environmental factors, and diet. Increased adherence to the Mediterranean diet was recently correlated with a reduced risk of neurodegenerative diseases, including prodromal Parkinson’s disease [5,42]. In this report, we sought to explore two common classes of polyphenols found in the Mediterranean diet, namely isoflavones and lignans, to investigate the bioavailability and bioactivity of these compounds and their metabolites.

Previously published literature suggests that for polyphenols to be bioactive, they must first be transformed in the colon by the gut microbiota into molecularly unique metabolites [16]. Compounds which are permeable through the gut mucosa enter the bloodstream and circulate in the body. The in vivo permeability may change if these substances are compatible with active transporters, as well as differences based on the individual’s GI environment and diet [43]. A number of factors contribute to the absorption ability of a compound, namely, physicochemical (e.g., pKa, solubility, polarity), physiological (e.g., GI pH, GI blood flow), and dosage form (e.g., tablet, capsule) [44].

To investigate the role of lignans, isoflavones, and PMMs in systemic circulation, we explored gut permeability through in silico (SwissADME) and in vitro (PAMPA) models. Gut PAMPA results largely coincided with those of in silico predictions and showed that the test compounds, with the exception of ED, passively permeate the gut. The presence of O-methyls on SECO and lactone moiety on EL may provide these molecules with additional lipophilicity needed to cross the membrane (Figure 1), whereas ED contains free hydroxyl groups, which may reduce passive permeability. These data are supported by previously published results such as the
evaluation of GI absorption of alkaloids from Coptis [45]. PAMPA is a useful tool for predicting a compound’s permeability through the human gut, however, it only considers the rate of passive transport [36].

The BBB serves as a protective barrier of the brain, comprised of endothelial cells that create tight junctions, allowing for extremely selective passive permeability [40]. This typically results in higher penetrability by lipophilic compounds through the BBB [46]. Compounds that pass through the BBB may influence the brain state and physiology. We sought to identify if the aforementioned isoflavones, lignans, and PMMs can passively cross the BBB and could be relevant in modulating the pathogenic features of neurodegenerative diseases.

Computational predictive software, SwissADME, identified EL, DAI and EQ as BBB-penetrable molecules. Interestingly, neither GEN nor SECO were considered permeable. Furthermore, our PAMPA in vitro study supported these results, reporting high permeability of EL and EQ. SECO and ED exhibited no apparent permeability. The parent compounds of isoflavones, GEN and DAI, were identified as intermediate permeable compounds. Similar investigative strategies have identified high permeability of compounds derived from natural sources through PAMPA–BBB [47]. While there are many other factors that contribute to BBB permeability, such as plasma concentration, plasma binding, and metabolic modifications by barrier enzymes, PAMPA is a good predictor of passive movement across the BBB [35,46]. The relationship between gut and BBB permeability is further complicated by presystemic metabolism. For instance, previous studies have shown that following gut metabolism, EL predominantly exists as a glucuronide conjugate, certainly affecting its BBB permeability and overall bioavailability [48].

We identified that these PMMs, specifically EL and EQ, passively cross both the gut and BBB barriers. To further identify the potential bioactivities of these molecules,
we examined their protective ability against inflammation in microglia. Microglia are the resident macrophages of the brain that work to eliminate debris from the brain [48]. However, continuous activation of microglia can lead to the over-production of inflammatory cytokines, as identified in postmortem brains of Alzheimer’s and Parkinson’s disease patients [49]. One mechanism of microglia activation is the increase in LPS levels in peripheral blood, due to poor diet [50,51]. The continued elevated levels of these pro-inflammatory cytokines, specifically IL-6 and TNF-α, can stimulate the recruitment and activation of other microglia, further inducing the production of reactive oxygen species and nitric oxide species [52]. NOS at low doses is critical for maintaining healthy microglia and neuron function, but at high doses can induce necrosis or apoptosis [53]. Phenolic compounds have previously been linked to reduced microglia-induced neuroinflammation [54]. At 20 µM, all tested isoflavones were able to significantly reduce nitric oxide production, and TNF-α and IL-6 concentrations compared to LPS alone. These results are consistent with previous reports of isoflavones [14]. However, GEN clearly showed the greatest anti-inflammatory properties when compared to SECO and EQ. Furthermore, we subjected SECO and its microbial-derived metabolites to neuroprotective assays. Among the lignans tested, only the gut-derived metabolite EL was able to significantly reduce IL-6 and TNF-α production. Additionally, EL showed significantly greater reduction in nitric oxide concentrations than its parent metabolite and ED. Recent studies with certain polyphenol metabolites, namely, gallic acid derivatives, demonstrated that these metabolites pass across BBB endothelium and provide neuroprotective effects through modulation of the NF-κB pathway [55]. It is clear from these previous studies and the work presented here that the neuroprotective potential
of BBB-permeable metabolites is an important area for further investigation to understand the relationship between dietary intake of polyphenols and brain health.

In summary, the fate of microbial metabolites is largely governed by their ability to permeate through biological barriers. After investigating two classes of polyphenols often found in the Mediterranean diet, namely, isoflavones and lignans, our data suggest that their gut microbial metabolites, but not parent compounds, may enter the blood, cross the BBB and provide protection against neuroinflammation. The isoflavone parent compound, DAI, exhibits high gut permeability, but intermediate BBB permeability. DAI’s microbial metabolite, EQ, exhibits high permeability in both the gut and BBB, as well as significantly reducing nitric oxide and the production of pro-inflammatory cytokines in murine microglia. GEN shows permeability through both the gut and BBB and very strong anti-inflammatory effects. However, gut microbial metabolism would likely limit the circulating levels of GEN in the blood. The lignan SECO has extremely limited membrane permeability, but its gut microbial metabolite EL passively penetrates both the gut and BBB. Additionally, EL was most effective out of the lignans tested in inhibiting NOS and pro-inflammatory cytokines in vitro.

These data, supported by previously published literature, suggest the further investigation of gut-microbial-derived metabolites, specifically EL and EQ, for the treatment of neurodegenerative diseases both in vitro and in vivo. Furthermore, using a system like PAMPA can aid in refining in vitro testing to ultimately inform the design of more efficacious animal studies.
Supplementary Materials: The following are available online at http://www.mdpi.com, Tables S1–S6, which detail additional statistical analysis.

Author Contributions: N.P.S and M.J.B conceived and designed the experiments; S.L.J., R.D.K., N.A.D., H.M., performed the experiments; S.L.J, R.D.K., N.P.S., and M.J.B., analyzed the data; N.P.S and M.J.B contributed reagents and materials. S.L.J., R.D.K., N.A.D., H.M., N.P.S and M.J.B wrote the paper and approved the final manuscript.

Funding: S.L.J. was supported by a fellowship from the George and Anne Ryan Institute for Neuroscience. PAMP A materials and spectroscopic data were obtained from instruments located in the Rhode Island-IDEA Network for Excellence in Biomedical Research core facility supported by Grant # P20GM103430 from the National Institute of General Medical Sciences of the National Institutes of Health.

Acknowledgments: We thank Grace Sun of the University of Missouri at Columbia for generously providing us with the BV-2 cells.

Conflicts of Interest: The authors declare no conflict of interest.
**Figure 1.** Overview of the polyphenol isoflavones and lignan parent compounds and their respective polyphenol microbial metabolites produced by gut microflora. (Genistein = GEN, daidzein = DAI, equol = EQ, secoisolariciresinol = SECO, enterodiol = ED, enterolactone = EL).
Table 1. In silico SwissADME predictive permeability of parent polyphenols and their microbial metabolites in the gut and blood–brain barrier (BBB).

| Compound   | Molecular Weight (g/mol) | Gut Absorption | BBB Permeability |
|------------|--------------------------|----------------|-----------------|
| SECO       | 362.42                   | High           | No              |
| ED         | 302.36                   | High           | No              |
| EL         | 298.33                   | High           | Yes             |
| GEN        | 270.24                   | High           | No              |
| DAI        | 254.24                   | High           | Yes             |
| EQ         | 242.27                   | High           | Yes             |
| Antipyrine | 188.23                   | High           | Yes             |
| Corticosterone | 346.46               | High           | Yes             |
| Ketoprofen | 254.28                   | High           | Yes             |
| Ranitidine | 314.40                   | High           | No              |
| Theophylline | 180.16               | High           | No              |
| Verapamil  | 454.60                   | High           | Yes             |
Figure 2. Parallel artificial membrane permeability assay (PAMPA) gut passive permeability at three relevant pH levels: 5.0 (A), 6.2 (B), and 7.4 (C). Controls verapamil, antipyrine and ranitidine exhibit high, medium and low penetrability, respectively. Ketoprofen shows variable permeability with pH change.
Figure 3. Assessment of blood–brain barrier passive permeability of polyphenols determined by PAMPA. Positive (verapamil), intermediate (corticosterone) and low (theophylline) permeability controls.
Figure 4. Effects of isoflavones against LPS-induced oxidative stress in BV-2 murine microglia. Isoflavones exhibited no cytotoxic effects in murine microglia (A). Isoflavones (20 µM and 10 µM) reduce nitric oxide production, as determined by the Griess Reagent (B). Isoflavones inhibited the production of the pro-inflammatory cytokines, TNF-α (C) and IL-6 (D), in murine microglia. All data expressed as mean ± standard error (n ≥ 3), significance was reported by analysis of variance (ANOVA) followed with Dunnett multiple comparison testing. Significance as compared with control $p \leq 0.0001$ (#####); as compared with LPS, $p \leq 0.03$ (*), $p \leq 0.002$ (**), $p \leq 0.0002$ (***), and $p \leq 0.0001$ (****).
Figure 5. Effects of lignans in murine microglia cells. Lignans were evaluated for cytotoxicity in BV-2 (A). Effect of lignan treatment (10 μM) on nitric oxide production, as determined by the Griess Reagent (B). Lignans reduce the production of pro-inflammatory cytokines in murine microglia, TNF-α (C) and IL-6 (D). All data expressed as mean ± standard error (n ≥ 3), significance was reported by analysis of variance (ANOVA) followed with Dunnett multiple comparison testing. Significance as compared with control $p \leq 0.0001 (#####)$; as compared with LPS, $p \leq 0.002 (**)$, $p \leq 0.0002 (***)$ and $p \leq 0.0001 (****)$.
References

1. Pi-Sunyer, X. The medical risks of obesity. *Postgrad. Med.* **2009**, *121*, 21–33.

2. Tsai, A.G.; Williamson, D.F.; Glick, H.A. Direct medical cost of overweight and obesity in the USA: A quantitative systematic review. *Obes. Rev.* **2011**, *12*, 50–61.

3. Grotto, D.; Zied, E. The standard American diet and its relationship to the health status of Americans. *Nutr. Clin. Pract.* **2010**, *25*, 603–612.

4. Sofi, F.; Macchi, C.; Abbate, R.; Gensini, G.F.; Casini, A. Mediterranean diet and health. *BioFactors* **2013**, *39*, 335–342.

5. Gardener, H.; Caunca, M.R. Mediterranean diet in preventing neurodegenerative diseases. *Curr. Nutr. Rep.* **2018**, *7*, 10–20.

6. Castro-Barquero, S.; Lamuela-Raventós, R.M.; Doménech, M.; Estruch, R. Relationship between Mediterranean dietary polyphenol intake and obesity. *Nutrients* **2018**, *10*, 1523.

7. Widmer, R.J.; Flammer, A.J.; Lerman, L.O.; Lerman, A. The Mediterranean Diet, its components and cardiovascular disease. *Am. J. Med.* **2015**, *128*, 229–238.

8. Braga, R.; Teles, D.A.; Diniz, T.C.; Coimbra, T.; Pinto, C.; Gonçalves, R.; Júnior, D.O.; Gama, M.; De Lavor, É.M.; Wilton, A.; et al. Flavonoids as therapeutic agents in Alzheimer’s and Parkinson’s Diseases: A systematic review of preclinical evidences. *Oxid. Med. Cell. Longev.* **2018**, *2018*, 7043213.

9. Jung, U.J.; Kim, S.R. Beneficial effects of flavonoids against Parkinson’s disease. *J. Med. Food* **2018**, *21*, 421–432.

10. Sirerol, J.A.; Rodríguez, M.L.; Mena, S.; Asensi, M.A.; Estrela, J.M.; Ortega, A.L. Role of natural stilbenes in the prevention of cancer. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 3128951.
11. Pandey, K.B.; Rizvi, S.I. Plant polyphenols as dietary antioxidants in human health and disease. *Oxid. Med. Cell. Longev.* 2009, 2, 270–278.

12. Yuan, T.; Ma, H.; Liu, W.; Niesen, D.B.; Shah, N.; Crews, R.; Rose, K.N.; Vattem, D.A.; Seeram, N.P. Pomegranate’s neuroprotective effects against Alzheimer’s disease are mediated by urolithins, its ellagitannin-gut microbial derived metabolites. *ACS Chem. Neurosci.* 2015, 7, 26–33.

13. D’Archivio, M.; Filesì, C.; Varì, R.; Scuzzocchio, B.; Masella, R. Bioavailability of the polyphenols: Status and controversies. *Int. J. Mol. Sci.* 2010, 11, 1321–1342.

14. Subedi, L.; Ji, E.; Shin, D.; Jin, J.; Yeo, J.; Kim, S. Equol, a dietary daidzein gut metabolite attenuates microglial activation and potentiates neuroprotection in vitro. *Nutrients* 2017, 9, 207.

15. Lewandowska, U.; Szewczyk, K.; Hrabec, E.; Janecka, A.; Gorlach, S. Overview of metabolism and bioavailability enhancement of polyphenols. *J. Agric. Food Chem.* 2013, 61, 12183–12199.

16. Marín, L.; Miguélez, E.M.; Villar, C.J.; Lombó, F. Bioavailability of dietary polyphenols and gut microbiota metabolism: Antimicrobial properties. *BioMed Res. Int.* 2015, 2015, 905215.

17. Esch, H.L.; Kleider, C.; Scheffler, A; Lehmann, L. Isoflavones: Toxicology aspects and efficacy. In *Nutraceuticals: Efficacy, Safety, and Toxicity*; Gupta, R.C., Ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2016; 465–487.

18. Rufer, C.E.; Kulling, S.E. Antioxidant activity of isoflavones and their major metabolites using different *in vitro* assays. *J. Agric. Food Chem.* 2006, 54, 2926–2931.

19. Ma, Y.; Sullivan, J.C.; Schreinhofer, D.A. Dietary genistein and equol (4′,7 isoflavandiol) reduce oxidative stress and protect rats against focal cerebral ischemia. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2010, 299, R871–R877.
20. Kunisue, T.; Tanabe, S.; Isobe, T.; Aldous, K.M.; Kannan, K. Profiles of phytoestrogens in human urine from several Asian countries. *J. Agric. Food Chem.* **2010**, *58*, 9838–9846.

21. Bang, O.Y.; Hong, H.S.; Kim, D.H.; Kim, H.; Boo, J.H.; Huh, K.; Mook-Jung, I. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. *Neurobiol. Dis.* **2004**, *16*, 21–28.

22. Ma, H.; Liu, W.; Frost, L.; Wang, L.; Kong, L.; Dain, J.A.; Seeram, N.P. The hydrolyzable gallotannin, penta-O-galloyl-β-D-glucopyranoside, inhibits the formation of advanced glycation endproducts by protecting protein structure. *Mol. BioSyst.* **2015**, *11*, 1338–1347.

23. Qian, Y.; Guan, T.; Huang, M.; Cao, L.; Li, Y.; Cheng, H.; Jin, H.; Yu, D. Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-κB activation in a cerebral ischemia mouse model. *Neurochem. Int.* **2012**, *60*, 759–767.

24. Kajta, M.; Rzemieniec, J.; Litwa, E.; Lason, W.; Lenartowicz, M.; Krzeptowski, W.; Wojtowicz, A.K. The key involvement of estrogen receptor B and G-protein-coupled receptor 30 in the neuroprotective action of daidzein. *Neuroscience* **2013**, *238*, 345–360.

25. Setchell, K.D.R.; Clerici, C. Equol: History, chemistry, and formation. *J. Nutr.* **2010**, *3*, 1355–1362.

26. Yuan, J.; Wang, J.; Liu, X. Metabolism of dietary soy isoflavones to equol by human intestinal microflora—Implications for health. *Mol. Nutr. Food Res.* **2007**, *51*, 765–781.

27. Barapatre, A.; Meena, A.S.; Mekala, S.; Das, A.; Jha, H. *In vitro* evaluation of antioxidant and cytotoxic activities of lignin fractions extracted from *Acacia nilotica*. *Int. J. Biol. Macromol.* **2016**, *86*, 443–453.
28. Peterson, J.; Dwyer, J.; Adlercreutz, H.; Scalbert, A.; Jacques, P.; McCullough, M.L. Dietary lignans: Physiology and potential for cardiovascular disease risk reduction. *Nutr. Rev.* **2010**, *68*, 571–603.

29. Zhang, W.; Wang, X.; Liu, Y.; Tian, H.; Flickinger, B.; Empie, M.W.; Sun, S.Z. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. *Br. J. Nutr.* **2018**, *99*, 1301–1309.

30. Bergman Jungeström, M.; Thompson, L.U.; Dabrosin, C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts *in vivo*. *Clin. Cancer Res.* **2007**, *13*, 1061–1067.

31. Prasad, K. Secoisolariciresinol diglucoside from flaxseed delays the development of type 2 diabetes in Zucker rat. *J. Lab. Clin. Med.* **2001**, *138*, 32–39.

32. Mukker, J.K.; Michel, D.; Muir, A.D.; Krol, E.S.; Alcorn, J. Permeability and Conjugative Metabolism of Flaxseed Lignans by Caco-2 Human Intestinal Cells. *J. Nat. Prod.* **2014**, *77*, 29–34.

33. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. *J. Nutr.* **2000**, *130*, 2073S–2085S.

34. Pimpão, R.C.; Ventura, M.R.; Ferreira, R.B.; Williamson, G.; Santos, C.N. Phenolic sulfates as new and highly abundant metabolites in human plasma after ingestion of a mixed berry fruit purée. *Br. J. Nutr.* **2015**, *113*, 454–463.

35. DeSesso, J.M.; Jacobson, C.F. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. *Food Chem. Toxicol.* **2001**, *39*, 209–228.

36. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of
passive absorption processes. *J. Med. Chem.* **1998**, *41*, 1007–1010.

37. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPA—Critical factors for better predictions of absorption. *J. Pharm. Sci.* **2007**, *96*, 2893–2909.

38. Müller, J.; Esso, K.; Dargó, G.; Könczöl, Á.; Balogh, G.T. Tuning the predictive capacity of the PAMPA-BBB model. *Eur. J. Pharm. Sci.* **2015**, *79*, 53–60.

39. Carpenter, T.S.; Kirshner, D.A.; Lau, E.Y.; Wong, S.E.; Nilmeier, J.P.; Lightstone, F.C. A Method to Predict Blood-Brain Barrier Permeability of Drug-Like Compounds Using Molecular Dynamics Simulations. *Biophys. J.* **2014**, *107*, 630–641.

40. Di, L.; Kerns, E.H.; Fan, K.; McConnell, O.J.; Carter, G.T. High throughput artificial membrane permeability assay for blood-brain barrier. *Eur. J. Med. Chem.* **2003**, *38*, 223–232.

41. Bicker, J.; Alves, G.; Fortuna, A.; Soares-Da-Silva, P.; Falcão, A. A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates. *Int. J. Pharm.* **2016**, *501*, 102–111.

42. Maraki, M.I.; Yannakoulia, M.; Stamelou, M.; Stefanis, L.; Xiromerisiou, G.; Kosmidis, M.H.; Dardiotis, E.; Hadjigeorgiou, G.M.; Sakka, P.; Anastasiou, C.A.; et al. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson’s disease. *Mov. Disord.* **2019**, *34*, 48–57.

43. Tang, W.H.W.; Kitai, T.; Hazen, S.L. Gut microbiota in cardiovascular health and disease. *Circ. Res.* **2017**, *120*, 1183–1196.

44. Shekhawat, P.B.; Pokharkar, V.B. Understanding peroral absorption: Regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. *Acta Pharm. Sin. B* **2017**, *7*, 260–280.

45. Cui, H.M.; Zhang, Q.Y.; Wang, J.L.; Chen, J.L.; Zhang, Y.L.; Tong, X.L. Poor
permeability and absorption affect the activity of four alkaloids from *Coptis*. *Mol. Med. Rep.* **2015**, *12*, 7160–7168.

46. Abbott, N.J. Prediction of blood-brain barrier permeation in drug discovery from *in vivo*, *in vitro* and *in silico* models. *Drug Discov. Today Technol.* **2004**, *1*, 407–416.

47. Könczöl, Á.; Müller, J.; Földes, E.; Béni, Z.; Végh, K.; Kéry, Á.; Balogh, G.T. Applicability of a blood-brain barrier specific artificial membrane permeability assay at the early stage of natural product-based CNS drug discovery. *J. Nat. Prod.* **2013**, *76*, 655–663.

48. Deczkowska, A.; Keren-Shaul, H.; Weiner, A.; Colonna, M.; Schwartz, M.; Amit, I. Disease-associated microglia: A universal immune sensor of neurodegeneration. *Cell* **2018**, *173*, 1073–1081.

49. Yuste, J.E.; Tarragon, E.; Campuzano, C.M.; Ros-Bernal, F. Implications of glial nitric oxide in neurodegenerative diseases. *Front. Cell. Neurosci.* **2015**, *9*, 1–13.

50. Cai, D. Neuroinflammation and neurodegeneration in overnutrition-induced diseases. *Trends Endocrinol. Metab.* **2013**, *24*, 40–47.

51. Cancello, R.; Clément, K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. *BJOG* **2006**, *113*, 1141–1147.

52. De Cesaris, P.; Starace, D.; Riccioli, A.; Padula, F.; Filippini, A.; Ziparo, E. Tumor necrosis factor-α induces interleukin-6 production and integrin ligand expression by distinct transduction pathways. *J. Biol. Chem.* **1998**, *273*, 7566–7571.

53. Garry, P.S.; Ezra, M.; Rowland, M.J.; Westbrook, J.; Pattinson, K.T. The role of the nitric oxide pathway in brain injury and its treatment—From bench to bedside. *Exp. Neurol.* **2015**, *263*, 235–243.

54. Hornedo-Ortega, R.; Cerezo, A.B.; De Pablos, R.M.; Krisa, S.; Richard, T.;
García-Parrilla, M.C.; Troncoso, A.M. Phenolic compounds characteristic of the mediterranean diet in mitigating microglia-mediated neuroinflammation. *Front. Cell. Neurosci.* 2018, 12, 1–20.

55. Figueira, I.; Garcia, G.; Pimpão, R.C.; Terrasso, A.P.; Costa, I.; Almeida, A.F.; Tavares, L.; Pais, T.F.; Pinto, P.; Ventura, M.R. Polyphenols journey through blood-brain barrier towards neuronal protection. *Sci. Rep.* 2017, 7, 11456.

56. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* 2017, 7, 42717.

57. Ma, H.; DaSilva, N.A.; Liu, W.; Nahar, P.P.; Wei, Z.; Liu, Y.; Pham, P.T.; Crews, R.; Vattem, D.A.; Slitt, A.L.; et al. Effects of a standardized phenolic-enriched maple syrup extract on β-amyloid aggregation, neuroinflammation in microglial and neuronal cells, and β-amyloid induced neurotoxicity in *Caenorhabditis elegans*. *Neurochem. Res.* 2016, 41, 2836–2847.
CHAPTER 2

MANUSCRIPT 4

Phytoestrogen, Equol, provides protection against toxin-induced models of Parkinson’s disease

Shelby L. Johnsona,b, Hyun Y. Parkc,d, Paula Grammasb, Dhiraj A. Vattemc,d, Hang Ma,ab, Navindra P. Seerama,b

Affiliations:

aDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA
bGeorge and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA
cEdison Biotechnology Institute, Ohio University, Athens, OH 45701, USA
dSchool of Applied Health Sciences and Wellness, Ohio University, Athens, OH 45701, USA

*Corresponding authors:

Navindra P. Seeram, Ph.D.

Email: nseeram@uri.edu

Phone: 401-874-9367
Abstract

Parkinson’s disease is a complex neurodegenerative disease that attacks dopaminergic neurons of the substantia nigra, resulting in a variety of locomotor deficits. Disease severity, progression, and drug response appear to be influenced by gender, suggesting a protective role of estrogen. Phytoestrogens, genistein, daidzein, and gut-derived microbial metabolite equol, exhibit antioxidant activity, alleviate oxidative stress, and most recently show neuroprotective ability. Herein, we investigate these three phytoestrogens’ for their protective abilities against toxin-induced models of Parkinson’s disease. In a co-culture model, isoflavones significantly improved cellular viability as compared to LPS-induced murine microglia cell supernatant. Equol was most successful in protecting against neuronal cell death induced by 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP⁺), improving cell viability by 31% and 18% at 20 μM, respectively. Parent compounds, genistein, and daidzein, failed to consistently improve cellular viability. Therefore, equol was assessed in Caenorhabditis elegans and Drosophila melanogaster. In C. elegans, equol significantly improved lifespan as compared to toxic agent MPP⁺. In D. melanogaster, equol treatment for 7 days exhibited minor improvements in climbing ability as compared to 6-OHDA alone. Moreover, our data suggest a potentially protective role of equol, but not parent compounds, against toxic models of Parkinson’s disease.

Keywords: Parkinson’s disease, phytoestrogens, isoflavones

Abbreviations: PD: Parkinson’s disease, ERβ: Estrogen receptor β, EST: 17β-Estradiol, GEN: Genistein, DAI: Daidzein, EQ: S-Equol, LPS: Lipopolysaccharide, 6-OHDA: 6-Hydroxydopamine, MPP⁺: 1-Methyl-4-phenylpyridinium
Introduction

Parkinson’s disease (PD) is a multifaceted neurodegenerative disease that can present as a wide variety of symptoms, but a clinical diagnosis is determined by the presence of motor difficulties such as tremors, bradykinesias, rigidity and postural instability, and exclusion of any other diseases\(^1\). PD is anticipated to affect 930,000 by 2020\(^2\). Pathological characteristics of PD are the loss of dopamine specifically in the substantia nigra, as well as the accumulation of \(\alpha\)-synuclein\(^3\). Pharmaceutical interventions primarily focus on replenishing the lost dopamine, typical treatment includes levodopa coupled with a dopamine decarboxylase inhibitor\(^4\). Recent focus has shifted to stop the progression of the disease by exploring alternative targets such as genetic mutations or neuroinflammation\(^5,6\). Interestingly, PD progression, incident rates, and pharmaceutical response seem to be influenced by gender\(^7\). For instance, male prevalence rates are 1.5 times higher than in females\(^8\). Additionally, risk substantially increases in females after menopause, suggesting a potential protective role of estrogen against PD\(^9\).

The protective role of estrogen in PD has been explored in multiple recent studies. In mice, estrogen treatment modified the activation of astroglia and microglia, and nigrostriatal disruption against toxin-induced PD\(^10\). Similarly, a recent clinical study compared striatal dopamine transporter (DAT) availability in females, reporting lower DAT in the brain, suggesting estrogen may have a beneficial effect on dopaminergic neurons\(^11\). Taken together, these studies support a protective role for estrogen against PD. A systematic meta-analysis found no positive relationship between hormone replacement therapy and a decreased risk in PD\(^12\). This discrepancy may be due to the massive role estrogen plays throughout the body.
Therefore, we hypothesize that naturally occurring estrogens may have similar neuroprotective abilities without performing all estrogenic activities. Phytoestrogens classified as isoflavones exhibit excessive antioxidant activity, alleviate oxidative stress, and selectively bind to ER-\(\beta\)^13–17. The two most common isoflavones, genistein (GEN) and daidzein (DAI) are found primarily in soy and have been extensively studied. Previous reports show GEN inhibits mitochondria-dependent apoptosis, and alleviates \(\beta\)-amyloid neurotoxicity, providing neuroprotection\(^{18–20}\). Similarly, DAI demonstrates pro-apoptotic and neurotoxic effects against glutamate treatment\(^{21}\). The bioavailability of these compounds after consumption has been disputed, evidence suggests that gut microbial-derived metabolites are much more abundant\(^{22}\). Gut microbial metabolite, equol (EQ), has been shown to protect against cardiovascular disease, bone health, and specific cancers\(^{23,24}\). In our recent publication, we showed that of these isoflavones, EQ is most likely to cross the blood-brain barrier and protects against inflammation in murine microglia models\(^{25}\).

As phytoestrogens and known agonists of estrogen receptor beta (ER-\(\beta\)), we hypothesized that these isoflavones, EQ, in particular, will provide protection in Parkinson’s disease models. Herein, we evaluate positive control 17\(\beta\)-estradiol, genistein, daidzein and equol in toxin-induced models of Parkinson’s disease in cells, Caenorhabditis elegans and Drosophila melanogaster.
Materials and Methods

Chemicals

Dimethylsulfoxide (DMSO), lipopolysaccharide (LPS), 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). DMEM/F-12, phenol red-free DMEM medium, and trypsin-versene were purchased from Life Technologies (Grand Island, NY, USA).

Compounds

17β-Estradiol (EST), daidzein (DAI), and genistein (GEN) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). S-Equol (EQ) was purchased from Chembest (Shanghai, China).

Cell Culture Maintenance

Murine microglia (BV-2) were generously gifted by Dr. Grace Y. Sun (University of Missouri at Columbia, MO, USA). Human neuroblastoma (SH-SY5Y) were obtained from American Type Culture Collection (ATCC, VA, USA). Cells were maintained in DMEM/F-12 high glucose (4.5 g/L), supplemented with 10% inactivated FBS and 1% P/S (100 U/mL penicillin, 100 mg/mL streptomycin) (Life Technologies, Gaithersburg, MD, USA) at 37°C in 5% CO₂. EST and isoflavones were prepared to 10 mM in DMSO, and further diluted in serum-free DMEM/F-12 media. Control wells contained 0.1% DMSO.

Cytotoxicity Screen

Cytotoxicity of compounds at 20 µM in SH-SY5Y were assessed with Cell Titer Glo 2.0 (CTG) (Promega, Madison, WI, USA) after 24 h treatment, cell viability was determined as percentage of control²⁶.

Non-Contact Co-Culture
The non-contact co-culture experiment was performed using treated media from BV-2 cells on human neuroblastoma, as previously described\textsuperscript{27}. BV-2 were pretreated with isoflavones for 1 h, then induced with lipopolysaccharide (1mg/mL) for 23 h. Media was removed from BV-2 and placed on SH-SY5Y, seeded in white-walled 96-well plates at 100,000 cells/mL. SH-SY5Y were then incubated for 24 h, cell viability was then assessed using CTG.

**Cellular Viability against Toxic Agents**

Human neuroblastoma were seeded in white-walled 96-well plates at 100,000 cells/mL for 24 h. Cells were incubated with corresponding treatments for 2 h in serum-free media, then induced with toxic agents for 24 h: 6-OHDA (100 μM) or MPP\textsuperscript{+} (2 mM). Cellular viability was determined by CTG, illustrated as percentage of control.

**Caenorhabditis elegans**

*C. elegans* were maintained and assayed for lifespan against MPP\textsuperscript{+} as previously described\textsuperscript{28}. Briefly, wild type (N2) were maintained on normal nematode growth media at 20°C. Nematodes were age synchronized, and at L1 40 μL worms were plated in a 96-well microplate (approximately 20 worms/well). Worms were plated with *Escherichia coli* OP50 (5 mg/mL), MPP\textsuperscript{+} (750 μM), and Equol (17.5°C or 30 μM). Control groups received S-complete media. Post treatment, live worms were counted every 12 h until no live worms remained.

**Drosophila Melanogaster Maintenance and Treatment**

Canton S (w\textsuperscript{*}) flies were a kind gift from Dr. Belinda Barbagallo (Salve Regina University, Newport, RI). Flies were maintained and age synchronized on Nutri-Fly BF (Genesee Scientific, San Diego, CA). On day 1 post eclosion, flies were separated by gender to approximately 20 flies per vial. Treatments were added to the media on day 3 post eclosion, control received 5% sucrose and equol received 100
μM diluted in 5% sucrose. Treatment vials were exchanged every other day for 7 days.

**Climbing Assay**

After 7 days of treatment, flies were assayed for climbing ability\textsuperscript{28,29}. Briefly, flies were placed in empty vials marked at 5 cm and allowed to acclimate for 30 minutes. Flies were gently tapped to the bottom of the vial and a picture was taken after 10 seconds using a Nikon D2200 camera (Nikon, Tokyo, JP). Percent climbing was calculated by ((# flies above line / total # flies)*100).

**Statistical Analysis**

All data are reported as mean ± standard errors of at least three independent biological samples. Analysis of all cellular and *Drosophila* data were conducted by ANOVA followed by Dunnett’s test for multiple comparisons of group means. Significance of the toxic agent compared to the control group is presented as p≤0.01 (##) and p≤0.0001 (#####). Significance for tests compared to toxic treatment was defined as: p≤0.05 (*), p≤0.01 (**), p≤0.001 (***) and p≤0.0001 (****). Lifespan analysis for *C. elegans* identified using the Kaplan–Meier, tested for statistical significance using the log-rank test (Mantel-Cox). GraphPad Prism software 8.0 (GraphPad Software, Inc., San Diego, CA) was used to create all graphs and for all statistical analysis calculations.
Results

Cytotoxicity Screen

Compounds were tested for cytotoxicity at 20 μM in neuroblastoma (Figure 1). No significant difference was seen between control and isoflavone treatment, indicating safe concentrations.

Effects of Isoflavones in Non-Contact Co-Culture

Treatment with LPS media reduced SH-SY5Y viability to 56.9 ± 1.2%, as compared to control, 100 ± 2.5% (Figure 2). Isoflavones at all concentrations exhibited significantly increased cellular viability as compared to LPS treatment alone. GEN significantly increased cellular viability by 11 and 6%, at 20 μM and 10 μM, respectively. Treatment with DAI (20 and 10 μM) increased cellular viability by 11 and 16%. EQ significantly increased cellular viability by 17 and 14% at 20 and 10 μM, respectively.

Human Neuroblastoma PD Model

Human neuroblastoma (SH-SY5Y) were analyzed against PD toxic insults 6-OHDA and MPP⁺ (Fig. 3). 6-OHDA significantly decreased cellular viability to 35.3% ± 6.8, as compared to control (100 ± 6.5). DAI (20 μM) improved viability by 26%, compared to 6-OHDA. EQ at both concentrations increased cellular viability by 31 and 27%, compared to toxic treatment.

In the MPP⁺ model, control exhibited 100 ± 3.0% viability, whereas MPP⁺ treatment significantly reduced cellular viability to 57.8 ± 2.3%. DAI significantly increased cellular viability by 20 and 15% at 20 μM and 10 μM, respectively. 20 μM and 10 μM of EQ significantly improved cellular viability by 18% and 19%, as compared to MPP⁺.

C. elegans Lifespan
We further evaluate EQ against toxic agent, MPP⁺, in the *C. elegans* model. MPP⁺ treatment alone significantly reduced lifespan to 72 h (Fig. 4A). EQ at 17.5 and 35 μM significantly improved the median lifespan to 108 h (Fig. 4B &C).

*Drosophila melanogaster* Negative Geotaxis

*D. melanogaster* were evaluated for EQ (100 μM) protection against 6-OHDA toxicity in the negative geotaxis assay (Fig. 5). 6-OHDA treatment for one week failed to significantly reduce the climbing ability of male flies. EQ treatment exhibited increased climbing ability as compared to 6-OHDA, however not significantly.
Discussion

There has been an increased interest in flavonoids for the prevention of neurodegenerative diseases, as they exhibit the ability to cross the BBB and have a wide range of bioactive properties including antioxidant, anti-inflammatory, antiapoptotic and lipid-lowering properties\textsuperscript{30,31}. PD is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra, leading to tremors, bradykinesias, and further dementias. Dopaminergic neuronal death in PD has also been heavily linked to increases in neuroinflammation\textsuperscript{32}. Endogenous estrogen exhibits the ability to reduce neuroinflammation and protects against neurodegeneration in PD\textsuperscript{33}. Herein, we explored the effects of naturally occurring phytoestrogens, namely, isoflavones, in the protection against toxin-induced PD models in neuroblastoma and drosophila.

Oxidative stress and inflammation induced by activated microglia have become key pathological features of PD, resulting in increased levels of cytokines and dopaminergic neuronal loss localized to the substantia nigra\textsuperscript{34,35}. Multiple recent publications have identified a protective role of gut-derived microbial metabolite, equol, in astrocytes and microglia induced with LPS\textsuperscript{36,37}. Further, we explored the relationship between activated microglia and neuronal death \textit{in vitro}\textsuperscript{27}. We show that EQ treatment in murine microglia followed by LPS-induced inflammation produces lower neuronal death in our co-culture experiment. This indicates that EQ may reduce oxidative and inflammatory stress in microglia, protecting neurons against toxic agents.

Toxin-induced models of PD have proven to be useful in discoveries regarding the treatment and progression of the disease. Human neuroblastoma cell line SH-SY5Y is heavily used in PD research as it has dopaminergic properties allowing for
PD-like phenotypes when induced with toxic agents such as 6-OHDA, or MPP⁺. 6-OHDA leads to the death of dopaminergic neurons, proposed to involve the generation of free radicals. MPP⁺ mimics PD symptoms by altering mitochondrial function, leading to increased oxidative stress and abnormal protein aggregation.

EQ exhibited significant protection against both 6-OHDA and MPP⁺ induced toxicity in the neuroblastoma model. Although EQ has not previously been published in PD models of SH-SY5Y, it is in agreement with previous reports of a combination of GEN, DAI and EQ neuroprotective abilities. Further in-vivo investigation supports this protective role of EQ against MPP⁺, but not 6-OHDA. Future investigations of EQ should explore both toxic and transgenic models of PD to determine mechanisms of protection.

Herein, we report that gut microbial metabolite, Equol, exhibits neuroprotective activities in Parkinson’s disease models in vitro and in vivo. Highlighted by the reduction in toxin-related cell and C. elegans death. Our results warrant further investigation of Equol as a future intervention for PD.
Acknowledgements

S.J. was supported by a fellowship from the George and Anne Ryan Institute for Neuroscience. Spectroscopic data were obtained from instruments located in the Rhode Island-IDeA Network for Excellence in Biomedical Research core facility supported by Grant # P20GM103430 from the National Institute of General Medical Sciences of the National Institutes of Health.

Conflict of Interest

The authors have declared no conflict of interest.
Figure 1. Cytotoxicity evaluation of isoflavones at 20 μM after 24h on human neuroblastoma (SHSY5Y). Data are expressed as mean ± standard error, presented as percentage compared to control (n≥3).
Figure 2. Effects of isoflavone treated, LPS-induced murine microglia cell supernatant on human neuroblastoma cellular viability. Data are expressed as mean ± standard error (n≥3), reported as percentage compared to control. Statistical significance was evaluated using ANOVA followed with Dunnett’s multiple comparison test, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 as compared to control cells. Toxin insult was compared to control, ##p < 0.01.
Figure 3. Isoflavones protect against toxic inducers of PD in human neuroblastoma.

Cells were treated, then exposed to 25 μM 6-OHDA (A) and 2 mM MPP⁺ (B) for 24h, where cellular viability was assessed. Data are expressed as mean ± standard error, exhibited as percentage compared to control (n≥6). Statistical significance was evaluated using ANOVA followed with Dunnett's multiple comparison test, *p < 0.05, ** p < 0.01, ***p < 0.001, and ****p < 0.0001. Toxin insult was compared to control, ####p < 0.0001.
Figure 4. Effects of Equol (17.5 and 35 μM) on lifespan of *C. elegans* exposed to MPP⁺ (750 μM). Toxin reduces lifespan in control group (A). EQ at 17.5 (B) and 35 μM (C) exhibit protective effects versus MPP⁺. Survival curves were statistically analyzed by log rank test (Mantel Cox), as compared to MPP⁺ treatment (n >100).
Figure 5. Effects of Equol on climbing ability of *Drosophila melanogaster*. Influence of equol (100 μM) treatment on wildtype flies alone and induced with 6-OHDA (1 mM) on climbing ability after 7 days of treatment.
References

1. Jankovic, J. Parkinson’s disease: clinical features and diagnosis. *J. Neurol. Neurosurg. Psychiatry* 368–376 (2008). doi:10.1136/jnnp.2007.131045

2. Marras, C. *et al.* Prevalence of Parkinson’s disease across North America. *npj Park. Dis.* 4, 21 (2018).

3. Kalia, L. V. & Lang, A. E. Parkinson’s disease. *Lancet* 386, 896–912 (2015).

4. Stocchi, F. Therapy for Parkinson’s Disease: What is in the Pipeline? *Neurotherapeutics* 11, 24–33 (2014).

5. Rane, P. *et al.* Novel targets for Parkinson’s Disease: Addressing different therapeutic paradigms and conundrums. *ACS Chem. Neurosci.* (2018). doi:10.1021/acschemneuro.8b00180

6. Lee, Y., Lee, S., Chang, S. C. & Lee, J. Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention. *Arch. Pharm. Res.* 42, 416–425 (2019).

7. Cerri, S., Mus, L. & Blandini, F. Parkinson’s Disease in Women and Men: What’s the Difference? *J. Parkinsons. Dis.* 9, 501–515 (2019).

8. Moisan, F. *et al.* Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. *J. Neurol. Neurosurg. Psychiatry* 0, 1–6 (2015).

9. Labandeira-Garcia, J. L., Rodriguez-Perez, A. I., Valenzuela, R., Costa-Besada, M. A. & Guerra, M. J. Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. *Front. Neuroendocrinol.* 43, 44–59 (2016).

10. Siani, F. *et al.* Influence of estrogen modulation on glia activation in a murine
model of parkinson’s disease. *Front. Neurosci.* **11**, 1–11 (2017).

11. Lee, Y. H. *et al.* Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease. *Sci. Rep.* **9**, 1–9 (2019).

12. Wang, P., Li, J., Qiu, S., Wen, H. & Du, J. Hormone replacement therapy and parkinson’s disease risk in women: A meta-analysis of 14 observational studies. *Neuropsychiatr. Dis. Treat.* **11**, 59–66 (2014).

13. Amer, D. A. M. *et al.* Activation of transgenic estrogen receptor-beta by selected phytoestrogens in a stably transduced rat serotonergic cell line. *J. Steroid Biochem. Mol. Biol.* **120**, 208–217 (2010).

14. Muthyala, R. S. *et al.* Equol, a natural estrogenic metabolite from soy isoflavones: Convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. *Bioorganic Med. Chem.* **12**, 1559–1567 (2004).

15. Rufer, C. E. & Kulling, S. E. Antioxidant activity of isoflavones and their major metabolites using different in vitro assays. *J Agric Food Chem* **54**, 2926–2931 (2006).

16. Ma, Y., Sullivan, J. C. & Schreihofer, D. A. Dietary genistein and equol (4’, 7 isoflavandiol) reduce oxidative stress and protect rats against focal cerebral ischemia. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **299**, R871-7 (2010).

17. Kunisue, T., Tanabe, S., Isobe, T., Aldous, K. M. & Kannan, K. Profiles of phytoestrogens in human urine from several Asian countries. *J. Agric. Food Chem.* **58**, 9838–9846 (2010).

18. Bang, O. Y. *et al.* Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. *Neurobiol. Dis.* **16**, 21–28 (2004).

19. Ma, W. *et al.* Genistein alleviates β-amyloid-induced inflammatory damage
through regulating Toll-like receptor 4/nuclear factor κB. *J. Med. Food* **18**, 273–9 (2015).

20. Qian, Y. *et al.* Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-κB activation in a cerebral ischemia mouse model. *Neurochem. Int.* **60**, 759–767 (2012).

21. Kajta, M. *et al.* The Key Involvement Of Estrogen Receptor B And G-Protein-Coupled Receptor 30 In The Neuroprotective Action Of Daidzein. *Neuroscience* **238**, 345–360 (2013).

22. Yuan, T. *et al.* Pomegranate’s Neuroprotective Effects against Alzheimer’s Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived Metabolites. *ACS Chem. Neurosci.* acschemneuro.5b00260 (2015). doi:10.1021/acschemneuro.5b00260

23. Setchell, K. D. R. *et al.* S-equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. in *American Journal of Clinical Nutrition* **81**, 1072–1079 (2005).

24. Yuan, J. P., Wang, J. H. & Liu, X. Metabolism of dietary soy isoflavones to equol by human intestinal microflora - Implications for health. *Mol. Nutr. Food Res.* **51**, 765–781 (2007).

25. Johnson, S. L. *et al.* Polyphenol Microbial Metabolites Exhibit Gut and Blood–Brain Barrier Permeability and Protect Murine Microglia against LPS-Induced Inflammation. *Metabolites* **9**, 78 (2019).

26. Ma, H. *et al.* Evaluation of polyphenol anthocyanin-enriched extracts of blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry for free radical scavenging, reactive carbonyl species trapping, anti-
glycation, anti-β-amyloid aggregation, and mic. *Int. J. Mol. Sci.* **19**, (2018).

27. Ma, H. *et al.* Effects of a Standardized Phenolic-Enriched Maple Syrup Extract on β-Amyloid Aggregation, Neuroinflammation in Microglial and Neuronal Cells, and β-Amyloid Induced Neurotoxicity in Caenorhabditis elegans. *Neurochem. Res.* (2016). doi:10.1007/s11064-016-1998-6

28. Johnson, S. L. *et al.* Levodopa-reduced mucuna pruriens seed extract shows neuroprotective effects against parkinson’s disease in murine microglia and human neuroblastoma cells, Caenorhabditis elegans, and Drosophila melanogaster. *Nutrients* **10**, 1–14 (2018).

29. Phom, L., Achumi, B., Alone, D. P., Muralidhara & Yenisetti, S. C. Curcumin’s Neuroprotective Efficacy in *Drosophila* Model of Idiopathic Parkinson’s Disease Is Phase Specific: Implication of its Therapeutic Effectiveness. *Rejuvenation Res.* **17**, 481–489 (2014).

30. Braga, R. *et al.* Review Article Flavonoids as Therapeutic Agents in Alzheimer ’ s and Parkinson ’ s Diseases: A Systematic Review of Preclinical Evidences. *Oxid. Med. Cell. Longev.* (2018). doi:10.1155/2018/7043213

31. Jung, U. J. & Kim, S. R. Beneficial Effects of Flavonoids Against Parkinson’s Disease. *J. Med. Food* **21**, jmf.2017.4078 (2018).

32. Hwang, O. Role of oxidative stress in Parkinson’s disease. *Exp. Neurobiol.* **22**, 11–7 (2013).

33. Villa, A., Vegeto, E., Poletti, A. & Maggi, A. Estrogens, Neuroinflammation, and Neurodegeneration. **37**, 372–402 (2016).

34. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? *Lancet Neurol.* **8**, 382–397 (2009).

35. Kim, Y. S. & Joh, T. H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. *Exp. Mol. Med.* **38**, 333–347
36. Moriyama, M. et al. S-equol, a major isoflavone from soybean, inhibits nitric oxide production in lipopolysaccharide-stimulated rat astrocytes partially via the GPR30-mediated pathway. *Int. J. Inflam.* **2018**, (2018).

37. Subedi, L. et al. Equol, a Dietary Daidzein Gut Metabolite Attenuates Microglial Activation and Potentiates Neuroprotection In Vitro. *Nutrients* **9**, 207 (2017).

38. Xicoy, H., Wieringa, B. & Martens, G. J. M. The SH-SY5Y cell line in Parkinson’s disease research: a systematic review. *Mol. Neurodegener.* **12**, 10 (2017).

39. Shimohama, S., Sawada, H., Kitamura, Y. & Taniguchi, T. Disease model: Parkinson’s disease. *Trends Mol. Med.* **9**, 360–365 (2003).

40. Dauer, W. & Przedborski, S. Parkinson’s Disease: Mechanisms and Models. *Neuron* **39**, 889–909 (2003).

41. Zhao, L., Mao, Z. & Brinton, R. D. A select combination of clinically relevant phytoestrogens enhances estrogen receptor ?-binding Selectivity and neuroprotective activities in vitro and in vivo. *Endocrinology* **150**, 770–783 (2009).
CHAPTER 3
MANUSCRIPT 5

Direct thrombin inhibitor, Dabigatran, protects against neuroinflammation in LRRK2 transgenic *Drosophila melanogaster* model of Parkinson’s disease

Shelby L. Johnson\textsuperscript{a,b}, Jaclyn Iannucci\textsuperscript{a,b}, Navindra P. Seeram\textsuperscript{a,b}, Paula Grammas\textsuperscript{a,b}

\textsuperscript{a} The George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI, 02881
\textsuperscript{b} Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881
Abstract

Parkinson’s disease (PD) is a complex neurodegenerative disease characterized by the presence of tremors, loss of dopaminergic neurons and accumulation of α-synuclein. While there is no single direct cause of PD, genetic mutations, exposure to pesticides, diet and traumatic brain injury have been identified as risk factors. Increasing evidence supports that activated microglia, and the resulting neuroinflammation plays a critical role in disease progression. Our lab has previously identified the neurotoxic role of thrombin, linked to neuroinflammation. For the first time, we explore direct thrombin inhibitor, dabigatran, in a transgenic Parkinson's disease Drosophila melanogaster model. After 7 days of dabigatran treatment, male flies exhibited significant improvement in climbing ability, as compared to the vehicle. To elucidate the mechanism of locomotor protection, we investigate the production of nitric oxide (NOS) and reactive oxygen species (ROS). Dabigatran significantly reduced both NOS and ROS in male transgenic fly head homogenates. Western blot analysis confirmed that iNOS correlates with NOS production in male flies. SOD1 and NOX4 expression were reduced with dabigatran treatment, potentially contributing to ROS reduction. Our results indicate that dabigatran treatment improves motor function by reducing oxidative stress. We propose that inhibiting thrombin may provide a new therapeutic opportunity for potentially reducing PD associated pathologies. These initial findings should be investigated in alternative transgenic models of PD and evaluated for effects on behavior as well as biochemical markers of pathology to further elucidate mechanisms of action.

Keywords: Parkinson’s disease, Dabigatran, Neuroinflammation
Introduction

Neurodegenerative diseases currently cost the United States billions of dollars annually\(^1,2\). The two most common neurodegenerative diseases are Alzheimer’s (AD) and Parkinson’s disease (PD)\(^3,4\). Currently, there are no interventions that can stop disease progression. Although the symptoms and disease progression of AD and PD are vastly different, both diseases are associated with protein aggregation, genetic predisposition, mitochondrial dysfunction, and neuroinflammation\(^5\).

Neuroinflammation has been recognized as a major factor in the pathogenesis AD and PD\(^1,2,6-10\). The neuroinflammatory response in AD and PD is similar, characterized by phenotypic alterations in several cell types, including astrocytes, microglia, and endothelial cells\(^5\). Under normal conditions, microglia work to detect pathogens or tissue damage and elicit a response to clear cellular debris and degenerating cells\(^10\). However, when microglia are continuously activated by external stimuli, such as aggregated protein or foreign pathogens, this response can exacerbate disease conditions and lead to further neuronal damage\(^11\). This toxic microglial inflammatory response includes the release of a variety of inflammatory mediators, such as chemokines, cytokines, cyclooxygenase-2 (COX-2), and reactive mediators, namely, reactive oxygen species (ROS) and nitric oxide species (NOS)\(^10,12,13\). The chronic production of these inflammatory mediators increases oxidative stress and contributes to neuronal death. Although quite complex, neuroinflammation plays a major role in neurodegenerative diseases and has been identified as a worthy target for pharmaceutical interventions in neurodegenerative diseases.

Cerebrovascular activation has been identified as a toxic contributor to both neuroinflammation and neurodegenerative diseases. Vascular activation is the result
of endothelial cell damage and leads to the upregulation of a number of noxious factors. One such factor is the protease thrombin, which is produced by injured endothelial cells both in vivo and in vitro, initiating a neurotoxic cascade\textsuperscript{14–16}. Elevated levels of thrombin can be lethal to neurons through the interaction with protease activated receptor 1 (PAR-1), leading to the release of ROS and increases in an array of inflammatory proteins\textsuperscript{17,18}. Cerebrovascular activation is likely present in both AD and PD, and increased levels of both thrombin and PAR-1 have been identified in both diseases\textsuperscript{19}.

Our lab has been interested in evaluating the direct thrombin inhibitor, Dabigatran etexilate (Pradaxa\textsuperscript{®}, Boehringer Ingelheim), for the treatment of vascular dysfunction in AD\textsuperscript{14–18}. Multiple studies have shown dabigatran treatment mitigates the neurotoxic effects of thrombin in transgenic AD models\textsuperscript{14,20,21}. A single publication previously explored dabigatran etexilate in a rotenone-induced rat model of PD, exhibiting neuroprotective effects through nuclear receptor-related 1 protein\textsuperscript{22}. Dabigatran treatment is yet to be explored in transgenic models of PD.

Therefore, we utilize a \textit{Drosophila melanogaster} model of PD expressing mutant leucine-rich repeat kinase 2 (LRRK2). \textit{Drosophila melanogaster} have been heavily used in neuroscience research as their neuronal structures and circuits and neurotransmitters, such as dopamine, are similar to those found in the human brain\textsuperscript{23–25}. When dopamine is dysfunctional in \textit{Drosophila}, locomotion is impaired, similar to symptoms seen in human PD\textsuperscript{26}. Leucine-rich repeat kinase 2 (LRRK2) has been identified in both idiopathic and inherited PD, accounting for as high as 40\% of familial cases\textsuperscript{27}. Postmortem analysis revealed LRRK2 is heavily expressed in the Lewy bodies of the brain stem and cortex, as well as in the brain vasculature, axons, and neuronal cell bodies\textsuperscript{28,29}. LRRK2 mutant \textit{Drosophila} exhibit reduced lifespan,
compromised motility, and mitochondria morphological changes as compared to wildtype$^{30}$.

Herein, we hypothesize that dabigatran treatment in LRRK2 transgenic *Drosophila melanogaster* will protect against motor function deficits by reducing oxidative stress.
Materials and Methods

Drosophila Melanogaster Maintenance and Treatment

LRRK2 mutant Drosophila melanogaster (#34750, w[*]; Lrrk[ex1]/TM6B, Tb[1]) were purchased from Bloomington Stock Center (Indiana University Bloomington, Bloomington, IN). Canton S (w[*]) flies were a kind gift from Dr. Belinda Barbagallo (Salve Regina University, Newport, RI). Flies were maintained and age synchronized on Nutri-Fly BF (Genesee Scientific, San Diego, CA). Flies were separated by gender to approximately 20 flies per vial. On day 3 post eclosion, corresponding treatments were added to the media, control received 5% sucrose and dabigatran received 25 μM diluted in 5% sucrose. Treatment vials were exchanged every other day for 7 days.

Toxicity Analysis

Toxicity of dabigatran at 25 μM was identified by recording deaths per vial every other day. At least 100 individual flies per treatment were monitored and evaluated over the course of one week.

Negative Geotaxis Assay

After 7 days of treatment, flies were assayed for climbing ability. Briefly, flies were placed in empty vials marked at 5 cm and allowed to acclimate for 30 minutes. Flies were gently tapped to the bottom of the vial and a picture was taken after 10 seconds using a Nikon D2200 camera (Nikon, Tokyo, JP). Percent climbing was calculated by ((# flies above line / total # flies)*100) and standardized as a percentage to control (gender-specific).
**Drosophila Head Homogenization**

*Drosophila* were flash-frozen on dry ice and heads were collected through brass sieves, as previously reported\(^3^3\). Heads were counted and 10 μL/head of phosphate buffered saline was added for NOS and ROS. For western blots, fly heads were homogenized in phosphate buffered saline with 1X protease inhibitors. Samples were frozen immediately on dry ice and stored at -80°C. To homogenize the heads for assays, they were sonicated in a water bath for 5 min, centrifuged (10,000 RCF, 5 min, 4°C), then placed at -80°C until frozen. This process was repeated 3 times and the supernatant was collected.

**Nitric Oxide Quantification**

Nitric oxide species was quantified in fly head homogenates using the Griess Reagent System (Promega, Madison, WI, USA)\(^3^4\).

**Reactive Oxygen Species Relative Quantification**

For reactive oxygen species relative quantification, homogenates were incubated with 20 μM 2′,7′-Dichlorofluorescin Diacetate (DCFDA) at 37°C for 1h in a black-walled, clear-bottom 96-well plate. Fluorescence was then read on Spectramax (M2) plate reader at 485 nm excitation and 535 nm emission\(^3^6\).

**Western Blotting**

Fly head homogenate samples were prepared for western blot by adding 40% 4x Sample buffer (4x Laemmli Sample Buffer (BioRad, Hercules, CA, USA) with 10% 2-mercaptoethanal), heated at 100°C for 10 minutes. 15 μg of total protein was loaded on a 4-20% Gel (Invitrogen, Carlsbad, CA) and ran for 1h and 5min at 105 V
in 1x SDS-running buffer. Proteins were transferred to nitrocellulose membranes using the iBlot2 Gel Transfer Device (ThermoFisher Scientific, Waltham, MA), and membranes were blocked for 1h using 5% bovine serum albumin (BSA) in 0.05% TBS-T. Primary antibodies were incubated at room temperature for 3 hours, and then over 3 nights at 4°C. Primary antibodies used for this study include iNOS (Abcam, MA, 1:500), NOX4 (Sigma-Aldrich, MO, 1:500), SOD1 (Abcam, MA, 1:1,000), Tyrosine Hydroxylase (TH) (Novus Biologicals, Co, 1:500), and B-actin (Santa Cruz, CA, 1:10,000). Membranes were washed three times for 10 minutes with 0.05% TBS-T and incubated with infrared secondary antibodies at room temperature for 1 h. Membranes were washed and imaged on a LiCor Odyssey (LI-COR Biosciences, Lincoln, NE). Western blots were quantified in ImageJ. Values for each protein were normalized to β-actin loading control on the same blot. Data are represented as fold change, as compared to gender-specific wild type control.

Statistical Analysis

All statistical analysis was performed in GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA). For toxicity analysis, log-rank (Mantel-Cox) tests were performed to identify significant differences between vehicle and dabigatran treatment. All other data were analyzed by unpaired one-tailed t-tests. Significance was compared and reported as p ≤0.05 (*), p ≤0.01 (**), p ≤ 0.001 (***).
Results

Toxicity Analysis

Throughout the experiment, fly deaths were recorded to evaluate toxicity related to dabigatran treatment (Figure 1). Dabigatran did not induce significant death in either gender or genotype. Therefore, treatment at 25 μM was regarded as safe in this experiment.

Negative Geotaxis

Motor impairments in Drosophila were evaluated using the negative geotaxis assay (Figure 2). In male flies, LRRK2 mutants exhibited a significant reduction in climbing ability as compared to wildtype control, reported as 22% ±12.1 and 110.8% ±16.8, respectively (Figure 2A). Additionally, in LRRK2 mutant flies, dabigatran significantly improved climbing ability to 52.2% ±7.3, as compared to transgenic control. Significant motor impairments were identified in LRRK2 female control flies, as compared to wildtype (LRRK2, 56.2% ±11.1; wildtype, 100% ±12.2) (Figure 2B). Dabigatran did not exhibit any significant effects as compared to control in female flies.

Nitric Oxide Species Production

NOS production was evaluated in fly head homogenates using the Griess reagent (Figure 3). Interestingly, LRRK2 mutant flies did not exhibit increased NOS as compared to wildtype control. In male LRRK2 flies, dabigatran exhibited a significant reduction in NOS as compared to control (control 38.8 ±5; dabigatran 26.8 ±3.3) (Figure 3A). NOS was unaltered by dabigatran treatment in female LRRK2 flies (Figure 3B).
Reactive Oxygen Species

ROS production in fly head homogenates was also investigated (Figure 4). LRRK2 mutant flies did show a change in ROS production as compared to wildtype control. In male LRRK2 mutant flies, dabigatran significantly reduced ROS as compared to control (control: 455.6 ± 26.8; dabigatran 351.8 ± 18.4). Female LRRK2 flies exhibited no difference in ROS production with dabigatran treatment (Figure 4B).

Western Blot Analysis

Tyrosine hydroxylase (TH; Figure 5) expression was significantly reduced in male transgenic flies (0.54 ± 0.09) as compared to wildtype control (1.08 ± 0.1). Female flies also exhibited significant loss of TH (wildtype 1.0 ± 0.17; transgenic 0.69 ± 0.01). Dabigatran treatment did not significantly alter TH expression in either gender.

Inducible nitric oxide synthase (iNOS) (Figure 6) is directly related to nitric oxide production. Herein, we evaluated the expression of iNOS in fly head homogenates. Transgenic male flies exhibit increased expression of iNOS, as compared to wildtype control, reporting 1.6 ± 0.32 and 0.89 ± 0.18, respectively. Dabigatran treatment in transgenic male flies reduced iNOS expression, though not significantly. Female flies exhibited no significant differences between groups.

Superoxide dismutase 1 (SOD1) is heavily involved in ROS production, herein, we evaluated protein expression by western blot (Figure 7). SOD1 was significantly elevated in male transgenic homogenates, as compared to wild type (transgenic 1.4 ± 0.16; wildtype 0.68 ± 0.07). Dabigatran treatment reduced SOD1 expression to 0.84 ± 0.05. Female fly homogenates followed a similar pattern. Wild type control flies exhibited 0.83 ± 0.1, whereas transgenic control showed 1.2 ± 0.09. In females, dabigatran treatment reduced SOD1 expression to 0.82 ± 0.09.
NADPH oxidase 4 (NOX4) expression was evaluated in Drosophila head homogenates (Figure 8). Transgenic male flies exhibit significantly increased expression of NOX4 compared to wildtype control, reporting $1.5 \pm 0.06$ and $1.0 \pm 0.03$, respectively. Dabigatran treatment in transgenic male flies reduced NOX4 expression to $0.61 \pm 0.14$. Females exhibited no significant changes in NOX4 expression.
Discussion

Currently, there are no treatments that stop or even slow the progression of neurodegenerative diseases. Therefore, it is imperative to explore novel approaches aside from classical targets. Neuroinflammation has been identified as a major contributor in AD and PD that may begin years before an official diagnosis. Activated brain vasculature can lead to an increase in disease severity. In PD, a variety of genetic mutations have recently been identified in disease pathology. One of the most common mutations, LRRK2, is heavily expressed in the vasculature of the brain. It was hypothesized that by inhibiting the vascular protein thrombin, neuroinflammation would be reduced in a transgenic PD model.

In PD, motor impairments are the main disease identifier, typically shown by tremors or motor function instabilities in humans. *Drosophila melanogaster* models of PD exhibit similar motor impairments that are believed to be linked to loss of dopaminergic neuronal function. Therefore, we first assayed motor function in wild type and transgenic flies in the negative geotaxis assay. As anticipated, in both genders, a significant reduction in climbing ability was seen in the transgenic as compared to the wildtype control. Dabigatran treatment in male transgenic flies alone exhibited improvement in climbing.

Parkinson’s disease loss of motor control is heavily regulated by the loss of functional neurotransmitter dopamine. *Drosophila melanogaster* exhibit many similarities to humans, namely, there are distinct dopamine clusters that correspond to locomotor control, and dopamine synthesis is conserved. Regulation of dopamine is limited by protein tyrosine hydroxylase (TH), which converts tyrosine to dopamine. Therefore, we performed western blotting to quantify tyrosine hydroxylase expression in fly head homogenates to identify the correlation between TH levels and the
observed motor function. In transgenic male flies, there was a significant reduction in TH as compared to wildtype control. However, dabigatran treatment did not improve the levels of TH. This suggests that alternative processes may be involved.

The production of nitric oxide and reactive oxygen species are linked to both neuroinflammation and damaged cerebrovasculature in neurodegenerative diseases\(^5,42,43\). Dabigatran treatment has been shown to decrease oxidative stress markers in diseased models\(^14,20,21\). LRRK2 has also been associated with increases in these mediators of oxidative stress\(^44\). In Drosophila melanogaster NOS and ROS production can be altered with dietary modifications\(^35,45,46\). Here, surprisingly, NOS was reduced in transgenic flies as compared to wildtype. However, dabigatran treatment significantly reduced NOS production as compared to control in transgenic male flies. No differences were found in the females. Additionally, ROS was significantly reduced in male LRRK2 flies following dabigatran treatment. To further investigate these results, we analyzed the expression of proteins in the regulatory pathways of each NOS and ROS production.

NOS is essential to normal function, but the continuous production of NOS leads to excessive toxicity in the central nervous system\(^47\). iNOS is one of three isoforms that contributes to the production of NOS. Activated microglia induce cytokine activity, leading to iNOS production which has been deemed neurotoxic\(^48,49\). We analyzed iNOS to get a better understanding of toxic NOS production. In transgenic male Drosophila, iNOS expression correlates to NOS levels. Females did not follow a similar trend.

Similar to NOS, ROS is toxic when overproduced. ROS is regulated by a variety of mediators. We chose two markers, namely, SOD1 and NOX4. Superoxide dismutases are essential in the breakdown of superoxide into oxygen and hydrogen peroxide\(^50\). Typically, an increase in the expression of SOD1 indicates an elevation in
ROS. In both male and female *Drosophila*, SOD1 was elevated in transgenic as compared to wildtype. Additionally, dabigatran treatment reduced SOD1 expression. Interestingly, these differences did not exactly mimic identified ROS levels. In *Drosophila melanogaster*, it has been contested whether SOD directly correlates to ROS\textsuperscript{50}. NADPH oxidases are another family of enzymes that regulate ROS production\textsuperscript{51}. NOX4 is heavily expressed in endothelial cells and contributes directly to ROS production\textsuperscript{52}. Male *Drosophila* exhibited increased NOX4 in transgenic flies. Additionally, dabigatran treatment reduced NOX4. Similar to SOD1, NOX4 expression does not directly correlate to ROS production.

Interestingly, our data reports differences in treatment response by gender. In human PD, the incidence, progression, and symptom severity present differently in males and females\textsuperscript{53,54}. These differences have been largely attributed to hormonal differences\textsuperscript{55,56}. Sex differences in *Drosophila* have frequently been overlooked. However, reports on lifespan indicate the potential of extreme differences between gender in flies\textsuperscript{57}. 
Conclusions

Here, we explore direct thrombin inhibitor, dabigatran, in a transgenic *Drosophila melanogaster* model for the first time. Our results indicate that dabigatran treatment improves motor function by reducing oxidative stress. Future research should evaluate dabigatran treatment in additional models of Parkinson’s disease, focusing on the progression and pathology. These initial findings should be investigated in alternative transgenic models of PD and evaluated for effects on behavior as well as biochemical markers of pathology to further elucidate mechanisms of action.
Funding
Spectroscopic data were collected from instruments in the Rhode Island-IDEA Network for Excellence in Biomedical Research core facility, supported by Grant # P20GM103430 from the National Institute of General Medical Sciences of the National Institutes of Health.

Acknowledgements
We would like to thank Belinda Barbagallo at Salve Regina University for contributing wildtype *Drosophila melanogaster*.

Conflicts of Interest
Authors declare no conflicts of interest.
Figure 1. Analysis of treatment induced toxicity in wildtype and transgenic *Drosophila melanogaster*. Flies were exposed to sucrose or dabigatran (25 µM) over 1 week of treatment in males (A) and females (B) (n≥100).
Figure 2. Effects of dabigatran on negative geotaxis in *Drosophila melanogaster*. Male (A) and female (B) flies were evaluated on negative geotaxis after seven days of treatment (n≥8). Data expressed as percent of wildtype control, significance determined by t-test, p ≤ 0.05 (*); p ≤ 0.001 (***).
Figure 3. Evaluation of nitric oxide species production in *Drosophila melanogaster* head homogenate. Male (A) and female (B) homogenates treated for 1 week with control or dabigatran (25 µM) (n≥8). Statistical significance determined by t-test, p ≤0.05 (*).
Figure 4. Effects of dabigatran (25 μM) on reactive oxygen species production in wildtype and transgenic *Drosophila melanogaster*. Head homogenates in males (A) and females (B) after 1 week treatment (n≥8). Significance determined by t-test, p ≤ 0.01 (**).
Figure 5. Quantification of tyrosine hydroxylase (TH) by western blot in *Drosophila melanogaster* head homogenates. Expression was evaluated in male (A) and female (B) homogenates after 1 week of control or dabigatran treatment (n≥3). Significance determined by t-test, p ≤ 0.05 (*); p ≤ 0.01 (**).
Figure 6. Western blot analysis of inducible nitric oxide synthase (iNOS) in *Drosophila melanogaster* head homogenate. Control or dabigatran (25 M) treatment for 1 week in males (A) and females (B) (n≥3). Statistical significance was determined by t-test, *p* ≤ 0.01 (**).
Figure 7. Superoxide dismutase 1 (SOD1) expression in *Drosophila melanogaster*. Evaluation of SOD1 after 1 week treatment with control or dabigatran in male (A) and female (B) *Drosophila* (*n*≥3). Statistical significance was determined by t-test, *p* ≤ 0.05 (*); *p* ≤ 0.01 (**).
Figure 8. Evaluation of NADPH (NOX4) by western blot in *Drosophila melanogaster*. Male (A) and female (B) flies were subject to treatment for 1 week \((n \geq 3)\). Statistical significance was determined by t-test, \(p \leq 0.01\) (**)\; \(p \leq 0.0001\) (***).
References

1. Rane, P. et al. Novel targets for Parkinson’s Disease: Addressing different therapeutic paradigms and conundrums. ACS Chem. Neurosci. 10, 44–57 (2019).

2. Lane, C. A., Hardy, J. & Schott, J. M. Alzheimer’s disease. Eur. J. Neurol. 25, 59–70 (2018).

3. Gaugler, J., James, B., Johnson, T., Scholz, K. & Weuve, J. 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 12, 459–509 (2016).

4. Marras, C. et al. Prevalence of Parkinson’s disease across North America. npj Park. Dis. 4, (2018).

5. Richard M. Ransohoff. How neuroinflammation contributes to neurodegeneration. Science (80-. ). 353, 772–777 (2016).

6. Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015).

7. Kaur, K., Gill, J. S., Bansal, P. K. & Deshmukh, R. Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson’s disease. J. Neurol. Sci. 381, 308–314 (2017).

8. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 8, 382–397 (2009).

9. Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358–72 (2015).

10. Fakhoury, M. Microglia and astrocytes in Alzheimer’s disease: implications for therapy. Curr. Neuropharmacol. 16, 508–518 (2018).

11. Subhramanyam, C. S., Wang, C., Hu, Q. & Dheen, S. T. Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin. Cell Dev. Biol. 94, 112–120 (2019).
12. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C. & Gage, F. H. Mechanisms Underlying Inflammation in Neurodegeneration. *Cell* **140**, 918–934 (2010).

13. Smith, J. A., Das, A., Ray, S. K. & Banik, N. L. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. *Brain Res. Bull.* **87**, 10–20 (2012).

14. Tripathy, D. *et al.* Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. *Front. Aging Neurosci.* **5**, 1–9 (2013).

15. Yin, X., Wright, J., Wall, T. & Grammas, P. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. *Am. J. Pathol.* **176**, 1600–1606 (2010).

16. Luo, J. *et al.* Hypoxia induces angiogenic factors in brain microvascular endothelial cells. *Microvasc. Res.* **83**, 138–145 (2012).

17. Coughlin, S. R. Thrombin signalling and protease-activated receptors. *Nature* **407**, 258–64 (2000).

18. Grammas, P. & Martinez, J. M. Targeting thrombin: An inflammatory neurotoxin in alzheimer's disease. *J. Alzheimer's Dis.* **42**, S537–S544 (2014).

19. Sokolova, E. & Reiser, G. Prothrombin/thrombin and the thrombin receptors PAR-I and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases. *Thromb Haemost* **100**, 576–581 (2008).

20. Lee, I.-O., Kratz, M. T., Schirmer, S. H., Baumhakel, M. & Bohm, M. The Effects of Direct Thrombin Inhibition with Dabigatran on Plaque Formation and Endothelial Function in Apolipoprotein E-Deficient Mice. *J. Pharmacol. Exp. Ther.* **343**, 253–257 (2012).

21. Hawkins, B. T., Gu, Y. H., Izawa, Y. & Del Zoppo, G. J. Dabigatran abrogates brain endothelial cell permeability in response to thrombin. *J. Cereb. Blood..."
Flow Metab. 35, 985–992 (2015).

22. Kandil, E. A., Sayed, R. H., Ahmed, L. A., Abd El Fattah, M. A. & El-Sayeh, B. M. Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etxilate in Rotenone-Induced Parkinson’s Disease in Rats. Mol. Neurobiol. 55, 4078–4089 (2018).

23. De Nobrega, A. K. & Lyons, L. C. Aging and the clock: Perspective from flies to humans. Eur. J. Neurosci. (2018). doi:10.1111/ejn.14176

24. Chiang, A. S. et al. Three-dimensional reconstruction of brain-wide wiring networks in drosophila at single-cell resolution. Curr. Biol. 21, 1–11 (2011).

25. Yu, H. H. et al. Clonal development and organization of the adult Drosophila central brain. Curr. Biol. 23, 633–643 (2013).

26. Hirth, F. Drosophila melanogaster in the Study of Human Neurodegeneration. CNS Neurol. Disord. -Drug Targets 9, 504–523 (2010).

27. Lesage, S. et al. LRRK2 G2019S as a Cause of Parkinson’s Disease in North African Arabs. N. Engl. J. Med. 354, 422–423 (2006).

28. Miklossy, J. et al. LRRK2 Expression in Normal and Pathologic Human Brain and in Human Cell Lines. J. Neuropathol. Exp. Neurol. 65, 953–963 (2006).

29. Zhu, X. et al. LRRK2 in Parkinson’s disease and dementia with Lewy bodies. Mol. Neurodegener. 1, (2006).

30. De Rose, F., Marotta, R., Poddighe, S. & Talani, G. Functional and Morphological Correlates in the Drosophila LRRK2 loss-of-function Model of Parkinson’s Disease: Drug Effects of Withania somnifera (Dunal) Administration. PLoS One (2016). doi:10.1371/journal.pone.0146140

31. Johnson, S. L. et al. Levodopa-reduced mucuna pruriens seed extract shows neuroprotective effects against parkinson’s disease in murine microglia and human neuroblastoma cells, Caenorhabditis elegans, and Drosophila
melanogaster. *Nutrients* **10**, 1–14 (2018).

32. Phom, L., Achumi, B., Alone, D. P., Muralidhara & Yenisetti, S. C. Curcumin’s Neuroprotective Efficacy in *Drosophila* Model of Idiopathic Parkinson’s Disease Is Phase Specific: Implication of its Therapeutic Effectiveness. *Rejuvenation Res.* **17**, 481–489 (2014).

33. Walker, J. M. *Methods in Molecular Biology: Circadian Rhythms Methods and Protocols*. (Humana Press Inc, 2007).

34. Ma, H. *et al.* Evaluation of polyphenol anthocyanin-enriched extracts of blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry for free radical scavenging, reactive carbonyl species trapping, anti-glycation, anti-β-amyloid aggregation, and mic. *Int. J. Mol. Sci.* **19**, (2018).

35. Poetini, M. R. *et al.* Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in Drosophila melanogaster model of Parkinson’s disease. *Chem. Biol. Interact.* **279**, 177–186 (2018).

36. Pilotto, A. *et al.* Vascular risk factors and cognition in Parkinson’s disease. *J. Alzheimer’s Dis.* **51**, 563–570 (2016).

37. Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W. & Zlokovic, B. V. The role of brain vasculature in neurodegenerative disorders. *Nat. Neurosci.* **21**, 1318–1331 (2018).

38. Grammas, P. *et al.* A New Paradigm for the Treatment of Alzheimer’s Disease: Targeting Vascular Activation. *J. Alzheimer’s Dis.* **40**, 619–630 (2014).

39. Lee, H., James, W. S. & Cowley, S. A. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson’s disease. *Biochem. Soc. Trans.* **45**, 131–139 (2017).

40. White, K. E., Humphrey, D. M. & Hirth, F. The dopaminergic system in the
aging brain of Drosophila. *Front. Neurosci.* **4**, 1–12 (2010).

41. Daubner, S. C., Le, T. & Wang, S. Tyrosine Hydroxylase and Regulation of Dopamine Synthesis. *Arch Biochem Biophys* **508**, 1–12 (2012).

42. Taylor, J. M., Main, B. S. & Crack, P. J. Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease. *Neurochem. Int.* **62**, 803–819 (2013).

43. Holmes, C. Inflammation in Alzheimer’s disease. *Dementia, Fifth Ed.* **14**, 508–518 (2017).

44. Li, J. Q., Tan, L. & Yu, J. T. The role of the LRRK2 gene in Parkinsonism. *Mol. Neurodegener.* **9**, 47 (2014).

45. Oboh, G., Ogunsuyi, O. B., Ojelade, M. T. & Akomolafe, S. F. Effect of dietary inclusions of bitter kola seed on geotactic behavior and oxidative stress markers in Drosophila melanogaster. *Food Sci. Nutr.* **6**, 2177–2187 (2018).

46. De Rose, F. *et al.* Drosophila Mutant Model of Parkinson’s Disease Revealed an Unexpected Olfactory Performance: Morphofunctional Evidences. *Parkinsons. Dis.* **2016**, 1–10 (2016).

47. Calabrese, V. *et al.* Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity. *Nat. Rev. Neurosci.* **8**, 766–775 (2007).

48. Yuste, J. E., Tarragon, E., Campuzano, C. M. & Ros-Bernal, F. Implications of glial nitric oxide in neurodegenerative diseases. *Front. Cell. Neurosci.* **9**, 1–13 (2015).

49. Garry, P. S., Ezra, M., Rowland, M. J., Westbrook, J. & Pattinson, K. T. S. The role of the nitric oxide pathway in brain injury and its treatment - From bench to bedside. *Exp. Neurol.* **263**, 235–243 (2015).

50. Wang, Y., Branicky, R., Noë, A. & Hekimi, S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. *J. Cell Biol.*
51. Paravicini, T. M. & Touyz, R. M. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. *Diabetes Care* **31 Suppl 2**, (2008).

52. Schröder, K. *et al.* Nox4 Is a protective reactive oxygen species generating vascular NADPH oxidase. *Circ. Res.* **110**, 1217–1225 (2012).

53. Cerri, S., Mus, L. & Blandini, F. Parkinson's Disease in Women and Men: What's the Difference? *J. Parkinsons. Dis.* **9**, 501–515 (2019).

54. Smith, K. M. & Dahodwala, N. Sex differences in Parkinson's disease and other movement disorders. *Exp. Neurol.* **259**, 44–56 (2014).

55. Siani, F. *et al.* Influence of estrogen modulation on glia activation in a murine model of parkinson's disease. *Front. Neurosci.* **11**, 1–11 (2017).

56. Rugbjerg, K., Christensen, J., Tjønneland, A. & Olsen, J. H. Exposure to estrogen and women’s risk for Parkinson’s disease: A prospective cohort study in Denmark. *Park. Relat. Disord.* **19**, 457–460 (2013).

57. Austad, S. N. & Fischer, K. E. Sex Differences in Lifespan. *Cell Metab* **23**, 1022–1033 (2016).
CHAPTER 4

MANUSCRIPT 6

Direct thrombin inhibitor, dabigatran etexilate, reduces oxidative stress in vivo in a transgenic mouse model of Alzheimer’s disease

Running Title: Thrombin inhibition in a tau-based AD model

Jaclyn Iannucci\textsuperscript{a,b,‡}, Shelby Johnson\textsuperscript{a,b,‡}, Mark Majchrzak\textsuperscript{a}, Benjamin J. Barlock\textsuperscript{b}, Fatemeh Akhlaghi\textsuperscript{b}, Navindra P. Seeram\textsuperscript{a,b}, Abhik Sen\textsuperscript{a}, William Renehan\textsuperscript{a}, Paula Grammas\textsuperscript{a,b,*}

\textsuperscript{a} The George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI, 02881
\textsuperscript{b} Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881

\‡ Equal contribution

* Corresponding author: Paula Grammas, University of Rhode Island, George and Anne Institute for Neuroscience, Department of Biomedical and Pharmaceutical Sciences, 7 Greenhouse Rd, Kingston, RI 02881 Email: pgrammas@uri.edu
Abstract

Background. Thrombin is neurotoxic and is elevated in the brain and cerebrovasculature in Alzheimer’s disease (AD). We have identified thrombin as a key mediator of vascular inflammation in AD with data demonstrating that thrombin inhibition is protective in an amyloid based animal model. Here, we investigate the role of thrombin as a pathological mediator in a tau-based animal model of AD. We hypothesize that thrombin inhibition will reduce oxidative stress, inflammation, and pathology related to tau in vivo.

Methods. 15-month-old Tg4510 mice were treated with the direct thrombin inhibitor dabigatran etexilate or control for 7 days. Brains were collected, and western blot and LC-MS/MS SWATH analysis were performed to evaluate proteins related to coagulation, oxidative stress, intracellular signaling, and tau-pathology.

Results. Dabigatran etexilate treatment reduces thrombin and thrombin-related proteins. MAPK related proteins exhibited significant differences following dabigatran etexilate treatment. Treatment also reduced oxidative stress-related proteins and increased expression of antioxidant proteins. Total tau and related phosphorylated tau species were significantly increased in transgenic mice compared to wild type. Dabigatran treatment slightly reduced expression of total tau and significantly altered the tau phosphorylation pattern. Proteins identified as downregulated in human AD were also significantly altered with dabigatran treatment compared to control.

Conclusions. Taken together, these data indicate short-term treatment with a direct thrombin inhibitor modulates protein expression in the brains of aged Tg4510 mice. This finding supports our hypothesis that targeting thrombin, a key mediator of neuroinflammation and neurotoxicity may be effective in reducing AD-related
pathology. Further studies are needed to better understand the mechanisms of action and possible neuroprotective benefits of thrombin inhibition.

**Keywords:** Alzheimer’s disease, Inflammation, Oxidative Stress, Thrombin, Tau
Introduction

Cardiovascular disease and cardiovascular risk factors (CVRFs) are strongly associated with an increased risk of developing dementia, particularly Alzheimer’s disease (AD). Hypertension, hypercholesterolemia, hyperhomocysteinemia, diabetes, atherosclerosis, and hypoxia are all linked with an increased risk of developing AD [1-5]. While the connection between CVRFs and AD is well-documented, the mechanism by which the disorders are connected is not well understood. It is likely there are several, pathological mediators involved in the progression of both disorders.

One such mediator is the serine protease thrombin, the main driver of the coagulation cascade [6]. Thrombin is indicated as a potential pathological mediator in both cardiovascular disease and AD. Thrombin has been implicated in atherosclerosis and diabetes-related pathology [7-11]. Thrombin is also elevated in the Alzheimer’s brain. Past studies found increased thrombin and reduced levels of the thrombin inhibitor protease nexin-1 in the brain of Alzheimer’s patients compared to healthy controls; this elevation was largely localized in vessels, amyloid deposits, and neurofibrillary tangles [12-14]. Thrombin is also elevated in AD patient-derived microvessels, and brain endothelial isolated from AD patients synthesize their own thrombin [15, 16]. Thrombin is a mediator of vascular-derived oxidative stress and inflammation. Aside from its pro-coagulant activity, thrombin has well-documented pro-inflammatory and pro-oxidative effects on several cell types in the body, largely through its activation of protease-activated receptors (PARs) [17, 18]. In the periphery, increased thrombin in disease is related to the formation of atherosclerotic plaques, endothelial cell activation, and an increase in both inflammatory cytokines and reactive oxygen species (ROS) [7, 19-21].
Thrombin has similar effects in the brain as it does in the periphery. Thrombin treatment induces alteration of endothelial cell phenotype at the blood-brain barrier (BBB), leading to changes in adhesion and tight junction formation [22, 23]. Thrombin also stimulates endothelial cells to release inflammatory factors and ROS; similar increases are found in the AD cerebrovasculature [15, 24-29]. Thrombin treatment of microglia induces a pro-inflammatory phenotype characterized by increases in ROS, NO, and cytokine production [30-33]. Thrombin is also associated with increased pro-inflammatory, reactive astrocytes in the brain [34-37]. Additionally, thrombin exerts direct neurotoxicity by several mechanisms, including alterations in the neuronal cell cycle, induction of pro-apoptotic proteins, and NADPH-oxidase mediated oxidative stress [38, 39].

Thrombin is also associated with AD-related hallmarks in the brain, including tau, amyloid aggregation, and apolipoprotein E [40-44]. Rats treated with thrombin in vivo exhibit cognitive deficits along with cell death and glial scarring [35]. Thrombin may be involved in the altered processing and secretion of amyloid precursor protein (APP), and thrombin cleavage of apolipoprotein E4 results in a neurotoxic fragment [42-44]. Thrombin accumulation has been identified in neurofibrillary tangles, and thrombin induces rapid tau aggregation [40, 41].

Thrombin is related to altered processing and aggregation of tau, but the role of thrombin as a pathological mediator has not yet been explored in a tau-based model of AD. Currently, a number of tauopathy animal models are being used to study AD. One such model is the Tg4510, which overexpresses human tau with a P301L mutation at 13:1 versus murine tau [45]. These mice exhibit profound tau pathology and neuronal loss in the hippocampus and cortex, as well as cognitive deficits and metabolic changes. The pathology starts early at about 2 to 4 months of
age and progresses with age [45, 46]. The pathological features, including tau hyperphosphorylation synapse loss, are more pronounced in females than males [47]. Additionally, the tg4510 mouse model displays blood vessel abnormalities accompanied by alterations in oxidative and inflammatory markers [48].

We suggest that thrombin is a mediator of cerebrovascular-derived inflammation and neurotoxicity in AD, and therefore targeting thrombin may be a worthy therapeutic strategy to combat Alzheimer’s disease-related pathology. Our lab has focused on the direct thrombin inhibitor Dabigatran etexilate (Pradaxa®, Boehringer Ingelheim), a commonly prescribed anticoagulant that is administered orally. In a previous paper, we identified that dabigatran etexilate treatment for 34 weeks in 3xTg AD mouse model reduced levels of oxidative stress and markers of cerebrovascular inflammation in the brain [49].

The objective of this study is to investigate the role of thrombin as a pathological mediator and the potential therapeutic benefits of inhibiting thrombin in an animal model of tauopathy and AD. We explore the effects of short-term treatment with direct thrombin inhibitor, dabigatran etexilate, in aged Tg4510 mice. We hypothesize that inhibiting thrombin will reduce oxidative stress and inflammation-related indicators corresponding to an overall reduction in tau-related dysfunction in the brain.
Materials and Methods

Animals and Treatment

Transgenic Tg4510 AD mice overexpressing human mutant tau (P301L) and background matched controls were a kind gift from MindImmune Therapeutics, Inc. originally obtained from Charles River (Wilmington, MA, USA). Mice were maintained on normal chow (ENVIGO 2020X, Huntingdon, UK) with water available ad libitum. At 15 months of age, mice were treated via oral gavage with vehicle (2.5% DMSO, 2.5% koliphor EL, 90% diH2O) or dabigatran etexilate (100 mg/kg in uniform suspension, Cayman Pharm, Ann Arbor, MI) for 7 days. After 7 days, mice were deeply anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) administered I.P. and euthanized.

Western blot

Whole brains were removed post-sacrifice and the cerebellum was detached. Tissues were homogenized by sonication (Branson SX150 Sonifier ®, Branson Ultrasonics, Danbury, CT) in 9x brain volume of 1X PBS with protease inhibitors. To prepare samples for western blot, samples were mixed with equal parts 2x Sample Buffer (4x Laemmli sample buffer with 10% 2-mercaptoethanol, 50% diH2O) and heated at 100°C for 10 minutes. Samples containing 25 µg total protein were loaded on a 4-20% Gel (NOVEX) that was run at 105 V for 1 hour and 5 minutes in 1x SDS-running buffer. Proteins were then transferred to nitrocellulose membranes using iBlot2 Gel Transfer Device (ThermoFisher Scientific, Waltham, MA). Membranes were blocked using antibody-specific concentration of BSA or Milk in 0.05% TBS-T for one hour. Primary antibodies for this study include thrombin (Abcam, MA; 1:500), fibrin (Santa Cruz, CA; 1:250), NOX4 (Sigma, MA; 1:1,000), iNOS (Abcam, MA; 1:250), SOD1 (Abcam, MA; 1:1,000), SOD2 (Abcam, MA; 1:2,000), GFAP (Abcam, MA;
1:10,000), Iba1 (GeneTex, CA; 1:1,000). Tau and p-tau species were detected using phosphor-tau family antibody sampler kit (Cell Signaling, MA). Primary antibodies were added overnight at 4°C. Membranes were washed three times for 5 minutes with 0.05% TBS-T and incubated with infrared secondary antibodies for 1 hour at room temperature. Membranes were washed as before and then imaged on a LiCor Odyssey (LI-COR Biosciences, Lincoln, NE). Quantification of western blots was done in ImageJ. Values for each protein were normalized to actin or GAPDH loading control on the same blot. Data represented as fold change, as compared to TgV.

**Pressure Cycling Technology Based Protein Digestion**

Whole brain homogenates were further digested using pressure cycling technology (PCT) for LC-MS/MS SWATH acquisition following the method by Jamwal et al. 2017 with slight modifications [50]. Each sample, containing 500 µg of protein, was spiked with 2 ng of bovine serum albumin (BSA). Samples were then incubated with dithiothreitol (100 mM) at 90°C for 15 minutes (100 rpm). Iodoacetamide (200 mM) was added and samples were incubated at room temp in the dark for 30 minutes. Protein was then precipitated by using the ice-cold chloroform, methanol and water method (1:2:1) followed by centrifugation at 12,000 RPM for 5 minutes at 10°C. The protein pellet was rinsed with methanol and resuspended in 3% w/v sodium deoxycholate (DOC) in 50 mM ammonium bicarbonate. Samples were placed in MicroTubes (Pressure BioSciences Inc, South Easton, MA) with trypsin at a 1:20 ratio of trypsin:protein. Digestion was performed at 55°C for 75 cycles (50 sec at 35kpsi, 10 sec at ambient pressure) in a Barocycler NEP2320-45k (Pressure BioSciences Inc). A second digestion was performed by adding fresh trypsin at the same ratio and running the barocycler for an additional 60 cycles. Samples were then transferred to microcentrifuge tubes where digestion was stopped and DOC was
precipitated by the addition of formic acid in acetonitrile at a final percentage of 0.5%. Samples were centrifuged and supernatant was collected for analysis.

*Mass Spectrometry Data Acquisition with SWATH-MS*

Mass spectrometry was performed as previously described with minor modifications [50]. Samples were analyzed on a SCIEX TripleTOF® 5600 mass spectrometer using a DuoSpray™ ion source (SCIEX, Framingham, MA) coupled to an Acquity HClass UHPLC system (Waters Corp., Milford, MA). Separation was achieved on an Acquity UPLC Peptide BEH C18 column (2.1 x 150 mm, 300 Å, 1.7 µm) with an Acquity VanGuard pre-column (2.1 x 5 mm, 300 Å, 1.7 µm). The column temperature was set to 50˚C and the autosampler was set to 10˚C. A linear gradient was used with a flow rate of 100 µL/min for 90 min. Mobile phase A consisted of 99.9% acetonitrile and 0.1% formic acid. Mobile phase B consisted of 99.9% water and 0.1% formic acid. The gradient was as follows: 98% A from 0 to 5 min, 98% to 75% from 5 to 55 min, 75% to 50% A from 55 to 60 min, 50% to 20% from 60 to 70 min. Mobile phase A was held at 20% from 70 to 75 min and returned to 98% A at 80 min. The column was held at 98% A for 10 min to equilibrate prior to the next sample. A mixture of trypsin-digested β-galactosidase peptides were used between every 8 samples to calibrate masses and monitor the TOF detector.

Positive ionization mode was used for data dependent acquisition. The mass spectrometer parameters are as follows: gas 1, gas 2, curtain gas, temperature and ion spray voltage floating were 55 psi, 60 psi, 25 psi, 450˚C, 5500 V, Respectively. Declustering potential was 10, collision energy 10 and collision energy spread 15. For data acquisition, a maximum of 50 candidate ions were monitored for each survey scan. All ions had a charge state from 2 to 4. A range of m/z 300-1250 was used for exclusion criteria and all ions that had an intensity greater than 25 cps were chosen.
for MS/MS analysis. The temperature was set at 450°C and the total cycle time was 3.5 sec with a mass tolerance of 50 mDa during the first 0.75 sec survey scan.

For SWATH analysis, all parameters were the same as above except for the following: Seventy SWATH windows per cycle were collected over m/z 400-1100 with each window size being m/z 10 and TOF masses were collected from m/z 300 to 1500.

**Mass Spectrometry Data Analysis**

LC-MS/MS SWATH data was used to generate spectral libraries through ProteinPilot (SCIEX, Framingham, MA). Proteins of interest were identified and investigated. FASTA files were downloaded from UniProt and imported into Skyline (MacCoss Lab, University of Washington). In Skyline, at least 3 transitions were selected per peptide, and at least 3 peptides per protein were chosen. Once data was analyzed, the MPPreport (MacCoss Lab, University of Washington) was generated and exported to excel. In excel, transitions were averaged, and the sum of each peptide was calculated to yield the total area under the curve representative of each protein. These were then standardized to internal standard, BSA.

**Statistical analysis**

Data from each experiment are expressed as mean +/- standard error (SEM), unless otherwise indicated. All tests were performed in GraphPad prism. Analysis was done by unpaired, one-tail t-test. Statistical significance was determined at p<0.05. Significance for all tests was defined as follows: p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***) and p ≤ 0.0001 (****).
Results

One-week dabigatran etexilate treatment reduces expression of coagulation related proteins

The expression of major proteins involved in coagulation, namely, thrombin, prothrombin and fibrin were evaluated by western blot. Thrombin levels remained unaltered in wild type as compared to Tg-Vehicle. Although not significant, dabigatran treatment decreased thrombin by 33% as compared to Tg-Vehicle (Figure 1A). Prothrombin was significantly lower in wild type mice by 44% compared to Tg-Vehicle (Figure 1B). Dabigatran treatment significantly reduced prothrombin by 46.7% as compared to Tg-Vehicle. Fibrin levels were slightly reduced in both wildtype (54.9%) and dabigatran etexilate (44.4%) as compared to Tg-Vehicle (Figure 1C).

Dabigatran etexilate reduces oxidative-stress related proteins

Inducible nitric oxide synthase (iNOS) and NADPH oxidase 4 (NOX4) are enzymes involved in the activation of oxidative stress by catalyzing the production of NOS and ROS. The expression of iNOS was significantly reduced in wild type and Tg-Dabigatran, as compared to Tg-Vehicle by 23.5% and 17.4%, respectively (Figure 2A). Tg-Dabigatran also significantly reduced NOX4 expression by 24.7% as compared to Tg-Vehicle (Figure 2B).

Dabigatran etexilate increases expression of superoxide dismutases

Expression of antioxidant related proteins, superoxide dismutase 1 (SOD1) and superoxide dismutase 2 (SOD2) was also evaluated by western blot (Figure 3). No differences were reported between wild type and Tg-Vehicle. Tg-Dabigatran significantly increased the expression of both SOD1 and SOD2 by 34.2% and 20.7%, respectively.

Effect of Dabigatran etexilate on neuroinflammatory proteins
Glial fibrillary acidic protein (GFAP) and ionized calcium binding adaptor molecule 1 (IBA1) are markers of activated astrocytes and microglia, respectively. These neuroinflammatory markers were significantly elevated in Tg-Vehicle as compared to wild type mice (Figure 4). Tg-Dabigatran exhibited slightly lower GFAP (0.78 ±0.12) and Iba1 (0.95 ±0.12) expression than Tg-Vehicle, but reductions were not significant.

*Dabigatran etexilate treatment alters tau phosphorylation but not overall expression*

Total tau and phosphorylated forms S396, S404 and S416 were evaluated by western blot (Figure 5). Tg-Vehicle expressed 75.9% more total tau than wild type mice (Figure 5A). Tg-Dabigatran exhibited 22.1% less total tau as compared to Tg-Vehicle. Wild type mice exhibited significantly lower levels of all three phosphorylated tau forms. Tg-Dabigatran showed decreased levels of S396 and S416, by 32.8 and 29.2%, respectively. Interestingly, S404 was elevated by 14.9% in Tg-Dabigatran, as compared to Tg-Vehicle.

*LC-MS/MS SWATH acquisition identifies significant proteomic differences between wild type and Tg-Vehicle mice*

Major proteins involved in coagulation, AD, inflammation and tau-related pathology were identified and evaluated using LC-MS/MS SWATH acquisition (Table 1). Significant differences in protein expression were first evaluated between wildtype and transgenic mice, visualized with a volcano plot (Figure 6A). Coagulation related proteins exhibited significant differences in FIBB, ICAM5, KPCD, MMP9, and RACK1. Differences were seen in inflammation related proteins DLG4, GFAP, NOS3 and TLR4. Alzheimer’s disease related proteins that were significantly altered in Tg4510 mice were A4, APOE, BACE1, TAU (Human), TAU (Mouse), and TAU (Total). A recent publication identified proteomic signatures in the human brain affected by tau
pathology (Mendoça, 2019). From this publication we identified a list of tau-related pathology proteins and explored these differences. Wildtype to Tg4510 brains exhibited significant differences in G6PD1, HPCA, KCC2A, NAC2, SV2B, TBB3 and VIME.

LC-MS/MS SWATH Acquisition identifies significant proteomic expression between vehicle and dabigatran etexilate treated transgenic mice

Alzheimer’s disease, coagulation, inflammation and Tau-related identified proteins were further evaluated to identify differences between vehicle and dabigatran etexilate treated transgenic mice (Figure 6B). The pathway most influenced by dabigatran etexilate treatment was the coagulation cascade. Significant differences were seen in ANT3, ICAM1, ITAL, ITB2, KPCB, KPCD, MK08, MK09, MP2K1, MP2K2, ROCK2 and VCAM (Figure 7A). Inflammatory proteins were also significantly altered, namely, COX2, DLG4, and DYN1 (Figure 7B). BACE1 was the single altered protein from the group of AD-related proteins. Significant differences were seen in Tau-related proteins, ANS1B, G3BP2, HPCA, NCKP1, SV2B, SYGP1 and TBB3 (Figure 7C).
Discussion

Increasing evidence has shown elevated levels of thrombin and thrombin-related proteins of the coagulation cascade in the brains of Alzheimer’s disease patients [12-14, 40-44, 51]. Further, thrombin accumulation is co-localized with tau aggregation [40, 41]. Herein, we propose that inhibiting thrombin in a tau-pathology mouse model may identify an alternative approach to combat Alzheimer’s disease-related pathology.

Our data shows the efficacy of treatment with a direct thrombin inhibitor, dabigatran etexilate, in a tau mouse model. As expected, the drug treatment reduces thrombin and proteins increased by thrombin activity (prothrombin, fibrin), confirming normal drug action. In addition to coagulation, dabigatran etexilate treatment also produced alterations in the expression of proteins involved in oxidative stress, inflammation, and tau-related pathology. These results suggest that inhibition and reduction of thrombin may affect aspects of AD pathology through the alteration of different thrombin-mediated signaling mechanisms in the brain.

Thrombin’s pro-inflammatory effects throughout the body, including in the brain, are largely mediated through the signaling of its receptors, protease-activated receptors (PARs) 1, 3, and 4. PARs represent a unique family of G-protein coupled receptors that are activated by a self-ligand [17]. PARs have been found in a number of cell types in the periphery and the brain, including endothelial cells, neurons, astrocytes, and microglia [52]. When cleaved and activated by thrombin, PAR1 initiates a variety of intracellular signaling. Among others, PAR1 activates the mitogen-activated protein kinase (MAPK) pathway which can lead to cell growth, proliferation or migration [53]. MAPK related proteins were analyzed by LC-MS/MS SWATH analysis, identifying significant differences between Tg-Vehicle and Tg-
Dabigatran etexilate in ANT3, ITB2, KPCB, MK08, MP2K1 and MP2K2. Interestingly, Dabigatran etexilate treatment did not alter proteins to wild type levels.

Thrombin activation of PARs is responsible for pro-inflammatory and oxidative effects in both the periphery and brain. Here, we identified significantly elevated levels of iNOS, GFAP, and IBA1 in transgenic mice as compared to wild type. Dabigatran etexilate treatment reduced iNOS, and NOX4, as compared to vehicle. Dabigatran etexilate significantly increased COX2, DYN1, SOD1, and SOD2. These increases may be due to the timing in the antioxidant cycle [54]. Together, these results indicate a shift towards reduced oxidative stress following dabigatran etexilate treatment.

Total tau and related phosphorylated (S396, S404, S416) tau species were significantly increased in transgenic mice compared to wild type, as was expected. Dabigatran treatment slightly reduced expression of total tau, significantly decreased S396, S416; but led to an increase in S404. S396 and S404 phosphorylation are found early in the disease course of AD [55, 56] and are related to destabilization of microtubules [57, 58]. S396 is also linked with abnormal truncation of the tau protein, indicating altered functionality [55]. Phosphorylation at S416 by CamKII is largely found within the neuronal soma, rather than localized to microtubules, and has been found to be associated with the promotion of AD-related cell death [59, 60]. Together, our findings indicate that dabigatran etexilate treatment may reduce AD-related tau dysfunction through altered phosphorylation, particularly decreased phosphorylation at S396 and S416.

To further explore tau pathology, we performed LC-MS/MS SWATH analysis on a variety of previously identified tau related proteins. ANS1B, NCKP1, SV2B and SYGP were significantly altered with dabigatran etexilate treatment, compared to Tg-
Vehicle. These proteins were previously found to be downregulated in tau pathology in AD brains across multiple proteomic studies [61]. These data indicate additional changes in tau-related dysfunction following dabigatran etexilate treatment.

It’s important to note that there may be alternative explanations for the effects seen with dabigatran etexilate treatment, particularly for the decreased expression of oxidative and inflammatory mediators. Fibrin, a coagulation protein found downstream of thrombin, has also been identified as a potential pathological mediator in Alzheimer’s disease [62]. Higher levels of fibrin have been identified in the AD brain compared to healthy controls [51]. Fibrin accumulation in AD, similar to thrombin, has been linked with increases in inflammation and oxidative stress, as well as alterations in both amyloid and tau pathology [62]. Our findings showed a decrease in fibrin expression as a result of dabigatran etexilate treatment, which is expected given thrombin catalyzes the conversion of fibrinogen into fibrin. It is possible that some of the other changes identified with dabigatran etexilate treatment, including decreases in oxidative stress-related and inflammatory proteins, are the result of decreased fibrin accumulation rather than reduced thrombin signaling activity.

Alternatively, there are anti-coagulant proteins, such as activated protein C (APC), that act in opposition to thrombin. These proteins may alternatively catalyze PARs and subsequently alter the signaling mechanism activated, producing anti-inflammatory and cytoprotective effects [63]. Further studies have shown anti-inflammatory effects of APC-like ligands mediated through PAR signaling [64]. Just as reduced thrombin activity may result in reduced fibrin accumulation and therefore reduced inflammation, reduced levels of thrombin may allow for APC and other anti-coagulant proteins to bind to PARs and activate anti-inflammatory signaling processes.
Thrombin has increasingly become a protein of interest in Alzheimer’s, with other investigators also investigating thrombin as a potential pathological mediator in AD, and therefore a potential therapeutic target. Studies have found that indirect thrombin inhibitors, such as warfarin, exert anti-inflammatory and neuroprotective effects in models of AD [65]. However, direct thrombin inhibition with dabigatran etexilate may be a safer treatment option, with a reduced risk of intracerebral hemorrhage [66]. In a longitudinal, community-based study use of dabigatran etexilate was associated with a lower risk of new-onset dementia compared to warfarin [67]. More recently, treatment with dabigatran etexilate TgCRND8 transgenic AD mice improved spatial memory deficits, reduced neuroinflammation and amyloid plaque formation [68]. These studies demonstrate beneficial effects of thrombin inhibition in AD models, further supporting our hypothesis that targeting thrombin, a key mediator of vascular inflammation and neurotoxicity, may be effective in reducing AD-related pathology.

While these findings are interesting, it is worthy to note that this study is limited in scope. The cohort analyzed was made up of a specific gender at a late age for a short treatment time. Future studies should analyze longer dabigatran etexilate treatment at various life stages to better identify the best time and length for pharmaceutical intervention for the alteration of AD-related pathology.

Here, we investigate the role of thrombin as a pathological mediator in Alzheimer’s disease, and the efficacy of a direct thrombin inhibitor, dabigatran etexilate, in a transgenic tau-based AD mouse model. After seven days of treatment, dabigatran etexilate treatment altered proteins related to coagulation, inflammation, oxidative stress and tau pathology. Further, data suggests that thrombin inhibition
may mediate AD pathology through multiple thrombin-mediated signaling mechanisms.

**Acknowledgements and Conflict of Interest**

The authors would like to thank MindImmune Therapeutics, Inc. for generously contributing animals for this project. Authors declare no conflicts of interest.
Table 1. List of proteins and corresponding abbreviations. Proteins analyzed in Skyline, data obtained by LC-MS/MS with SWATH acquisition.

| Pathway               | Abbreviation | Full Protein Name                                               |
|-----------------------|--------------|-----------------------------------------------------------------|
| Alzheimer’s Disease   | A4           | Amyloid-beta A4 protein (ABPP)                                  |
|                       | APOE         | Apolipoprotein E (Apo-E)                                        |
|                       | BACE1        | Beta-secretase 1                                                |
|                       | BACE2        | Beta-secretase 2                                                |
|                       | Tau (Human)  | Microtubule-associated protein tau                              |
|                       | Tau (Mouse)  | Microtubule-associated protein tau                              |
|                       | TTBK2        | Tau-tubulin kinase 2                                            |
| Coagulation Cascade   | ANT3         | Antithrombin-III                                                |
|                       | FA5          | Coagulation factor V (Activated protein C cofactor)             |
|                       | FA8          | Coagulation factor VIII (Procoagulant component)               |
|                       | FA10         | Coagulation factor X                                            |
|                       | FIBB         | Fibrinogen beta chain                                           |
|                       | ICAM1        | Intercellular adhesion molecule 1                               |
|                       | ICAM5        | Intercellular adhesion molecule 5                              |
|                       | ITAL         | Integrin alpha-L                                                |
|                       | ITAM         | Integrin alpha-m                                                |
|                       | ITAV         | Integrin alpha-V                                                |
|                       | ITB2         | Integrin beta-2                                                 |
|                       | ITB3         | Integrin beta-3                                                 |
|                       | KPCA         | Protein kinase C alpha type                                     |
|                       | KPCB         | Protein kinase C beta type                                      |
|                       | KPCD         | Protein kinase C delta type                                     |
|                       | MK01         | Mitogen-activated protein kinase 1                              |
|                       | MK03         | Mitogen-activated protein kinase 3                              |
|                       | MK04         | Mitogen-activated protein kinase 9                              |
|                       | MMP2         | Matrix metalloproteinase-2; 72 kDa type IV collagenase          |
|                       | MMP9         | Matrix metalloproteinase-9                                      |
|                       | MP2K1        | Dual specificity mitogen-activated protein kinase 1             |
|                       | MP2K2        | Dual specificity mitogen-activated protein kinase 2             |
|                       | RACK1        | Receptor of activated protein C kinase 1                        |
|                       | ROCK1        | Rho-associated protein kinase 1                                 |
|                       | ROCK2        | Rho-associated protein kinase 2                                 |
|                       | VCAM1        | Vascular cell adhesion protein 1                                |
| Inflammation Related  | CDK5         | Cyclin-dependent-like kinase 5                                  |
|                       | COX2         | Cytochrome c oxidase subunit 2                                  |
|                       | DLG4         | Discs large homolog 4                                           |
|                       | DYN1         | Dynamin-1                                                       |
|                       | GFAP         | Glial fibrillary acidic protein (GFAP)                          |
|                       | MILK2        | MICAL-like protein 2                                             |
|                       | NFkB1        | Nuclear factor NF-kappa-B p105 subunit                          |
|                       | NOS3         | Nitric oxide synthase, endothelial                              |
|                       | PARK7        | Protein/nucleic acid deglycase DJ-1                             |
|                       | PTTPC        | Receptor-type tyrosine-protein phosphatase C                    |
|                       | TLR4         | Toll-like receptor 4                                             |
| Tau Related           | ACTN2        | Alpha-actinin-2                                                 |
|                       | ANS1B        | Ankyrin repeat and sterile alpha motif domain-containing protein 1B (Amyloid-beta protein intracellular domain-associated protein 1) |
|                       | G3BP2        | Ras GTPase-activating protein-binding protein 2                  |
|                       | G6PD1        | Glucose-6-phosphate 1-dehydrogenase X                           |
|                       | GNAZ         | Guanine nucleotide-binding protein G(2) subunit alpha            |
|                       | HPC1A        | Neuron-specific calcium-binding protein hippocalcin             |
|                       | KCNQ2A       | Calcium/calmodulin-dependent protein kinase type II subunit alpha |
|                       | NAC2         | Sodium/calcium exchanger 2                                      |
|                       | NCKP1        | Nick-associated protein 1                                        |
|                       | PACN1        | Protein kinase C and casein kinase substrate in neurons protein 1 (Synaplin-1) |
|                       | QGCFX3       | Protocadherin-1                                                 |
|                       | SV2B         | Synaptic vesicle glycoprotein 2B                                |
|                       | SYGAP1       | Ras/Rap GTPase-activating protein SynGAP                        |
|                       | TBB3         | Tubulin beta-3 chain                                            |
|                       | TLN1         | Talin-1                                                         |
|                       | VIME         | Vimentin                                                        |

163
Figure 1. One-week dabigatran etexilate treatment reduces expression of coagulation-associated proteins in Tg4510 mouse brain. Western blot evaluation of expression for proteins involved in coagulation, namely, thrombin (A), prothrombin (B) and fibrin (C). All data expressed as mean ± standard error (n=4-6), significance reported by t-test, *p ≤ 0.05, **p < 0.01, ***p < 0.001.
Figure 2. One-week dabigatran etexilate treatment reduces expression of oxidative-stress related proteins in Tg4510 mouse brains. Evaluation of expression of oxidative stress proteins by western blot, iNOS (A) and NOX4 (B). All data expressed as mean ± standard error (n=4-6), significance reported by t-test, *p ≤ 0.05, **p<0.01.
Figure 3. One-week dabigatran etexilate treatment increases expression of antioxidant proteins in Tg4510 mouse brain. Western blot analysis of antioxidant proteins SOD1 (A) and SOD2 (B). All data expressed as mean ± standard error (n=4-6), significance reported by t-test, *p ≤ 0.05, ****p ≤ 0.0001.
Figure 4. Dabigatran etexilate treatment does not alter expression of neuroinflammation-associated proteins in Tg4510 mouse brain. Investigation of proteins involved in neuroinflammation by western blot GFAP (A) and IBA1 (B). All data expressed as mean ± standard error (n=4-6), significance reported by t-test, ***p ≤ 0.001; ****p ≤ 0.0001.
Figure 5. Evaluation of total Tau, and phosphorylated protein expression by western blot. Total Tau (A), phosphorylated Tau at sites S396 (B), S404 (C) and S416 (D). All data expressed as mean ± standard error (n≥4), significance reported by t-test, *p ≤ 0.05, **p ≤ 0.01; **** p ≤ 0.0001 (***)
Figure 6. Volcano plots comparing LC-MS/MS SWATH data of wild type mice to Tg-Vehicle (A) and Tg-Vehicle to Tg-Dabigatran (B). All data expressed as fold change (n=5).
Figure 7. LC-MS/MS SWATH data analyzed for coagulation (A), inflammation (B) and tau-pathology related (C). Data expressed as fold change (n=5).
References

[1] Dickstein DL, Walsh J, Brautigam H, Stockton SD, Jr., Gandy S, Hof PR (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. *Mt Sinai J Med* **77**, 82-102.

[2] Tolppanen AM, Solomon A, Soininen H, Kivipelto M (2012) Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. *J Alzheimers Dis* **32**, 531-540.

[3] Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. *Arch Neurol* **66**, 343-348.

[4] Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. *Lancet* **349**, 151-154.

[5] Daulatzai MA (2012) Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease. *Neurochem Res* **37**, 2627-2658.

[6] Palta S, Saroa R, Palta A (2014) Overview of the coagulation system. *Indian J Anaesth* **58**, 515-523.

[7] Kalz J, ten Cate H, Spronk HM (2014) Thrombin generation and atherosclerosis. *J Thromb Thrombolysis* **37**, 45-55.

[8] Jaberi N, Soleimani A, Pashirzad M, Abdeahad H, Mohammadi F, Khoshakhlagh M, Khazaei M, Ferns GA, Avan A, Hassanian SM (2019) Role of thrombin in the pathogenesis of atherosclerosis. *J Cell Biochem* **120**, 4757-4765.
[9] Borissoff JI, Joosen IA, Versteylen MO, Spronk HM, ten Cate H, Hofstra L (2012) Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. *JACC Cardiovasc Imaging* **5**, 1201-1210.

[10] Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, Weiler H, Owens AP, 3rd, Mackman N, Goss A, van Ryn J, Luyendyk JP, Flick MJ (2017) Thrombin promotes diet-induced obesity through fibrin-driven inflammation. *J Clin Invest* **127**, 3152-3166.

[11] Abu El-Asrar AM, Alam K, Nawaz MI, Mohammad G, Van den Eynde K, Siddiquei MM, Mousa A, De Hertogh G, Opdenakker G (2016) Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy. *Curr Eye Res* **41**, 1590-1600.

[12] Akiyama H, Ikeda K, Kondo H, McGeer PL (1992) Thrombin accumulation in brains of patients with Alzheimer’s disease. *Neurosci Lett* **146**, 152-154.

[13] Wagner SL, Geddes JW, Cotman CW, Lau AL, Gurwitz D, Isackson PJ, Cunningham DD (1989) Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. *Proc Natl Acad Sci U S A* **86**, 8284-8288.

[14] Vaughan PJ, Su J, Cotman CW, Cunningham DD (1994) Protease nexin-1, a potent thrombin inhibitor, is reduced around cerebral blood vessels in Alzheimer’s disease. *Brain Res* **668**, 160-170.

[15] Grammas P, Samany PG, Thirumangalakudi L (2006) Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. *J Alzheimers Dis* **9**, 51-58.
[16] Yin X, Wright J, Wall T, Grammas P (2010) Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. *Am J Pathol* **176**, 1600-1606.

[17] Coughlin SR (2000) Thrombin signalling and protease-activated receptors. *Nature* **407**, 258-264.

[18] Luo W, Wang Y, Reiser G (2007) Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. *Brain Res Rev* **56**, 331-345.

[19] ten Cate H (2012) Tissue factor-driven thrombin generation and inflammation in atherosclerosis. *Thromb Res* **129 Suppl 2**, S38-40.

[20] Lee IO, Kratz MT, Schirmer SH, Baumhakel M, Bohm M (2012) The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. *J Pharmacol Exp Ther* **343**, 253-257.

[21] Hao JS, Zhu CJ, Yan BY, Yan CY, Ling R (2018) Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus. *Biomed Pharmacother* **99**, 859-866.

[22] Brailoiu E, Shipsky MM, Yan G, Abood ME, Brailoiu GC (2017) Mechanisms of modulation of brain microvascular endothelial cells function by thrombin. *Brain Res* **1657**, 167-175.

[23] Alabanza LM, Bynoe MS (2012) Thrombin induces an inflammatory phenotype in a human brain endothelial cell line. *J Neuroimmunol* **245**, 48-55.

[24] Frohman EM, Frohman TC, Gupta S, de Fougerolles A, van den Noort S (1991) Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. *J Neurol Sci* **106**, 105-111.
[25] Maragoudakis ME, Tsopanoglou NE, Andriopoulou P (2002) Mechanism of thrombin-induced angiogenesis. *Biochem Soc Trans* **30**, 173-177.

[26] Sanchez A, Tripathy D, Luo J, Yin X, Martinez J, Grammas P (2013) Neurovascular unit and the effects of dosage in VEGF toxicity: role for oxidative stress and thrombin. *J Alzheimers Dis* **34**, 281-291.

[27] Grammas P, Ovase R (2001) Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. *Neurobiol Aging* **22**, 837-842.

[28] Grammas P, Tripathy D, Sanchez A, Yin X, Luo J (2011) Brain microvasculature and hypoxia-related proteins in Alzheimer's disease. *Int J Clin Exp Pathol* **4**, 616-627.

[29] Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P (2006) Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. *J Alzheimers Dis* **10**, 111-118.

[30] Ye X, Zuo D, Yu L, Zhang L, Tang J, Cui C, Bao L, Zan K, Zhang Z, Yang X, Chen H, Tang H, Zu J, Shi H, Cui G (2017) ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia. *Biochem Biophys Res Commun* **485**, 499-505.

[31] Yang Y, Zhang M, Kang X, Jiang C, Zhang H, Wang P, Li J (2015) Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice. *Behav Brain Funct* **11**, 30.

[32] Lee DY, Park KW, Jin BK (2006) Thrombin induces neurodegeneration and microglial activation in the cortex in vivo and in vitro: proteolytic and non-proteolytic actions. *Biochem Biophys Res Commun* **346**, 727-738.
Huang C, Ma R, Sun S, Wei G, Fang Y, Liu R, Li G (2008) JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. *J Neuroimmunol* **204**, 118-125.

Lin CC, Lee IT, Wu WB, Liu CJ, Hsieh HL, Hsiao LD, Yang CC, Yang CM (2013) Thrombin mediates migration of rat brain astrocytes via PLC, Ca(2)(+), CaMKII, PKCalpha, and AP-1-dependent matrix metalloproteinase-9 expression. *Mol Neurobiol* **48**, 616-630.

Mhatre M, Nguyen A, Kashani S, Pham T, Adesina A, Grammas P (2004) Thrombin, a mediator of neurotoxicity and memory impairment. *Neurobiol Aging* **25**, 783-793.

Piao C, Ralay Ranaivo H, Rusie A, Wadhwani N, Koh S, Wainwright MS (2015) Thrombin decreases expression of the glutamate transporter GLAST and inhibits glutamate uptake in primary cortical astrocytes via the Rho kinase pathway. *Exp Neurol* **273**, 288-300.

Cavanaugh KP, Gurwitz D, Cunningham DD, Bradshaw RA (1990) Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1. *J Neurochem* **54**, 1735-1743.

Rao HV, Thirumangalakudi L, Grammas P (2009) Cyclin C and cyclin dependent kinases 1, 2 and 3 in thrombin-induced neuronal cell cycle progression and apoptosis. *Neurosci Lett* **450**, 347-350.

Park KW, Jin BK (2008) Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase. *J Neurosci Res* **86**, 1053-1063.
[40] Suo Z, Wu M, Citron BA, Palazzo RE, Festoff BW (2003) Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling. *J Biol Chem* **278**, 37681-37689.

[41] Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL (2006) Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. *J Neuropathol Exp Neurol* **65**, 19-25.

[42] Ciallella JR, Figueiredo H, Smith-Swintosky V, McGillis JP (1999) Thrombin induces surface and intracellular secretion of amyloid precursor protein from human endothelial cells. *Thromb Haemost* **81**, 630-637.

[43] Igarashi K, Murai H, Asaka J (1992) Proteolytic processing of amyloid beta protein precursor (APP) by thrombin. *Biochem Biophys Res Commun* **185**, 1000-1004.

[44] Marques MA, Tolar M, Harmony JA, Crutcher KA (1996) A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. *Neuroreport* **7**, 2529-2532.

[45] Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. *Science* **309**, 476-481.

[46] Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory
impairment in a mouse model of human tauopathy (P301L). *J Neurosci* **25**, 10637-10647.

[47] Buccarello L, Grignaschi G, Castaldo AM, Di Giancamillo A, Domeneghini C, Melcangi RC, Borsello T (2017) Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy. *J Alzheimers Dis* **56**, 1279-1292.

[48] Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, Das S, Hyman BT (2018) Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. *Proc Natl Acad Sci U S A* **115**, E1289-e1298.

[49] Tripathy D, Sanchez A, Yin X, Luo J, Martinez J, Grammas P (2013) Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. *Front Aging Neurosci* **5**, 19.

[50] Jamwal R, Barlock BJ, Adusumalli S, Ogasawara K, Simons BL, Akhlaghi F (2017) Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS. *J Proteome Res* **16**, 4134-4143.

[51] Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S (2015) Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. *Neurobiol Aging* **36**, 608-617.

[52] Sokolova E, Reiser G (2008) Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. *Thromb Haemost* **100**, 576-581.

[53] Krenzlin H, Lorenz V, Alessandri B (2017) The involvement of thrombin in the pathogenesis of glioblastoma. *J Neurosci Res* **95**, 2080-2085.
[54] Miao L, St Clair DK (2009) Regulation of superoxide dismutase genes: implications in disease. *Free Radic Biol Med* **47**, 344-356.

[55] Mondragon-Rodriguez S, Perry G, Luna-Munoz J, Acevedo-Aquino MC, Williams S (2014) Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome. *Neuropathol Appl Neurobiol* **40**, 121-135.

[56] Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B (2018) Phosphorylation of different tau sites during progression of Alzheimer's disease. *Acta Neuropathol Commun* **6**, 52.

[57] Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. *Neuron* **10**, 1089-1099.

[58] Evans DB, Rank KB, Bhattacharya K, Thomsen DR, Gurney ME, Sharma SK (2000) Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly. *J Biol Chem* **275**, 24977-24983.

[59] Yamamoto H, Hiragami Y, Murayama M, Ishizuka K, Kawahara M, Takashima A (2005) Phosphorylation of tau at serine 416 by Ca2+/calmodulin-dependent protein kinase II in neuronal soma in brain. *J Neurochem* **94**, 1438-1447.

[60] Seward ME, Swanson E, Norambuena A, Reimann A, Cochran JN, Li R, Roberson ED, Bloom GS (2013) Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. *J Cell Sci* **126**, 1278-1286.
Mendonca CF, Kuras M, Nogueira FCS, Pla I, Hortobagyi T, Csiba L, Palkovits M, Renner E, Dome P, Marko-Varga G, Domont GB, Rezeli M (2019) Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. *Neurobiol Dis* 130, 104509.

Petersen MA, Ryu JK, Akassoglou K (2018) Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. *Nat Rev Neurosci* 19, 283-301.

Rezaie AR (2014) Protease-activated receptor signalling by coagulation proteases in endothelial cells. *Thromb Haemost* 112, 876-882.

Wang Y, Zhao Z, Chow N, Ali T, Griffin JH, Zlokovic BV (2013) Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. *Brain Res* 1507, 97-104.

Rami BK (2012) Direct thrombin inhibitors' potential efficacy in Alzheimer's disease. *Am J Alzheimers Dis Other Demen* 27, 564-567.

Choi HJ, Kim NE, Kim J, An S, Yang SH, Ha J, Cho S, Kwon I, Kim YD, Nam HS, Heo JH (2018) Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization. *Thromb Res*.

Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, Bunch TJ (2016) Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. *Am J Cardiol* 118, 210-214.

Cortes-Canteli M, Kruyer A, Fernandez-Nueda I, Marcos-Diaz A, Ceron C, Richards AT, Jno-Charles OC, Rodriguez I, Callejas S, Norris EH, Sanchez-
Gonzalez J, Ruiz-Cabello J, Ibanez B, Strickland S, Fuster V (2019) Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model. *J Am Coll Cardiol* **74**, 1910-1923.
CONCLUDING REMARKS

An exponential increase in the prevalence of neurodegenerative diseases has led to a worldwide health crisis. The two most common neurodegenerative diseases, Alzheimer’s and Parkinson’s disease constitute the largest majority of cases. Although research has been ongoing, no successful interventions have been discovered that stop the progression of the disease. Focus has shifted from targeting disease characteristic protein aggregations, namely β-amyloid and α-synuclein, to identifying targets earlier in disease progression, such as neuroinflammation or cognitive decline. Herein, we utilize two independent strategies: the use of natural products and repurposed pharmaceuticals to target neuroinflammation in models of Alzheimer’s and Parkinson’s disease.

Natural products have been utilized for centuries in traditional medicines to combat a wide variety of illnesses. The therapeutic potential of thousands of plants has yet to be fully elucidated, posing a major source of untapped resources. Our research analyzed Mucuna pruriens and a common class of plant compounds, polyphenols, for their protective effects against neuroinflammation and potential as nutraceutical interventions. A levodopa-reduced Mucuna pruriens seed extract exhibited protective effects against toxin-induced inflammation and neuronal death. After isolation, no single compound exhibited these protective effects, supporting a potential synergistic effect in the extract. Further, polyphenol microbial metabolites, but not parent compounds showed protective effects in vitro against toxins. Equol, a gut-derived metabolite, was also effective in vivo against Parkinson’s disease-specific toxic agents. These natural products exhibit protective effects in Parkinson’s disease models, suggesting potential therapeutic in neurodegenerative diseases.
A newer approach to identify new therapeutics is to repurpose previously approved pharmaceuticals for new indications. Repurposing pharmaceuticals is a drug discovery approach that may fast track pharmaceuticals to a new targeted patient population. We analyzed direct thrombin inhibitor, dabigatran etexilate (Pradaxa®), against neuroinflammation in AD and PD models. In a transgenic *Drosophila melanogaster* model of Parkinson’s disease, dabigatran improved motor control, related to the reduction in neuroinflammation as exhibited by decreased levels of reactive oxygen and nitric oxide species. Short-term treatment with dabigatran in a transgenic tau-based animal model of Alzheimer’s disease alters protein expression. These studies identify that repurposed pharmaceuticals may be effective in reducing neuroinflammation in neurodegenerative diseases.

While our results indicate these interventions may reduce neuroinflammation in models of neurodegeneration, extensive research is still necessary. Further elucidation of the mechanism of action in additional animal models is necessary before clinical trials can be conducted. Realistically, these natural products may be extremely far from reaching the clinic. However, dabigatran may be much closer to the targeted population. Moreover, these results support our initial hypothesis that natural products and repurposing pharmaceuticals are strategies that can target neuroinflammation in neurodegenerative diseases.